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Abstract 
Chronic obstructive pulmonary disease (COPD) is an important cause of morbidity and 
mortality but widely underdiagnosed. This thesis explores methods to improve case finding 
for COPD in primary care. It includes two systematic reviews- the first evaluated the 
diagnostic accuracy of screening tests and showed that handheld flow meters are more 
accurate than the COPD Diagnostic Questionnaire. The second evaluated the comparative 
effectiveness of different case finding strategies and found that inviting symptomatic ever 
smokers for a screening assessment may be more efficient than inviting all ever smokers 
directly for diagnostic spirometry. The thesis then reports the development and external 
validation of two risk prediction models for COPD using data from electronic health records 
and a cluster randomised controlled trial. These models can be used to assess the risk of 
undiagnosed COPD to help target patients for case finding and can potentially be integrated 
with clinical information systems. Finally, primary care providers were interviewed to explore 
their views on case finding for COPD, including potential benefits and harms, as well as 
barriers and facilitators. This suggests that more training and support for community 
respiratory services may be needed in order to improve the timely diagnosis of COPD. 
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CHAPTER 1: INTRODUCTION 
1.1 A personal perspective on a major public health challenge 
Chronic obstructive pulmonary disease (COPD) represents a major public health 
challenge and is currently the third leading cause of death worldwide (Figure 1.1).(1) It 
has risen from being a relatively neglected condition to one that is now recognized as 
a major priority for health services and public health.(3, 4) As a junior doctor I 
personally found managing patients with COPD, both in primary and secondary care, 
challenging. COPD is a complex condition with a wide spectrum of disease severity 
 
Figure 1.1 Causes of death estimated in the Global Burden of Diseases Study (2010) 
(Reproduced with permission from the Institute for Health Metrics and Evaluation (2)) 
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(5) and patients with more advanced disease often suffer with recurrent hospital 
admissions (6) and poor quality of life.(7) Seeing this first hand made me appreciate 
the vital importance of preventive medicine in the management of chronic respiratory 
disease. This has been recognised at a national and international level through the 
prioritisation of legislation to curb tobacco exposure (8) and improve air quality (9) but 
also by the recognition of the high prevalence of undiagnosed COPD (10) and a 
growing consensus on the importance of early diagnosis.(11)  
While working as a specialty trainee in public health, I was introduced to my current 
academic supervisors Professor Peymane Adab and Dr Rachel Jordan who offered 
the opportunity to conduct a pilot randomised controlled trial (RCT) comparing two 
approaches to case finding for COPD in primary care.(12) During the course of this 
study it became apparent that primary care organizations in the UK and worldwide 
were actively involved in case finding for COPD. However, this was largely being 
undertaken in the absence of robust evidence or guidelines. This highlighted that 
there is a need for further research to improve our understanding of the optimal 
approach for identifying patients with undiagnosed COPD, and that this is highly 
relevant for policy makers, clinicians and above all, patients. This introduction to the 
epidemiology of COPD then led to the development of the body of work presented in 
this PhD thesis, which has been conducted in collaboration with the Birmingham 
Lung Improvement Studies (BLISS) programme.(13) I hope it goes some way to 
bridging gaps in the evidence on identifying patients with undiagnosed COPD in 
primary care. 
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1.2 Pathology 
COPD is characterised by persistent, often progressive and not fully reversible airflow 
obstruction associated with chronic airway inflammation in response to noxious 
particles or gases.(14) However, the disease is highly heterogeneous with a number 
of overlapping clinical phenotypes and pathophysiological processes.(15) This mainly 
consists of varying degrees of small airways disease and destruction of the gas-
exchanging surface of the lung (emphysema).(16) The small airways undergo 
structural changes and progressive narrowing while destruction of lung parenchyma 
reduces its elastic recoil, limiting the ability of airways to remain open during 
expiration.(17) COPD is often accompanied by chronic bronchitis which is 
characterised by airway mucociliary dysfunction and mucus hypersecretion.(18) In 
addition, COPD often overlaps with asthma and in older individuals with COPD, as 
many as half or more may have overlapping diagnoses, which has led to the 
recognition of the asthma-COPD overlap syndrome.(19) COPD is also characterised 
by multi-morbidity (20, 21) (Figure 1.2) which is related to the effects of ageing and 
 
Figure 1.2 Prevalence of comorbidities associated with increased risk of death in patients 
with COPD (20) 
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other shared risk factors as well as systemic inflammation.(22)  
1.3 Symptoms 
People with COPD suffer with chronic  respiratory symptoms such as cough, 
shortness of breath, wheeze and sputum production, and often experience recurrent 
exacerbations (although the latter may be more characteristic of a specific phenotype 
(23)), which are often triggered by both bacterial and viral respiratory infections.(24) 
They may also experience more systemic symptoms such as fatigue, weight loss, 
muscle weakness and anorexia,(25, 26) and can suffer with depression and 
anxiety.(27) Lung function decline, reduction in muscle strength, and reduced 
exercise capacity all contribute to increasing disability.(28)  
1.4 Diagnosis 
The most widely recommended diagnostic criteria for COPD used in clinical practice 
requires the presence of relevant symptoms (as described above) and a compatible 
clinical history (aged over 35 years with a history of smoking or other noxious 
exposures) together with objective measures of airflow obstruction as defined by a 
post-bronchodilator forced expiratory volume in one second (FEV1) to forced vital 
capacity (FVC) ratio of less than 0.7.(29)  
However the approach and threshold used to define airflow obstruction remains in 
dispute because it may over-diagnose males aged >40 years and females >50 years 
(30) as well as asymptomatic older never smokers.(31) The European Respiratory 
Society and the American Thoracic Society as well  as a large number of 
epidemiological studies have thus adopted a different criterion for airflow obstruction 
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which is an FEV1/FVC less than the 
lower limit of normal (5th percentile) after 
adjusting for age, sex, height, and ethnic 
group.(32, 33)  
Disease severity has traditionally been 
graded according to the ratio of the observed FEV1 to the predicted value (Table 
1.1).(14) However a different classification for severity grading recently proposed by 
the GOLD committee, which incorporates information about symptoms and frequency 
of exacerbations, has been incorporated into their most recent guidance.(14) Other 
clinical investigations including chest radiography and a full blood count are also 
indicated for the diagnosis of COPD and to exclude differential diagnoses.(29) 
1.5 Risk factors 
The main risk factor for COPD is cigarette smoking which has an estimated 
population attributable risk (PAR) ranging from 48-76%.(34, 35) Other risk factors 
have also been implicated including exposure to industrial fumes and dust,(36) 
outdoor air pollution,(37) second hand smoke,(38) biomass smoke,(39) and chronic 
asthma.(40) Alpha-1 antitrypsin deficiency is a well-established genetic risk factor for 
COPD although other rare genetic syndromes such as cutis laxa (41) (caused by 
mutations in the elastin gene) may also cause COPD.(40) There is increasing 
evidence that lung function development is influenced both in utero and in the early 
years of life by factors such as maternal smoking, low birth weight, diet, and 
nutrition.(42) Factors such as parental and childhood asthma, maternal smoking and 
Table 1.1 Global Initiative for Obstructive 
Lung Disease (GOLD) COPD severity 
staging classification 
GOLD Stage Criteria 
1 FEV1 ≥ 80% predicted 
2 50% ≤ FEV1 <80% predicted 
3 30% ≤ FEV1 <50% predicted 
4 FEV1 < 30% predicted 
FEV1=forced expiratory volume in one second 
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childhood respiratory infections have been shown to permanently lower lung function 
and predispose to COPD in later life as much as heavy smoking.(43) 
1.6 Public health impact 
About one in four individuals are likely to be diagnosed with COPD during their 
lifetime (44) and COPD rose from being the fourth leading cause of death worldwide 
in 1990 to now being the third.(1) It is also the ninth leading cause of disability 
adjusted life years lost.(45) The incidence is approximately one case per 100 person 
years and ten times higher in smokers than nonsmokers.(46) Although COPD is 
almost twice as prevalent in males as females (47) the disease burden is rising 
among women as a consequence of increasing tobacco consumption over the last 
few decades.(48)  
Diagnosis and management of the disease has significant resource implications for 
health services. In the UK, COPD is associated with over 100,000 emergency 
hospital attendances (2% of all emergency visits),(49)  1 million inpatient days, 1.4 
million general practice consultations and costs the health service over £800 million 
per year.(50) Most of these costs are associated with inpatient hospitalisations.(51)  
COPD also has wider societal implications. Lost productivity can account for roughly 
half the overall societal costs, which range from £641 to £3850 per patient in Western 
Europe and the USA.(51) People with COPD often have difficulty maintaining 
employment due to chronic symptoms and exacerbations. One international survey 
suggested that individuals with COPD in active employment incurred average lifetime 
losses of £4661 from time off work and that 40% of those of working age with COPD 
retire early because of their condition.(52)  
7 
 
People with COPD tend to have both poorer physical and mental health than those 
without COPD (53) and COPD even in its milder stages can significantly affect quality 
of life and limit activities of daily living.(54) COPD is also likely to have a significant 
impact on the quality of life of carers, particularly in the latter stages of the disease 
when access to specialist palliative care is often limited.(55)  
1.7 Prevalence of COPD 
A systematic review and meta-analysis by Halbert and colleagues (47) attempted to 
quantify the global prevalence of COPD in the population aged over 40 years, which 
they estimated at 9-10% for physiologically defined disease. Heterogeneity in 
population characteristics and diagnostic criteria make it difficult to produce precise 
estimates of COPD prevalence globally. However pooled estimates from the Burden 
of Obstructive Lung Disease (BOLD) study, which used a uniform methodology for 
assessing population-based prevalence of airflow obstruction (defined as post-
bronchodilator FEV1/FVC<0.7) as a proxy for COPD across 12 international sites, 
suggested that the overall prevalence at GOLD stage II-IV is 10% (11.8% for men 
and 8.5% for women).(10) However, this varied significantly by country from 8.5-
22.2% among men and from 1.3-16.7% among women. The Latin American Project 
for the Investigation of Obstructive Lung Disease (PLATINO) similarly investigated 
the prevalence of COPD (again defined as post-bronchodilator FEV1/FVC<0.7) in 
five Latin American cities, with estimates ranging from 7.8-19.7% in adults aged over 
40 years.(56) Among young adults with normal lung function and no history of 
asthma, the European Community Health Survey II (which defined airflow obstruction 
as pre-bronchodilator FEV1/FVC<0.7) showed an incidence rate of 2.8 cases per 
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1000 person-years, with the presence of chronic cough and phlegm being associated 
with a nearly threefold increased risk.(57)  
1.8 The burden of undiagnosed disease 
Estimates of prevalence from population-based healthcare data are unreliable 
because COPD is largely underdiagnosed (Figure 1.3). For example in England the 
recorded prevalence of COPD in primary care registers in those aged over 35 years 
is 1.6% (58, 59) whereas model based estimates of predicted prevalence are closer 
to 5%.(60) The prevalence of airflow obstruction is even higher, with one analysis of 
the Health Survey for England estimating it at 13.3% (airflow obstruction defined as 
pre-bronchodilator FEV1/FVC<0.7) among people aged over 35 years, 80% of whom 
had no respiratory diagnosis.(61) Overall estimates from large international 
prevalence surveys suggest that four out of five smokers aged over 40 years have 
 
Figure 1.3 Estimated prevalence of diagnosed and undiagnosed COPD by general practice in 
England in 2012/2013 (58-60) 
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undiagnosed COPD.(62, 63) Although this varies by country and healthcare system it 
is now widely accepted that COPD remains universally underdiagnosed. 
The reasons for this are multifactorial. Firstly, patients often do not recognise that 
their symptoms are due to an underlying disease and instead attribute them to, for 
example, a smoker’s cough or simply old age.(64) Because of the progressive nature 
of COPD, patients often gradually adapt to their symptoms without necessarily 
consulting the health services. COPD still remains poorly understood by the general 
public (65) in stark contrast to conditions such as cardiovascular disease, stroke and 
cancer. Knowledge of COPD can often even be poor among patients with an 
established diagnosis.(66)  
Secondly, clinicians often miss cues to the diagnosis such as presentation with 
recurrent respiratory symptoms and lower respiratory tract infections. A recent 
analysis of routine data from primary care health records in the UK by Jones and 
colleagues (67) suggested that opportunities to diagnose COPD were missed in 85% 
of patients with COPD in the five years preceding diagnosis. Missed cues included 
presentations to primary care with lower respiratory tract infections, and requirements 
for antibiotic prescriptions and chest radiography.(67) Knowledge of COPD and its 
management by clinicians in primary care in some areas has been poor.(68, 69)  
Furthermore, limited access to high quality spirometry, which is essential for the 
diagnosis of COPD, has historically been highly variable (70, 71) and has resulted in 
both missed diagnoses as well as misdiagnosis.(72) However this is improving with 
increasing emphasis on training primary care staff to achieve good spirometry 
standards.(73) Historically there has also been a somewhat nihilistic attitude towards 
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COPD among clinicians.(74) This no longer justified with the current availability of 
evidence-based therapeutic options, particularly for improving symptoms and quality 
of life and potentially even reducing hospitalisations and mortality.(75) The views of 
clinicians in primary care on the underdiagnosis of COPD and factors influencing this 
have not been widely researched and will be addressed as part of this thesis. 
1.9 Therapies for COPD 
The UK National Institute for Health and Care Excellence (NICE) has produced  
comprehensive guidelines on the management of patients with COPD.(29) Below is a 
summary of some of the key components of care. 
1.9.1 Smoking cessation 
Although COPD is irreversible, there are a number of therapies that can improve 
symptom burden and quality of life and potentially slow disease progression. Chief 
among these is smoking cessation. As far back as the 1970s Fletcher and Peto 
demonstrated that smokers susceptible to the harmful effects of tobacco smoke who 
quit smoking can reduce the rate of lung function decline to that of a non-smoker.(76) 
Smoking cessation is also associated with a significant reduction in the risk of future 
hospitalisations (77) and mortality.(78)  
15% of the world’s population now has access to smoking cessation programmes 
(79) and smoking cessation services are widely available in the UK and shown to be 
effective at improving smoking quit rates with four week and one year quit rates of 
53% and 15%, respectively.(80) Treatments for smoking cessation such as 
bupropion have been shown to be effective at improving quit rates in patients with 
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COPD.(81) The Lung Health Study which randomised 5,887 patients with mild COPD 
(airflow obstruction defined as pre-bronchodilator FEV1/FVC<0.7 and FEV1 55-90% 
of predicted) to either an intensive smoking cessation programme and inhaled 
anticholinergic or usual care showed a sustained smoking quit rate of 22% at 5 years 
and reduced age-related decline in FEV1.(82)  
A simulation modelling study based on a Dutch population estimated the cost-benefit 
of pharmacotherapy and intensive counselling for smoking cessation for patients with 
COPD to be £8490 per QALY gained,(83) which is well within the accepted 
incremental cost-effectiveness ratio threshold used by NICE. 
1.9.2 Pulmonary rehabilitation 
NICE guidelines for COPD recommend that patients who consider themselves 
functionally disabled by their condition, usually with MRC grade three dyspnoea or 
above, and those who have experienced a recent hospitalisation due to an 
exacerbation should be offered pulmonary rehabilitation.(29) A Cochrane review 
published in 2006 incorporated data from 31 RCTs that compared pulmonary 
rehabilitation against usual care among patients with COPD with an FEV1<70% of 
predicted.(84) This concluded that pulmonary rehabilitation is significantly effective at 
relieving dyspnoea and fatigue, improving emotional function and enhancing patients’ 
sense of control over their condition. Another systematic review of six RCTs for 
pulmonary rehabilitation following acute exacerbations of COPD suggested that it 
significantly reduces the risk of hospital admissions and mortality, improves disease-
related quality of life and improves exercise capacity.(85) Furthermore, an economic 
evaluation of a multidisciplinary outpatient pulmonary rehabilitation programme 
showed it was likely to be cost-effective.(86) The cost-benefit of pulmonary 
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rehabilitation for moderate-to-severe COPD has been estimated at £13,515 per 
QALY gained over a ten year time horizon.(83)  
1.9.3 Immunisations 
Annual influenza vaccination is recommended for all patients with COPD irrespective 
of their severity.(29) Evidence from at least six RCTs suggest that influenza 
vaccination significantly reduces frequency of exacerbations compared with placebo 
while causing only mild and transient local adverse reactions.(87) A national cross-
sectional study in England found a significant protective association between levels 
of influenza immunisation and COPD hospital admission rates.(88) 
Pneumococcal vaccination is also recommended for all patients with COPD.(29) 
Streptococcus pneumoniae is a common bacterial pathogen implicated in the 
pathogenesis of COPD exacerbations.(89) However a Cochrane systematic review 
published in 2010 failed to find strong evidence from RCTs that pneumococcal 
vaccination protects against exacerbations, hospitalisations and mortality in patients 
with COPD (90) which suggests that current recommendations for pneumococcal 
vaccination in this patient group should re-evaluated. 
1.9.4 Pharmacotherapy 
A number of inhaled medications are available to treat the symptoms of COPD 
including short-acting beta agonists (e.g. salbutamol) and short-acting antimuscarinic 
antagonists (e.g. ipratropium) for treating breathless and/or exercise limitation, and 
long-acting beta agonists (e.g. salmeterol), long-acting antimuscarinic antagonists 
(e.g. tiotropium), corticosteroids (e.g. fluticasone) and combination inhalers (e.g. 
salmeterol and fluticasone) for treating exacerbations or persistent 
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breathlessness.(29) These may improve symptoms and quality of life and in some 
cases reduce lung function decline. For example, a large multi-centre RCT that 
compared a combination of inhaled fluticasone and salmeterol against either agent 
alone and placebo over a period of one year, among COPD patients with a baseline 
FEV1 25-70% of predicted, demonstrated that those receiving the combination inhaler 
experienced a clinically significant improvement in health status as well as lung 
function and lower frequency of exacerbations relative to the comparison groups.(91, 
92) Other RCTs have similarly shown clinical benefits for inhaled therapies in terms 
of improved symptoms and quality of life and reduced frequency of 
exacerbations.(93) However the evidence for the effectiveness of inhaled therapies 
for COPD is largely limited to patients with moderate-to-severe disease and there is 
little evidence for their effectiveness in patients with mild (GOLD stage I) COPD. 
These treatments are likely to be cost-effective. A combination of inhaled 
corticosteroids and long-acting beta agonists are estimated to have an incremental 
cost-benefit ratio of £6519 per QALY gained.(83) Inhaled bronchodilators and 
corticosteroids are thus a cornerstone of COPD management in national and 
international guidelines.(14, 29) However pharmacotherapy for COPD is not without 
side effects. A recent observational analysis of an administrative health insurance 
database in Quebec of 163,514 patients suggested that current use of inhaled 
corticosteroids was associated with a 69% relative increase in the risk of serious 
pneumonia.(94) In addition, to-date clinical trials for inhaled therapies for COPD have 
failed to demonstrate reductions in mortality.  
Patients with COPD may also be prescribed oral corticosteroids and antibiotics for 
exacerbations. Findings from three systematic reviews suggest that oral 
14 
 
corticosteroids improve FEV1 and hypoxaemia as well as reduce the duration of 
hospitalisation following exacerbations.(95-97) Treatment with antibiotics has also 
been shown to reduce the risk of mortality, treatment failure and sputum 
purulence.(98) Finally, patients with severe COPD may be eligible for long-term 
oxygen therapy which has been shown to reduce the five-year relative risk of 
mortality by 58% in patients with severe hypoxaemia but few comorbidities.(99)  
1.10 Rationale for early detection 
There is a large burden of undiagnosed COPD and the majority of these individuals 
present with moderate-to-severe disease (GOLD stage II or worse) at the time of 
diagnosis.(100) They are likely to have experienced symptoms (such as 
breathlessness) for a considerable period of time without access to evidence-based 
healthcare interventions, such as pulmonary rehabilitation and inhaled therapy that 
would otherwise be indicated. An analysis of the Third National Health and Nutrition 
Examination Survey (NHANES III) in the USA showed that undiagnosed airflow 
obstruction (defined as pre-bronchodilator FEV1/FVC<0.7 and FEV1<80% predicted) 
was associated with impaired health and functional status.(101) Furthermore, 
patients with COPD often receive their diagnosis at the time of an emergency 
admission for an acute exacerbation,(102) which carries an overall inpatient mortality 
of 7.5%.(103) A national survey in England of COPD-related hospital admissions 
showed a positive association between the prevalence of undiagnosed COPD and 
the rate of hospitalisations.(88)  
Early detection of COPD may enable timely access to appropriate care, which could 
help relieve symptoms, improve quality of life and reduce acute hospital admissions, 
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although this remains to be demonstrated empirically. Only limited evidence from a 
COPD-improvement programme in Finland suggested that efforts to improve the 
diagnosis and management of COPD may significantly reduce COPD-related 
hospital admissions.(104) 
Smoking cessation has been shown to significantly improve the trajectory of lung 
function decline in smokers,(76, 105) reduce all-cause and cardiovascular 
mortality,(106) and reduce respiratory symptoms.(107) A diagnosis of COPD could 
plausibly encourage a decision to quit smoking and thus improve prognosis. 
However, the effect of diagnosing COPD or impaired lung function on smoking 
cessation has shown inconsistent results. In a COPD screening study in 
Poland,(108) smokers diagnosed with airflow limitation were slightly more likely to 
quit smoking at one year compared to smokers with normal lung function (10.1% 
versus 8.4%, respectively) although this difference was not statistically significant. A 
similar but much larger screening study that recruited over 4000 current smokers also 
found that subjects who were informed of their COPD diagnosis had higher smoking 
cessation rates at one year than those with normal lung function (16.3% versus 
12.0%, p<0.001).(109) Similar findings were also shown in a screening study in 
Sweden that compared the effect of a combination of annual spirometry and brief 
smoking cessation advice on smoking cessation rates between smokers diagnosed 
with COPD and smokers without COPD (abstinence at three years 29% versus 14%, 
respectively).(110)  
One RCT in the UK compared reporting lung age versus raw spirometry results 
(FEV1) to current smokers in primary care.(111) While those who received their lung 
age were significantly more likely to quit smoking at 12 months (13.6% versus 6.4%, 
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p=0.005), subjects with worse spirometric lung age were no more likely to quit 
smoking than those with normal lung age. In Denmark Ulrik and colleagues (112) 
found that when screening patients (mostly smokers) with respiratory symptoms 
(dyspnoea, cough, wheeze, sputum, and/or recurrent chest infections), 50% of 
current smokers stated that they were not interested in quitting smoking, and this did 
not differ between those with and without airflow obstruction. In another RCT, Buffels 
and colleagues (113) randomised smokers in primary care receiving smoking 
cessation support to additionally receive a single spirometry assessment but found 
no significant difference in smoking cessation rates between both groups although 
this was from a relatively small sample (n=89). 
While there are good intuitive reasons for detecting COPD early, it remains unclear 
whether doing so actually improves prognosis and reduces mortality. Prospective 
studies evaluating the effectiveness of early detection on reducing exacerbations, 
hospital admissions and mortality are currently underway (the Birmingham COPD 
Study), the findings of which must be reported before robust recommendations on 
case finding for COPD can be made.  
1.11 Screening and case finding for COPD 
The UK National Screening Committee (NSC) defines screening as a process of 
identifying apparently healthy people who may be at an increased risk of a disease or 
condition.(114) High risk individuals can then be offered information, diagnostic tests, 
and treatment to reduce risk and complications arising from the disease. Case finding 
is the active and systematic search for individuals at high risk of disease.(115) Both 
screening and case finding greatly overlap in the context of identifying undiagnosed 
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COPD in primary care. However they appear to have been interpreted differently in 
the literature with the term “screening” often being used to refer to the use of 
spirometry on a population-wide basis (116) and case finding to the identification of 
symptomatic patients for further clinical evaluation.(117) In this thesis, both terms are 
used synonymously since they both essentially refer to the systematic identification 
of high risk individuals for further diagnostic assessment (however the term 
“screening” will be used in the context of studies evaluating the test accuracy of 
screening tests such as questionnaires and handheld flow meters). 
There has recently been an international drive to identify individuals with 
undiagnosed COPD. In the UK this was spearheaded first by the Chief Medical 
Officer’s annual report in 2004 (3) which emphasised the importance of early 
diagnosis, and later by the British Lung Foundation at the launch of its “missing 
millions” campaign.(118) This highlighted the huge burden of undiagnosed COPD 
and advocated for systematic case finding to improve patient outcomes. Case finding 
and early detection of COPD has been encouraged by NICE guidelines (29) and the 
GOLD strategy,(119) and was advocated by the UK Department of Health’s 
Outcomes Strategy for COPD and Asthma in England.(120)    
To this end a large number of studies have evaluated the effectiveness of a variety of 
screening tests and approaches for COPD. In 2008 the US Preventive Service Task 
Force commissioned a review on screening for COPD with spirometry which 
concluded that this should not be recommended on the basis that hundreds of 
patients would need to be screened in order to prevent one exacerbation of 
COPD.(116) However there are a number of other approaches that could improve 
the efficiency of case finding such as the use of screening questionnaires,(121) a 
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number of which have been evaluated in prospective studies,(122-124) as well as 
handheld flow meters (e.g. COPD-6®).(125) The latter differ from diagnostic 
spirometers in that they only measure FEV1 and FEV6, are cheaper and quicker to 
administer, and are predominantly being marketed as screening devices. Other 
screening modalities have also been evaluated in primary care including use of peak 
flow meters (126) and chest radiography.(127) The efficiency of case finding may 
also be further enhanced through the use of risk prediction models using routine 
healthcare data.(128) This could potentially help to identify patients at the highest risk 
of undiagnosed disease based on the presence of risk factors and target those most 
likely to benefit from further clinical assessment. The latter approach has now been 
used widely for cardiovascular risk assessment (129) and is gradually being used for 
an increasing number of chronic conditions.(130-132) 
The most efficient approach for identifying individuals with undiagnosed COPD 
remains unknown, which has partly formed the basis for a decision against screening 
made by the UK NSC.(133) In addition, it is important that case finding initiatives aim 
to diagnose patients with clinical disease and not those with asymptomatic airflow 
obstruction for whom there is uncertainty regarding treatment options.(116) NICE 
guidelines recommend that the diagnosis of COPD should be made in patients with 
relevant exposures who have respiratory symptoms and spirometric evidence of 
airflow limitation.(29) Current therapeutic interventions for COPD, such as inhaled 
bronchodilators and pulmonary rehabilitation, are largely aimed at relieving 
symptoms rather than improving lung function decline.(119) There have been no 
published RCTs evaluating interventions for patients with asymptomatic airflow 
obstruction. However the presence of symptoms may be difficult to elicit in the clinical 
19 
 
history since patients often adapt to their symptoms and therefore underestimate 
their impact on quality of life.(134)  
In a time of increasing constraints on healthcare budgets,(135) addressing these 
questions will be important for developing a clinically relevant and economically 
sustainable pathway for timely diagnosis. Finding accurate methods for 
discriminating between patients with and without COPD is important to minimize 
harms from false positive and false negative screening tests. Evidence on which 
patients to target, how best to identify and reach them, and the effectiveness of using 
different screening and diagnostic tests is needed to provide guidance on the most 
efficient approach. Also, for it to be implemented in day-to-day clinical practice, the 
views of patients and healthcare professionals should be elicited to gain an insight 
into potential benefits, harms, barriers and facilitators to undertaking case finding for 
COPD as part of routine care. Answering these questions will be important for 
informing future updates of screening policy for COPD in primary care and forms the 
focus of this thesis. 
1.12 Birmingham Lung Improvement Studies 
Birmingham Lung Improvement Studies (BLISS) is an NIHR-funded research 
programme based at the University of Birmingham that aims to investigate COPD in 
primary care. One of its main studies is TargetCOPD, a cluster RCT based in the 
West Midlands, UK.(123) The trial recruited 54 general practices and aims to 
compare the effectiveness and cost-effectiveness of case finding for COPD against 
usual care. Within the case finding arm is an individually randomised RCT that 
compares opportunistic case finding by providing a respiratory questionnaire at 
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routine primary care visits with a more active approach in which questionnaires were 
additionally posted to patients. Patients reporting chronic respiratory symptoms 
(chronic cough or phlegm, wheeze or dyspnoea) were then invited for an assessment 
that included post-bronchodilator spirometry. As part of this trial, data from electronic 
health records were extracted to help characterise enrolled patients in terms of their 
demographic characteristics, comorbidities and health service use. Data from this 
trial has formed an important component of this thesis, which is described below. 
1.13 Aims and objectives of this thesis 
1. To evaluate the diagnostic accuracy of screening tests for COPD in primary care 
(Chapter 2). 
2. To evaluate the effectiveness of alternative case finding strategies for COPD in 
primary care (Chapter 3). 
3. To develop a prediction model to risk stratify patients for undiagnosed COPD using 
routine primary care data (Chapters 4 and 5). 
4. To explore the views of primary healthcare providers on case finding for COPD, 
including the benefits, harms, barriers and facilitators (Chapter 6). 
1.14 Thesis outline  
Chapters 2 and 3 of this thesis consist of two linked systematic reviews. The first 
aims to determine the accuracy (sensitivity and specificity) of screening tests for 
COPD while the second addresses the effectiveness of alternative strategies for case 
finding in primary care. This should help policy makers, commissioners and clinicians 
determine how best to identify undiagnosed COPD with existing tools, help 
researchers identify gaps in the evidence base that should to be bridged, and help 
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inform the UK National Screening Committee for future policy recommendations on 
case finding or screening for COPD.  
Chapter 4 describes the development of a prediction model and clinical score for 
assessing the risk of undiagnosed COPD in primary care using routine healthcare 
data from a large nationally representative dataset. Chapter 5 builds on this using 
data from a large cluster RCT of COPD case finding based in primary care (the 
TargetCOPD trial).(123) The objective of these prediction models is to provide 
primary care clinicians with tools that can help them target high risk patients for 
systematic case finding. 
Chapter 6 explores the views of general practitioners, nurses and practice managers 
on case finding for COPD in order to gain an understanding of their current practices, 
their attitudes towards case finding, and identify barriers and facilitators that may 
affect its implementation in real life practice. 
The findings of these chapters and their clinical implications are then summarised 
and discussed in Chapter 7.
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CHAPTER 2: DIAGNOSTIC 
ACCURACY OF SCREENING TESTS 
FOR COPD: A SYSTEMATIC 
REVIEW AND META-ANALYSIS 
This chapter is based on a published systematic review protocol: Haroon S, Adab 
PA, Jordan RE. Case finding for COPD in primary care: a systematic review 
(protocol). Primary Care Respiratory Journal. 2012: 21(3):354-7.  
2.1 Abstract 
Background 
COPD is widely under-diagnosed. A number of studies have evaluated the accuracy 
of screening tests for COPD but their findings have not been formally summarised. 
This review aims to determine and compare the diagnostic accuracy of screening 
tests for COPD in primary care. 
Methods 
Systematic review and meta-analysis of the diagnostic accuracy of screening tests 
for COPD confirmed by spirometry in primary care. Medline, Embase, and other 
bibliographic databases were searched from 1997 to 2013 for diagnostic accuracy 
studies that evaluated one or more index tests in primary care among individuals 
aged ≥35 years with no prior diagnosis of COPD. Bivariate meta-analysis of 
sensitivity and specificity was performed where appropriate. Methodological quality 
was assessed independently by two reviewers using the QUADAS-2 tool. 
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Results 
Ten studies were included. Eight assessed screening questionnaires (the COPD 
Diagnostic Questionnaire [CDQ] was the most evaluated, n=4), four assessed 
handheld flow meters (e.g. COPD-6®), and one assessed their combination. Post-
bronchodilator spirometry was used as the reference standard in all studies included 
in the meta-analyses. Among ever smokers the CDQ (score threshold ≥19.5; n=4) 
had a pooled sensitivity of 64.5% (95% CI 59.9% to 68.8%) and specificity 65.2% 
(52.9 to 75.8%), and handheld flow meters (n=3) had a sensitivity of 79.9% (95% CI 
74.2% to 84.7%) and specificity 84.4% (68.9 to 93.0%). Inadequate blinding between 
index tests and spirometry was the main risk of bias. 
Conclusions 
Handheld flow meters demonstrated higher test accuracy than the CDQ for COPD 
screening in primary care. However there is a need for high quality studies directly 
comparing screening tests for COPD, that use a clinical rather than just a 
physiological definition of COPD. 
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2.2 Introduction 
Chronic Obstructive Pulmonary Disease (COPD) is the third leading cause of 
death,(1) ranks ninth for lost disability adjusted life years,(2) and is an important 
cause of healthcare expenditure.(3) Despite this, as much as 50-90% of the disease 
burden remains undiagnosed.(4) Patients often under-recognise the significance of 
respiratory symptoms,(5) and clinicians frequently miss opportunities to diagnose 
COPD at primary care consultations.(6) Early detection may offer opportunities to 
reduce disease progression and improve quality of life, for example through smoking 
cessation interventions (7) and pulmonary rehabilitation.(8)  
There is now a policy drive to identify undiagnosed COPD.(8-11) However, a 
systematic review of spirometric screening concluded that this should not be 
recommended, partly because it estimated that hundreds of smokers would need to 
be screened to prevent a single COPD exacerbation.(12) Furthermore this approach 
could potentially identify asymptomatic individuals with airflow obstruction, who would 
not meet the clinical criteria for COPD according to current guidelines.(11) A number 
of studies have evaluated the diagnostic accuracy of a variety of other screening 
tests and approaches, which are likely to be more efficient than performing 
spirometry on all high risk individuals.(13, 14) However the findings of these studies 
have not been systematically reviewed and quantitatively synthesised. Although one 
narrative review (15) compared existing symptom-based questionnaires, it did not 
include other screening tests and needs updating.  
This is a systematic review and meta-analysis of published studies that summarises 
and compares the accuracy of screening tests for COPD in primary care. 
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2.3 Methods 
2.3.1 Protocol and registration 
The protocol for this review was previously published (16) and registered.(17) 
2.3.2 Eligibility criteria  
Diagnostic accuracy studies were sought, of any design that evaluated one or more 
index tests, were conducted in primary care (including general practices and 
community pharmacies), and recruited individuals aged ≥35 years with no prior 
diagnosis of COPD. Index tests included screening questionnaires, handheld flow 
meters (e.g. Piko-6® or COPD-6®), peak flow meters, chest radiography, and risk 
prediction models or decision aids, either alone or in combination. Studies were only 
included if they used pre- or post-bronchodilator spirometry as the reference test and 
specified the target condition as COPD, defined by the presence of airflow 
obstruction using diagnostic criteria from internationally/nationally accepted 
standards (although studies were ideally sought that used a clinical definition of 
COPD, requiring both relevant symptoms [e.g. dyspnoea, cough, sputum production, 
wheeze] and airflow obstruction).  
2.3.3 Outcomes 
The primary outcome was identification of COPD, defined by the presence of pre- or 
post-bronchodilator airflow obstruction. The main measures of test accuracy 
examined were sensitivity and specificity. 
2.3.4 Search strategy 
The following databases were searched from March/April 2012 for the previous 15 
years: Medline, Embase, CINAHL, Cochrane Central Register of Controlled Trials, 
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and the Health Technology Database. An updated search was performed on Medline 
and Embase up to December 2013. Searches limited to the first 100 articles were 
also performed on Google Scholar, Turning Research into Practice, HTAi VORTAL 
and DogPile, and selected conference abstracts for the previous two years. Search 
terms (Table 2.1) included Medical Subject Heading terms and free text synonyms for 
COPD, screening tests and measures of test accuracy, with no language restrictions. 
2.3.5 Study selection and data extraction 
Titles and abstracts were screened independently by two reviewers. Relevant full text 
articles were independently assessed for eligibility by two reviewers and 
disagreements resolved through discussion. Pre-specified data were extracted from 
full text articles by one reviewer and verified by a second. The number of true 
positives, false positives, true negatives and false negatives were extracted for 
Table 2.1 Search terms 
Disease AND Index test 
Chronic obstructive pulmonary disease Case finding 
OR OR 
Chronic obstructive airways disease Screening 
OR OR 
Chronic obstructive lung disease Early detection 
OR OR 
COPD Secondary prevention 
OR OR 
COAD Spirometry 
OR OR 
Emphysema Questionnaire 
OR OR 
Chronic bronchitis Peak flow 
OR OR 
Airflow obstruction Chest X-ray 
OR  OR 
Airflow limitation Decision aid 
 OR 
 Algorithm 
 OR 
 Sensitivity 
 OR 
 Specificity 
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construction of two-by-two contingency tables. Where these data were not provided, 
reported measures of test accuracy were used to derive these values.  
2.3.6 Risk of bias assessment 
Included studies were assessed independently by two reviewers for risk of 
methodological bias and applicability concerns against criteria from the QUADAS-2 
tool.(18) Disagreements were resolved through discussion. 
2.3.7 Statistical analysis 
Forest plots of sensitivity and specificity were constructed using Review Manager 
(RevMan) version 5.2 (Copenhagen: The Nordic Cochrane Centre, The Cochrane 
Collaboration, 2012). These plots were used to visually explore between-study 
variation in the diagnostic accuracy of each test. Differences in population screened, 
screening test, diagnostic criteria, and study design were also explored.  
Where there was sufficient clinical and methodological homogeneity, the xtmelogit 
command was used in Stata version 13.1 (Stata-Corp, College Station, Texas, USA) 
to fit the bivariate model (19, 20) to derive summary estimates of sensitivity and 
specificity and their 95% confidence intervals. If there were fewer than four studies, 
the bivariate model was simplified to two univariate random effects logistic regression 
models for sensitivity and specificity by assuming no correlation between both 
measures. Two approaches were used to compare the diagnostic accuracy of the 
screening tests. First, all relevant studies were used that evaluated one or more 
tests, and second, the analysis was restricted to studies that made direct (head-to-
head) comparisons. Where meta-analysis was possible, tests were compared by 
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adding a covariate for test type to the bivariate model to assess whether average 
sensitivity and/or specificity differed between the tests. 
Positive and negative predictive values (PPV and NPV) were estimated from the 
sensitivity and specificity of each test, assuming a prevalence of undiagnosed COPD 
of 5.5% (21) in a hypothetical population of 1000 patients aged ≥40 years. The 
number-needed-to-screen (NNS) to identify one individual with COPD was estimated 
as the total number screened divided by the number of true positives, and the 
number of diagnostic assessments needed (NND) as the reciprocal of the PPV.  
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2.4 Results 
2.4.1 Study selection 
The stages of study selection are shown in Figure 2.1. After excluding duplicates the 
search yielded 2605 records. From these, full text articles were retrieved for 266 
studies. Ten studies met the inclusion criteria, and five were suitable for meta-
analysis (since these were sufficiently similar with respect to the included population, 
screening tests, and definition of COPD). Figure 2.1 lists the reasons for excluding 
articles, the most common of which was the inclusion of patients with previously 
known COPD. 
2.4.2 Study characteristics 
Characteristics of included studies are summarised in Tables 2.2 and 2.3 (see Tables 
S2.1-2.3 for details of each study). All were cross-sectional test accuracy studies, of 
which two used a paired design to compare two screening tests (screening 
questionnaires and handheld flow meters).(14, 22) Nine studies were multicentre and 
all were based in general practices.  
2.4.3 Recruitment and population selection 
Four studies opportunistically recruited patients routinely attending primary care, 
three actively recruited participants through postal invitations or local advertisements, 
two used a combination of both strategies, and one study did not report the method 
of recruitment.(23) All studies specified age in the inclusion criteria with most 
requiring subjects to be over 40 years. Seven studies also required a positive 
smoking history but only one required participants to report respiratory symptoms as 
36 
 
part of the entry criteria.(24) The main exclusion criterion was an established history 
of lung disease.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 Study selection 
 
 
Records identified through 
database searching 
(n=3299) 
Additional records identified through 
other sources 
(n=0) 
Records after duplicates removed 
(n=2605) 
Records screened 
(n=2605) 
Records excluded 
(n=2339) 
Full-text articles assessed 
for eligibility  
(n=266) 
Full-text articles excluded  
(n=256): 
Not a screening study (14) 
Ineligible 
setting/population (64) 
Not a primary study (42) 
Inadequate outcome 
ascertainment (7) 
Primarily focused on 
detecting conditions other 
than COPD (15) 
Unclear population (7) 
Included patients with 
known COPD (47) 
Ineligible population (4) 
No relevant outcomes (41) 
Insufficient data (4) 
Unable to acquire full text 
article (11) 
Studies included  
(n=10) 
Studies included in  
meta-analysis 
(n=5) 
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Table 2.2 Characteristics of studies evaluating screening questionnaires (8 studies) (13, 14, 22-
27) 
Characteristic  Range/no. of studies 
Study designs Cross-sectional test accuracy 8 
Participants   237-3158 
Mean age (years)  52.3-65.3 
Male (%)  38.1-69.0 
Required smoking status: Only current/ex-smokers 5 
 Included never smokers 3 
Required respiratory symptoms  1 
Setting General practice(s) 8 
Number of centres  1-36 
 Multicentre 7 
 Single centre 1 
Recruitment strategy Active 2 
 Opportunistic 3 
 Active & opportunistic 2 
 Not reported 1 
Questionnaires COPD Diagnostic Questionnaire* 4 
 Lung Function Questionnaire 2 
 Not named 2 
Common items   
 Age 7 
 Smoking status 7 
 Respiratory symptoms 8 
 Allergies 5 
Reference test- spirometry   
Post-bronchodilator  6 
Definition of AO Post-BD FEV1/FVC<0.7 7 
 Other** 1 
Included symptoms in definition of COPD 1 
Spirometry quality control Yes 8 
Range of results   
Sensitivity  57-93% 
Specificity  24-80% 
Severity of new COPD cases  ≥80% 11-39% 
(FEV1 % predicted)*** 50-80% 43-61% 
 <50% 10-37% 
AO=airflow obstruction, BD=bronchodilator, FEV1=forced expiratory volume in 1 second, FVC=forced 
vital capacity 
*Also referred to as the Respiratory Health Screening Questionnaire and the International Primary 
Airways Group (IPAG) questionnaire 
**Pre-BD FEV1/FVC<88.5% predicted for men & FEV1/FVC<89.3% for women 
***Based on 5 studies 
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Table 2.3 Characteristics of studies evaluating handheld flow meters (4 studies) (14, 22, 28, 29) 
Characteristic  Range/no. of studies 
Study designs Cross-sectional test accuracy study 4 
Participants  305-2464 
Mean age (years)  52.0-65.3 
Male (%)  43.3-99.7 
Required smoking status Only current/ex-smokers 3 
 Included never smokers 1 
Required respiratory symptoms  0 
Setting General practice(s) 4 
Number of centres  4-25 
 Multicentre 4 
Recruitment strategy Active 1 
 Opportunistic 2 
 Active & opportunistic 1 
Handheld flow meter   
Device Piko-6® 3 
 COPD-6® 1 
Operator Nurse 2 
 GP 1 
 Not reported 1 
Use of bronchodilator Pre-bronchodilator 3 
 Post-bronchodilator 1 
Test threshold FEV1/FEV6< 0.70-0.75 
Reference test- spirometry   
Post-bronchodilator  4 
Definition of AO Post-BD FEV1/FVC<0.7 4 
Included symptoms in definition of COPD 0 
Spirometry quality control Yes 2 
 No 1 
 Unclear 1 
Range of results   
Sensitivity  79-86% 
Specificity  71-99% 
Severity of new COPD cases  ≥80% 35-48% 
(FEV1 % predicted) 50-80% 48-65% 
 <50% 0-16% 
AO= airflow obstruction, BD=bronchodilator, FEV1=forced expiratory volume in 1 second, FVC=forced 
vital capacity, RCT=randomised controlled trial 
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2.4.4 Index and reference tests 
All studies first applied one or more index tests to the eligible population and then 
performed the reference test (spirometry) on either all (n=8 studies) or a random 
sample (25, 28) (n=2) of subjects. Index tests included screening questions or 
questionnaires (n=8) and handheld flow meters (n=4). One study also assessed the 
combined accuracy of using a screening questionnaire sequentially with a handheld 
flow meter.(14) No studies evaluating other screening tests met the inclusion criteria.  
2.4.5 Reference standard 
Pre- and post-bronchodilator spirometry was the reference standard in two (25, 27) 
and eight studies, respectively. Most studies sufficiently described spirometry and 
quality control procedures. Spirometry was performed by trained technicians (n=4), 
GPs (n=1), pulmonary physicians (n=1) and nurses (n=2), while quality control was 
usually performed by a respiratory specialist or physiologist who reviewed spirometry 
results. 
2.4.6 Methodological quality 
Most studies gave a clear description of participants, index and reference tests, and 
diagnostic criteria (Figure 2.2 and Table S2.4). However there was often 
underreporting of withdrawals (n=4), participant flow diagrams (n=5), and 
uninterpretable spirometry tests (n=5). The main risk of bias arose from inadequate 
blinding between index and reference tests (n=7; Figures 2.3 and 2.4). There was 
also potential for bias in the flow and timing domain (n=5), where the number of 
participants undergoing index and reference tests was unclear, and where significant 
numbers of participants were excluded from the analysis.  
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Figure 2.2 Quality of reporting
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Uninterpretable, indeterminate or intermediate results reported
Clinical data available representative of routine practice
Index test described sufficiently to permit replication
Index test performed and interpreted independently of spirometry
Spirometry performed and interpreted independently of index test
All/random selection of participants underwent spirometry
Spirometry performed within six months of index test
Quality diagnostic spirometry as reference standard
Standard diagnostic criteria
Spirometry quality control
Participant flow diagram
Clear description of withdrawals
Representative spectrum of patients
Clear description of participants
Clear description of selection criteria
Clear description of recruitment
Yes
No
Unclear
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Figure 2.3 Risk of bias and applicability concerns graph: review authors' judgements about 
each domain presented as percentages across included studies 
 
  
Figure 2.4 Risk of bias and applicability concerns summary: review authors' judgements about 
each domain for each included study 
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2.4.7 Screening questionnaires 
Altogether four screening questionnaires were evaluated on a total of 9472 
participants in eight studies (Table 2.2), of which the COPD Diagnostic Questionnaire 
(CDQ),(13) also referred to as the International Primary Airways Group (IPAG) 
Questionnaire,(14) was the most widely validated (n=4).  All instruments included 
questions related to the presence of respiratory symptoms (usually cough, dyspnoea 
and wheeze). Other items included in some, but not all questionnaires related to 
smoking history, allergies, age, body mass index (BMI) and physical functioning. 
Overall, participants were similar in age (range 52.3 to 65.3 years) but varied by sex 
(range 38 to 69% male). 
2.4.7.1 COPD Diagnostic Questionnaire 
Four studies (13, 14, 22, 24) that evaluated the CDQ in ever smokers were included 
in a meta-analysis. Using a score threshold of ≥19.5 the pooled sensitivity was 64.5% 
(95% CI 59.9% to 68.8%) and specificity 65.2% (95% CI 52.9% to 75.8%; Table 2.4). 
With a prevalence of undiagnosed COPD of 5.5%, this gave a PPV of 9.7% (95% CI 
6.9% to 14.2%), NPV of 96.9% (95% CI 95.8% to 97.7%), and would require 29 
individuals (95% CI 27 to 31) to complete the CDQ and 11 (95% CI 7 to 15) to 
undergo a diagnostic assessment to identify one individual with COPD.  At a lower 
score threshold of ≥16.5, the pooled sensitivity was higher but the specificity lower, 
requiring 21 individuals (95% CI 20 to 22) to complete the questionnaire and 13 (95% 
CI 11 to 16) to undergo a diagnostic assessment for each new diagnosis. 
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2.4.7.2 All other questionnaires 
There was considerable between-study heterogeneity in the design of other 
screening questionnaires, which precluded their meta-analysis. In these four studies, 
sensitivities ranged from 57% to 88% and specificities from 25% to 80% (Figure 2.5). 
 
Figure 2.5 Forest plot of sensitivity and specificity of each screening test 
TP= true positive, FP= false positive, FN= false negative, TN= true negative 
1. Binary response questionnaire, 2. Multiple response questionnaire  
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Table 2.4 Summary estimates of the accuracy of each test for diagnosis of COPD in ever smokers 
Index test Studies Cases/ 
Participants 
Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
PPV 
(95% CI) 
NPV 
(95% CI) 
NNS 
(95% CI) 
NND 
(95% CI) 
CDQ (score ≥19.5) 3 495/1703 64.5 
(59.9-68.8) 
65.2 
(52.9 -75.8) 
9.7 
(6.9-14.2) 
96.9 
(95.8-97.7) 
29 
(26-31) 
11 
(7-15) 
CDQ (score ≥16.5) 4 580/2322 87.5 
(83.1-90.9) 
38.8 
(27.7-51.3) 
7.7 
(6.3-9.8) 
98.2 
(96.6-99.0) 
21 
(20-22) 
13 
(11-16) 
Handheld flow meters 3 224/1133 79.9 
(74.2-84.7) 
84.4 
(68.9-93.0) 
23.0 
(12.2-41.3) 
98.6 
(97.9-99.1) 
23 
(22-24) 
5 
(3-9) 
CDQ &  
handheld flow meter 
1 90/624 74.4 
(64.2-83.1) 
97.0 
(95.2-98.3) 
59.1 
(43.8-74.0) 
98.5 
(97.9-99.0) 
25 
(22-29) 
2 
(2-3) 
CDQ=COPD Diagnostic questionnaire, PPV=positive predictive value, NPV=negative predictive value, NNS=number-needed-to-screen to identify one with 
COPD, NND=number of diagnostic assessments needed to identify one individual with COPD 
The PPV, NPV, NNS and number of subjects requiring a diagnostic assessment to identify one individual with COPD have been calculated assuming a 
prevalence of undiagnosed COPD of 5.5% in a theoretical population of 1000 people. 
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2.4.8 Handheld flow meters 
The test accuracy of handheld flow meters was evaluated in 1400 participants across 
four studies (Table 2.3).(14, 22, 28, 29) Subjects were similar in age (range 52 to 
65.3 years) but varied by sex (range 43 to 99.7% male). Only one study included 
never smokers and stratified the results by smoking status.(14)  
Handheld flow meters differ from diagnostic spirometers in that they are limited to 
measuring the forced expiratory volume in one and six seconds (FEV1 and FEV6, 
respectively), are usually performed with three blows and are cheaper and quicker to 
administer. They were used without a bronchodilator in three studies (22, 28, 29) and 
were supervised by either trained nurses or GPs. A narrow range of thresholds were 
used to denote a positive test ranging from FEV1/FEV6<0.7-0.75. 
Their sensitivity ranged from 79% to 86% and specificity from 71% to 99% (Table 
2.3). Three studies (14, 22, 29) that enrolled ever smokers were similar enough to be 
included in a meta-analysis. The pooled sensitivity was 79.9% (95% CI 74.2% to 
84.7%) and specificity was 84.4% (95% CI 68.9% to 93.0%). Using the same 
assumptions, this would require 23 individuals (95% CI 22 to 24) to be screened and 
5 (95% CI 3 to 9) to undergo a diagnostic assessment to identify one individual with 
COPD (Table 2.4). 
3.4.9 Combination of tests 
In the single study that reported the combined accuracy of a screening questionnaire 
(CDQ) with a handheld flow meter, the sensitivity was 74% (95% CI 64 to 83%) and 
specificity 97% (95% CI 95 to 98%).(14) This would reduce the need for diagnostic 
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assessment to two individuals (95% CI 2 to 3) to identify one with COPD (Table 2.4 
and Figure 2.6). 
2.4.10 Comparison of test accuracy 
Based on an indirect comparison in ever smokers, there was evidence that the CDQ 
at a score threshold of ≥19.5 had a lower sensitivity (p=0.003) but no difference in 
specificity (p=0.09) compared to handheld flow meters. At the lower score threshold 
of ≥16.5 (or 17), there was evidence to suggest a higher sensitivity (p=0.03) but a 
much lower specificity (p=0.01) than handheld flow meters. Two studies directly 
compared handheld flow meters and the CDQ (14, 22) and their findings were 
consistent with the results of the indirect comparison. Furthermore, Frith and 
colleagues (22) also reported both higher sensitivity and specificity of handheld flow 
meters compared to the CDQ at the score threshold of ≥19.5. 
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Figure 2.6 Test accuracy of each screening test in a hypothetical population of 100 individuals, 
five of whom have undiagnosed COPD 
CDQ=COPD Diagnostic Questionnaire (score threshold) 
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2.5 Discussion  
2.5.1 Summary of evidence 
This review incorporated evidence on the test accuracy of questionnaires and 
handheld flow meters for COPD screening in primary care. The CDQ developed by 
Price and colleagues (13) was the most widely validated of the four screening 
questionnaires included. However use of handheld flow meters under the supervision 
of trained health professionals was significantly more accurate than the CDQ for 
discriminating between ever smokers with and without COPD and a combination of 
both instruments may improve the accuracy still further, potentially reducing the 
number of diagnostic assessments required.(14) Studies evaluating the CDQ and 
handheld flow meters had generally few methodological biases, the main being 
insufficient clarity on blinding between index and reference tests. 
Unfortunately only one study by Kotz and colleagues (24) considered the accuracy of 
a screening test (handheld flow meter) for identifying airflow obstruction in 
symptomatic patients (reporting cough, sputum, or dyspnoea), which is closer to 
identifying clinical COPD. The remainder evaluated the accuracy for identifying 
airflow obstruction without explicitly requiring the presence of symptoms. 
Nevertheless the results are still likely to apply since the findings from Kotz et al (24) 
were very similar to studies that did not exclusively select patients with respiratory 
symptoms. 
2.5.2 Relationship to other studies 
The US Preventive Services Task Force (USPSTF) and the UK National Screening 
Committee recommended against routine screening for COPD partly due to concerns 
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about efficiency and costs.(12, 30) However the USPTF evidence review did not 
consider the use of screening tests such as questionnaires and handheld flow meters 
that may help triage high risk patients for diagnostic assessment as suggested by our 
findings. Screening was recommended against on the basis that it would lead largely 
to the diagnosis of mild disease, for which there is limited evidence on effective 
interventions.(12, 31) However, a significant proportion of new diagnoses of COPD in 
our included studies had moderate-to-severe airflow obstruction (48.9% (24) to 
88.5% (27) with an FEV1 <80% predicted)- these patients are likely to benefit from 
established therapies for COPD.(8) 
In 2005 van Schayck and colleagues (15) compared symptom-based questions for 
identifying COPD (pre-bronchodilator FEV1/FVC<lower limit of normal) and validated 
their accuracy using data from NHANES III. Age, BMI, smoking status, smoking 
intensity, self-reported asthma, chronic bronchitis or emphysema, and chronic cough 
or phlegm represented the optimal combination of variables for identifying individuals 
with airflow obstruction, having a sensitivity of 71% and specificity of 67%. Many of 
these risk factors have been incorporated in screening questionnaires evaluated in 
our review and their combined accuracy appears to be lower than handheld flow 
meters. Furthermore a meta-analysis of studies evaluating the accuracy of 
FEV1/FEV6 measured by standard diagnostic spirometry for detecting airflow 
obstruction showed it has a sensitivity of 89% (95% CI 83 to 93%) and specificity of 
98% (95 to 99%).(32) While the accuracy of handheld flow meters (which measure 
FEV1/FEV6) appears to be lower than this, the findings from the current review 
suggest that they are still sufficiently accurate to screen for airflow limitation. 
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Finally, two recent relevant studies were identified that fell outside the time window of 
the literature search. The first invited ever smokers aged 40-85 years from 36 
general practices to complete the CDQ and perform pre- and post-bronchodilator 
spirometry.(33) The CDQ showed a sensitivity and specificity of 63.0% and 70.1%, 
respectively when using a score threshold of ≥19.5 and 79.7% and 46.8% using a 
cut-point of ≥16.5. The second study evaluated the NPV of handheld flow meters 
among a small sample (n=54) of ex-smokers aged ≥50 years who had been referred 
for diagnostic post-bronchodilator spirometry by their GP.(34) The NPV was 
estimated at 94.4% (95% CI 86.4 to 98.5%) when using the fixed ratio of 
FEV1/FVC<0.7 to define airflow obstruction. Both findings are in keeping with the 
meta-analyses in the current review. 
2.5.3 Strengths and weaknesses of the review 
Strengths of this review include the methods used to identify and appraise the 
available literature. Other than the limitation of the case definition discussed above, 
the weaknesses result mainly from the methodological limitations of included studies, 
particularly with respect to inadequate reporting of withdrawals and indeterminate 
results and blinding of operators performing and interpreting index and reference 
tests. This may have resulted in overestimation of test accuracy since positive index 
tests could plausibly influence performance and interpretation of reference 
spirometry. There was also a lack of head-to-head comparisons with only two studies 
evaluating more than one screening test.(14, 22) Indirect comparisons are potentially 
biased because of differences in population and study characteristics. 
The criteria for airflow obstruction used in the included studies is also a point of 
contention given that that using a fixed cut-off of FEV1/FVC<0.7 may lead to 
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overdiagnosis of the elderly.(35) Future studies should therefore consider using a 
definition that accounts for age, sex and ethnicity biases, ideally using an FEV1/FVC 
ratio below the lower limit of normal (36) and using the fixed ratio for sensitivity 
analyses. Interpretation and comparison of studies included in this review was made 
difficult due to differences in the definition of COPD, including differences in the use 
of pre- and post-bronchodilator spirometry to demonstrate and define airflow 
obstruction. Future studies should use standard definitions of COPD to ensure the 
reference standards are consistent across studies. 
Finally, the included studies did not report acceptability and uptake of screening 
tests, which are all important for evaluating their overall effectiveness. This review 
can therefore only be used to comment on test accuracy and not on comparative 
clinical and cost-effectiveness in routine practice, which ideally should be evaluated 
through head-to-head trials. 
2.5.4 Implications for research and practice 
The findings suggest that handheld flow meters are likely to be more accurate than 
questionnaires for COPD screening in primary care. This finding is perhaps 
predictable, given that in the majority of included studies COPD was defined solely 
by the presence of airflow obstruction demonstrated by spirometry. Handheld flow 
meters measure two parameters (FEV1 and FEV6) captured by standard spirometry 
(the reference standard), and therefore are likely to be superior to questionnaires. 
However several key limitations of previous studies are also highlighted. Future 
studies should provide clear descriptions of withdrawals, including participant flow 
diagrams, ensure that spirometry is performed without prior knowledge of index tests, 
and that indeterminate results particularly with respect to spirometry, are reported. 
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Future studies should also aim to recruit subjects with no prior diagnosis of COPD 
(thus reducing the risk of spectrum bias (37)) and use a case definition that includes 
presence of respiratory symptoms to increase generalizability to real-life practice. 
More studies are needed to evaluate the accuracy and effectiveness of combining 
screening tests and to assess their cost-effectiveness. Finally, it remains unclear 
whether early detection of COPD significantly improves clinical outcomes and quality 
of life. This should first be demonstrated in prospective studies before firm 
recommendations are made. 
2.5.5 Conclusions 
Handheld flow meters used under the supervision of a trained health professional are 
more accurate than the CDQ for detecting spirometry-confirmed COPD in primary 
care. Limited evidence suggests that combining both tests may potentially improve 
test accuracy. Future studies should employ a case definition of COPD that aligns 
with current recommendations and include head-to-head comparisons.  
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2.6 Supplementary Tables 
Table S2.1 Characteristics of included studies 
Study Country Setting Recruitment method Eligibility criteria Index/reference tests Definition of COPD 
Buffels 
2004 (25) 
Belgium 20 general 
practitioners 
Invited patients routinely 
attending general practice over a 
12 week period in 1999. 
Inclusion criteria: 
Age 35-70 years 
Exclusion criteria: 
Receiving bronchodilators 
and/or inhaled 
corticosteroids 
Index test:  
Screening questionnaire 
Reference test:  
Pre-BD spirometry in all 
subjects with respiratory 
symptoms and 10% 
sample of asymptomatic 
subjects 
Pre-BD 
FEV1/FVC<88.5% 
predicted for men & 
FEV1/FVC<89.3% for 
women 
Duong-
Quy  
2009 (28) 
Vietnam 12 primary 
care medical 
centres in 
one city 
Broadcast an advertisement on 
the local television daily for one 
week. A recruitment company 
was used to help with participant 
recruitment (details not 
reported). Eligible subjects 
expressing an interest in 
participating were advised to 
attend one of the 12 primary 
care centres from January 2007 
to February 2008. 
Inclusion criteria: 
Active and former 
smokers with >10 pack-
years and aged >40 years 
Exclusion criteria: 
Previously diagnosed 
respiratory disease 
(asthma, COPD and 
tuberculosis) 
Index test: 
Pre-BD handheld flow 
meter (Piko-6®) 
Reference test: 
Full medical assessment 
including clinical 
examination, pulmonary 
radiology, ECG, and 
post-BD spirometry for 
those who had an index 
FEV1/FEV6<0.7 and a 
sample of those with 
FEV1/FEV6≥0.7 
Post-BD 
FEV1/FVC<0.7 with 
<200mL or 12% 
reversibility 
54 
 
Study Country Setting Recruitment method Eligibility criteria Index/reference tests Definition of COPD 
Freeman 
2005 (26) 
UK One general 
practice 
Postal invitation from October 
1997 to April 2002. 
Inclusion criteria: 
Age ≥40 years & 
current/ex-smoker & had 
either received respiratory 
medications in the 
preceding 2 years or had 
a history of asthma  
Exclusion criteria: 
None 
 
Index test:  
Screening questions 
Reference test:  
Pre-/ post-BD 
spirometry on all 
subjects 
Post-BD 
FEV1/FVC<0.7 and 
lack of reversibility 
(reversibility defined 
as increase in FEV1 
of 200mL and 15% 
from pre-BD FEV1 
(not clear if all were 
post-BD) 
Frith  
2011 (22) 
Australia 4 primary 
care 
practices 
Recruited during routine practice 
visits, invitation to study days, 
and local newspaper 
advertisement between August 
and December 2006. 
Inclusion criteria: 
Age ≥50  years & 
current/ex- smoker & no 
prior diagnosis of 
obstructive lung disease 
(COPD, emphysema, 
chronic bronchitis, 
asthma) & no treatment 
for obstructive lung 
disease in past 12months 
Exclusion criteria: 
Refusal or inability to give 
consent, pre-existing non-
obstructive lung disease, 
symptoms suggestive of 
unstable heart disease, 
and spirometry 
contraindications  
Index test:  
Pre-BD handheld flow 
meter (Piko-6®) & 
screening questionnaire 
(COPD Diagnostic 
Questionnaire) 
Reference test:  
Pre-/ post-BD 
spirometry on all 
patients 
 
Post-BD 
FEV1/FVC<0.7 
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Study Country Setting Recruitment method Eligibility criteria Index/reference tests Definition of COPD 
Hanania 
2010 (27) 
US Two family 
physician 
group offices 
Invited patients aged ≥40 years 
visiting the practices from 
March-May 2008 
Inclusion criteria: 
Age ≥40 years 
Exclusion criteria: 
None 
Index test:  
Screening questionnaire 
(Lung Function 
Questionnaire) 
Reference test:  
Pre-BD spirometry 
Pre-BD 
FEV1/FVC<0.7 
Kotz  
2008 (24) 
Netherlands General 
population 
and primary 
care 
practices 
Advertisements in a local 
newspaper, flyers, posters and 
mailings to households and 
invitation during primary care 
consultations from 
Jan 2005-Dec 2006. 
Inclusion criteria: 
Age 40-70 years  & 
current smoker with ≥10 
pack years & motivated to 
stop smoking & able to 
read and speak Dutch & 
reporting a respiratory 
symptom (cough, phlegm 
or dyspnoea) 
Exclusion criteria: 
Prior respiratory 
diagnosis, spirometry in 
previous 12 months or 
contraindications to 
smoking cessation therapy 
Index test:  
Questionnaire (COPD 
Diagnostic 
Questionnaire) 
Reference test:  
Pre-/post-BD spirometry 
in all participants 
Post-BD 
FEV1/FVC<0.7 
Mintz 
2011 (23) 
US 36 primary 
care centres 
NR Inclusion criteria: 
Age ≥30 years old & 
current/ex- smoker with 
≥10 pack years  
 
Exclusion criteria: 
Regular use of respiratory 
medications within 4 
weeks of the study, known 
diagnosis of substantial 
lung conditions with 
regular use of respiratory 
medications. 
Index test:  
Screening questionnaire 
(Lung Function 
Questionnaire) 
Reference test:  
Pre-/ post-BD 
spirometry 
LFQ≤18 & post-BD 
FEV1/FVC<0.7 
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Study Country Setting Recruitment method Eligibility criteria Index/reference tests Definition of COPD 
Price  
2006 (13) 
UK & US 2 primary 
care 
practices 
Postal invitation Inclusion criteria: 
Age ≥40 years & 
current/ex-smoker 
Exclusion criteria: 
Refusal to consent, history 
of non-obstructive lung 
disease, use of respiratory 
medications in past year, 
acute symptoms of 
unstable heart disease 
Index test:  
Screening questionnaire 
(COPD Diagnostic 
Questionnaire) 
Reference test:  
Pre-/post-BD spirometry  
Post-BD 
FEV1/FVC<0.7 
Sichletidis 
2011 (14) 
Greece 25 general 
practices 
Invited first 50 patients meeting 
the inclusion criteria who visited 
each participating GP from 1st 
March-31st May 2009. 
Inclusion criteria: 
Age >40 years 
Exclusion criteria: 
Confirmed diagnosis of 
lung disease, thoracic 
surgery in previous 6 
months, acute respiratory 
infection, uncontrolled 
cardiac disease, or could 
not perform acceptable 
spirometry 
Index tests:  
1. Screening 
questionnaire 
(International Primary 
Airways Group 
Questionnaire, also 
known as the COPD 
Diagnostic 
Questionnaire) 
2. Post-BD  handheld 
flow meter (Piko-6®) 
(Bronchodilator=400µg 
salbutamol) 
Reference test:  
Pre-/post-BD spirometry  
Post-BD 
FEV1/FVC<0.7 
Thorn 
2012 (29) 
Sweden 21 primary 
healthcare 
centres 
Invited patients attending 
participating primary healthcare 
centres over a 5 month period. 
Inclusion criteria: 
Age 45-85 years 
& current/ex-smoker with 
≥15 pack years 
Exclusion criteria: 
None 
Index test:  
Pre-BD handheld flow 
meter (COPD-6) 
Reference test:  
Pre-/post-BD spirometry  
Post-BD 
FEV1/FVC<0.7 
BD=bronchodilator, FEV1=forced expiratory volume in one second, FEV6=forced expiratory volume in 6 seconds, FVC=forced vital capacity, NR=not reported 
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Table S2.2 Results: studies evaluating screening questionnaires 
Study Population Questionnaire Spirometry (reference test) Number screened New COPD cases  
Buffels  
2004 (25) 
Eligible: 3158 
Invited: 3158 
Attended: 3158  
Data on subjects 
who underwent 
spirometry 
Mean age: NR 
Male: 45%  
Smoking status 
Current: 30.7%  
Former: 18.1% 
Never: 50.1%  
 
Items 
 Cough >2 weeks 
 Dyspnoea during 
mild exercise/at 
night 
 Nasal allergy/hay 
fever 
 Visit to doctor for 
wheeze or chronic 
cough 
Threshold  
≥1 symptom 
 
Device: Spirobank spirometer with Winspiro 
software 
Bronchodilator: None 
Operator: GPs who had received 12 hours 
of training 
Standard: NR 
Quality control: Technical support was 
provided to GPs throughout the study. 
Accuracy of GP-performed spirometry was 
compared to that from a lab technician. 
Index test 
Total: 3158 
Positive: 728 
Reference test 
(spirometry) 
Total: 703 with positive 
index test and 222 with 
negative index test. 
Acceptable quality: NR 
Subjects with 
positive index test: 
126/703 (17.9%)  
Subjects with 
negative index test: 
9/222 (4.1%)  
FEV1 % predicted 
>80%: 53 (39%) 
50-80%: 69 (51%) 
30-50%: 12 (9%) 
≤30%: 1 (<1%) 
 
Freeman  
2005 (26) 
Eligible: 1195 
Invited: 1195 
Attended: 624 
Data on subjects 
who performed 
spirometry 
Mean age: 61.7   
Male: 52%  
Smoking status 
Current: 54.1%  
Former: 45.9% 
Items 
 Age 
 Smoking status 
 Pack-years 
 Cough 
 Dyspnoea 
 Wheeze 
Threshold  
NR (included only “best” 
reported) 
 
Device: Micro-Med handheld spirometer 
with Spida software 
Bronchodilator: 5mg salbutamol for those 
with prior respiratory medication or history 
of asthma or FEV1<80% predicted 
Operator: Trained respiratory nurse 
Standard: ATS standards. Minimum of 3 
tests or until reproducibility within 5%. 
Quality control: All spirometry results were 
reviewed by a physician to ensure 
compliance with ATS standards. 
Index test 
Total: 369 
Positive: 121* (multiple 
response questionnaire), 
142* (binary response 
questionnaire) 
Reference test 
(spirometry) 
Total: 369 
Acceptable quality: NR  
62/369 (16.8%) 
FEV1 % predicted  
NR 
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Study Population Questionnaire Spirometry (reference test) Number screened New COPD cases  
Frith  
2011 (22) 
Eligible: 233 
Invited: 237 
Attended:237 
Data on subjects 
with acceptable 
spirometry 
Mean age: 61   
Male: 69%  
Smoking status 
Current: 45%  
Former: 55%  
Never: <1% 
COPD diagnostic 
questionnaire (CDQ) 
Items 
See Price 2006 (below) 
Thresholds: 
Score ≥19.5, ≥16.5 
Device: EasyOne spirometer (ndd Medical) 
Bronchodilator: 360mcg salbutamol 
Operator: trained operators using ATS/ERS 
guidelines 
Standard: ATS/ERS standards. At least 3 
adequate baseline and post-BD FVC 
manoeuvres performed. 
Quality control: spirometry quality 
monitored by a respiratory physiologist 
blinded to the questionnaire and Piko-6® 
results. 
Index test 
Total: 233 
Positive: 
110* (threshold ≥19.5), 
165* (threshold ≥16.5) 
Reference test 
(spirometry) 
Total: NR 
Acceptable quality: 204 
57/204 (27.9%) 
FEV1 % predicted 
>80%: 19 (33.3%) 
50-80%: 35 (61.4%) 
30-50%: 3 (5.3%) 
<30%: 0 
Hanania  
2010 (27) 
Eligible: NR 
Invited: NR 
Attended: 937 
Data on subjects 
with acceptable 
spirometry and 
adequate data 
Mean age: NR 
Male: 38.1%  
Smoking status  
NR 
Lung Function 
Questionnaire (LFQ) 
Items: 
 Age 
 Cough 
 Wheeze 
 Dyspnoea 
 Smoking 
Threshold:  
Score ≤18 
Device: EasyOne spirometer (ndd Medical) 
Bronchodilator: None 
Operator: NR 
Standard: NR 
Quality control: Investigators rated 
spirometry quality based on reliability and 
reproducibility. Only included traces 
considered reliable. 
Index test 
Total: 937 
Positive: 484* 
Reference test 
Total: 937  
Acceptable quality: NR 
Analysed: 837 
156/837 (18.6%) 
FEV1 % predicted 
≥80%: 17 (11.5%) 
50-80%: 76 (51.4%) 
30-50%: 44 (29.7%) 
<30%: 11 (7.4%) 
(NB. Reported 
numbers do not add 
up to 156) 
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Study Population Questionnaire Spirometry (reference test) Number screened New COPD cases  
Kotz  
2008 (24) 
Eligible: 1052 
Invited: 1052 
Attended: 826 
Data on subjects 
with spirometry 
Mean age:52.3  
Male:58.7% 
Smoking status 
Current: 100% 
COPD Diagnostic 
Questionnaire (CDQ) 
Items: 
See Price 2006 (below) 
Thresholds: 
Score ≥19.5, ≥16.5 
Device: Vitalograph 2120  
Bronchodilator: 500 µg terbutaline 
Operator: Two qualified research assistants 
under the supervision of a pulmonologist 
Standard: ATS/ERS standards 
Quality control: spirometry performed 
according to ATS/ERS standards. All 
spirometry test results were validated by a 
pulmonologist and specialised lung function 
laboratory assistant not involved in the trial- 
both were blinded to the questionnaire 
scores. 
Index test 
Total: 1052 
Analysed: 676  
Positive:  
549* (threshold ≥16.5)  
366* (threshold ≥19.5)  
Reference test 
Total: 826  
Acceptable quality: 716 
278/676 (41.1%) 
FEV1 % predicted 
≥80%: 142 (51.1%) 
50-80%: 119 
(42.8%) 
<50%: 17 (6.1%) 
  
 
Mintz  
2011 (23) 
Eligible: 1724 
Invited: 4956 
Attended: 2284 
Data on subjects 
who completed 
index test  
Mean age: 53.9* 
Male: 51.2% 
Smoking status 
Current: 57.6% 
Former: 42.4% 
Lung Function 
Questionnaire (LFQ) 
Items 
 Age 
 Cough 
 Wheeze 
 Dyspnoea 
 Smoking 
 Activity limitation 
Threshold 
Score ≤18 
Device: Biomedical Systems, St Louis, MO 
Bronchodilator: 360µg albuterol 
Operator: Trained site staff 
Standard: ATS standards 
Quality control: Only data collected from 
acceptable spirometric manoeuvres were 
included. Patients producing unacceptable 
spirometry were allowed to repeat this 
within 7 days of the study visit. 
Index test 
Total: 1575 
Positive: 1216 
Reference test 
(spirometry) 
Total: 1225 
Acceptable quality: 849 
(713 in subjects ≥40 
years)  
162/713 (22.7%) 
(NB. restricted to 
subjects ≥40 years) 
FEV1 % predicted  
NR 
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Study Population Questionnaire Spirometry (reference test) Number screened New COPD cases  
Price  
2006 (13) 
Eligible: NR 
Invited: 17,361 
Attended: 898 
Data on subjects 
with acceptable 
spirometry 
Mean age: 58.2 
Male: 49.3% 
 
Smoking status 
Current: 44.5% 
Former: 55.5% 
COPD Diagnostic 
Questionnaire 
Items 
 Age 
 Pack-years 
 Weather-affected 
cough 
 Productive phlegm 
in absence of a cold 
 Early morning cough 
 Wheeze  
 Allergies 
Thresholds 
Score ≥19.5, ≥16.5 
Device: EasyOne spirometer (ndd Medical)  
Bronchodilator: 2.5mg salbutamol/albuterol 
Operator: NR 
Standard: ATS standards 
Quality control: Principal investigators 
conducted blinded review of all spirometry 
loops. A pulmonologist not associated with 
the study reviewed all loops on which there 
was disagreement 
Index test 
Total: 898 
Positive:  
267* (threshold ≥16.5) 
446* (threshold ≥19.5) 
Reference test 
(spirometry) 
Total: 898 
Acceptable quality: 818 
572 (70%) used for 
questionnaire 
development, 246 (30%) 
used for validation 
155/818 (18.9%) 
FEV1 % predicted  
NR  
Sichletidis  
2011 (14) 
Eligible: 1250 
Invited: 1250 
Attended: 1250 
Data on subjects 
with acceptable 
spirometry 
Mean age: 65.3 
Male: 57.1% 
Smoking status 
Ever: 48.8% 
Never: 51.2% 
COPD Diagnostic 
Questionnaire (also 
referred to as 
International Primary 
Airways Group 
questionnaire) 
Items: 
See Price 2006 (above) 
Threshold 
Score ≥17 
Device: Vitalograph 
Bronchodilator:400µg salbutamol 
Operator: Pulmonary specialists 
Standard: ATS/ERS standards 
Quality control: Spirometry performed and 
interpreted by pulmonary specialists 
according to ATS/ERS standards 
Index test 
Total: 1250 
Positive: 
409* (smokers) 
594* (smokers & non-
smokers) 
Reference test 
(spirometry) 
Total: NR 
Acceptable quality: 1078 
Ever smokers: 
90/624 (14.4%) 
Ever smokers & 
non-smokers: 
111/1078 (10.3%) 
FEV1 % predicted 
≥80%:40 (36.0%) 
50-80%:53 (47.7%)  
30-50%:16 (14.4%) 
<30%:2 (1.8%) 
 
*Derived values (may differ from reported test performance) 
BD= bronchodilator, NR= not reported, FEV1= forced expiratory volume in 1 second, FVC= forced vital capacity, FEV6= forced expiratory volume in 6 seconds
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Table S2.3 Results: studies evaluating handheld flow meters 
Study Recruited 
population 
Handheld flow meter Spirometry (reference test) Number screened New COPD cases  
Duong-
Quy 
2009 (28) 
Eligible: 2464 
Invited: NR 
Attended: 2464 
Data on subjects 
who undertook index 
test 
Mean age: 52 
Male:99.7% 
Smoking status 
Current: 88.9% 
Former: 11.1% 
Pre-BD Piko-6® 
Operator: NR 
3 manoeuvres were 
taken and the best of 
3 selected. 
All measures where 
FEV1/FEV6>1 were 
excluded. 
Threshold 
FEV1/FEV6<0.7  
Device: SpiroLab II 
Bronchodilator: short-acting β2 agonist 
(unspecified) 
Operator: NR 
Standard: Required at least 3 measures 
and at least 2 within 150mL to ATS/ERS 
standards. 
Quality control: NR 
Index test 
Total: 2464 
Positive: 324 
Reference test 
(spirometry) 
Total: 144 subjects with 
positive index test and 
123 with negative index 
test. 
Acceptable quality: NR 
 
Subjects with 
positive index test: 
136/144 (94.4%)  
Subjects with 
negative index test: 
 3/123 (2.4%)  
FEV1 % predicted  
(in subjects with 
positive index test) 
<80%: 65 (47.8%) 
50-79%: 63 (46.3%) 
30-49%: 8 (5.9%) 
<30%: 0 
Frith  
2011 (22) 
Eligible: 233 
Invited: 237 
Attended:237 
Data on subjects 
with acceptable 
spirometry 
Mean age: 61   
Male: 69%  
Smoking status 
Current: 45%  
Former: 55%  
Never: <1% 
Pre-BD Piko-6®  
Operator: Study nurse 
or GP 
Threshold  
FEV1/FEV6<0.75 
(optimal cut-point) 
 
Device: EasyOne spirometer (ndd Medical) 
Bronchodilator: 360mcg salbutamol 
Operator: trained operators using ATS/ERS 
guidelines 
Standard: ATS/ERS standards. At least 3 
adequate baseline and post-BD FVC 
manoeuvres performed. 
Quality control: spirometry quality 
monitored by a respiratory physiologist 
blinded to the questionnaire and Piko-6® 
results. 
Index test 
Total: 233 
Positive: 101* 
Reference test 
(spirometry) 
Total: NR 
Acceptable quality: 204 
57/204 (27.9%) 
FEV1 % predicted 
>80%: 19 (33.3%) 
50-80%: 35 (61.4%) 
30-50%: 3 (5.3%) 
<30%: 0 
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Study Recruited 
population 
Handheld flow meter Spirometry (reference test) Number screened New COPD cases  
Sichletidis  
2011 (14) 
Eligible: 1250 
Invited: 1250 
Attended: 1250 
Data on subjects 
with acceptable 
spirometry 
Mean age: 65.3  
Male: 57.1% 
Smoking status 
Ever: 48.8% 
Never: 51.2% 
Post-BD Piko-6®  
Bronchodilator: 400µg 
salbutamol 
Operator: GPs with 2 
hours training 
Threshold  
Post-BD 
FEV1/FEV6<0.7 
Device: Vitalograph 
Bronchodilator: 400µg salbutamol 
Operator: Pulmonary specialists 
Standard: ATS/ERS standards 
Quality control: Spirometry performed and 
interpreted by pulmonary specialists 
according to ATS/ERS standards 
Index test 
Total: 1250 
Positive ǂ: 
104* (ever smokers) 
137* (ever smokers & 
non-smokers)  
Reference test 
(spirometry) 
Total: NR 
Acceptable quality: 1078 
Ever smokers: 
90/624 (14.4%) 
Ever smokers & 
non-smokers: 
111/1078 (10.3%) 
FEV1 % predicted 
≥80%:40 (36.0%) 
50-80%:53 (47.7%)  
30-50%:16 (14.4%) 
<30%:2 (1.8%) 
 
Thorn  
2012 (29) 
Eligible: NR 
Invited: NR 
Attended: 305 
Data on subjects 
who performed the 
index and reference 
tests 
Mean age: 61.2  
Male: 43.3% 
Smoking status 
Ever: 100% 
Pre-BD COPD 6® 
Operator: Nurses 
Threshold  
FEV1/FVC<0.73 
Device: NR 
Bronchodilator: 0.5mg terbutaline 
Operator: Nurses 
Standard: ATS standards 
Quality control: Spirometry performed 
according to ATS standards. No other 
quality control measures reported. 
Index test 
Total: 305 
Positive: 106* 
Reference test 
(spirometry) 
Total:305 
Acceptable quality: NR 
 
77/305 (25.2%) 
FEV1 % predicted 
≥80%:35 (45.5%) 
50-80%:41 (53.2%) 
30-50%:1 (1.3%) 
<30%:0 
 
*Derived values (may differ from reported test performance) 
ǂ 83* (smokers) and 109* (smokers & non-smokers) positive index tests when using a combination of the CDQ and handheld flow meter 
BD= bronchodilator, NR= not reported, FEV1= forced expiratory volume in 1 second, FVC= forced vital capacity, FEV6= forced expiratory volume in 6 seconds 
 
 
63 
 
Table S2.4 Quality of reporting 
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Clear description of recruitment Y Y Y Y Y Y N Y Y Y 
Clear description of participants N Y Y Y Y Y Y Y Y Y 
Clear description of withdrawals Y Y N N U Y Y Y Y N 
Participant flow diagram Y N N Y N Y Y Y N N 
Spirometry quality control Y N Y Y Y Y Y Y Y U 
Standard diagnostic criteria Y Y Y Y Y Y Y Y Y Y 
Representative spectrum of patients U N Y Y U Y Y Y Y Y 
Clear description of selection criteria Y Y Y Y Y Y Y Y Y Y 
Spirometry as reference standard Y Y Y Y Y Y Y Y Y Y 
Spirometry performed within six months of index test Y U Y Y Y U Y Y U Y 
All or random selection of participants underwent spirometry Y N Y Y Y Y N Y Y Y 
Spirometry performed and interpreted independently of screening test result U U U Y U Y U Y U U 
Screening test performed and interpreted independently of spirometry  Y Y U Y U Y U Y Y Y 
Intervention described in sufficient detail to permit its replication Y Y Y Y Y Y Y Y Y Y 
Clinical data available representative of routine practice Y Y Y Y Y Y Y Y Y Y 
Uninterpretable, indeterminate or intermediate results reported  N N N Y N Y Y Y Y N 
Y=yes, N=no, U=unclear 
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CHAPTER 3: EFFECTIVENESS OF 
COPD CASE FINDING IN PRIMARY 
CARE: A SYSTEMATIC REVIEW 
AND META-ANALYSIS 
This chapter is based on a published systematic review protocol: Haroon S, Adab PA, Jordan 
RE. Case finding for COPD in primary care: a systematic review (protocol). Primary Care 
Respiratory Journal. 2012: 21(3):354-7.  
3.1 Abstract 
Objective 
There is a large underdiagnosis of COPD worldwide but the most effective approach 
for identifying these patients is unknown. We report a systematic review to 
summarise relevant published literature. 
Methods 
Systematic review and meta-analysis of primary studies of any design evaluating 
case finding strategies for COPD in primary care among individuals aged ≥35 years 
with no prior diagnosis. Medline, Embase and other bibliographic databases were 
searched from 1997 to 2013 and methodological quality of included studies assessed 
using criteria adapted from the QUADAS-1, QUADAS-2 and Cochrane Risk of Bias 
tools. Results were tabulated and described and meta-analysis of the uptake of 
screening and diagnostic tests and the yield from different approaches was 
performed where there was sufficient homogeneity. 
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Results 
3 RCTs, 1 controlled trial and 35 uncontrolled studies were identified assessing the 
yield from case finding. A range of approaches were evaluated including use of 
screening questionnaires (n=13) or handheld flow meters (n=5) prior to diagnostic 
spirometry, or direct invitation to diagnostic spirometry (n=30). Studies were 
heterogeneous and were limited by a lack of comparison groups, inadequate 
reporting, and diversity in the definition of COPD. The comparative studies suggest 
that nurse-led case finding may be more effective than routine care, and that 
opportunistic invitation of patients clinically suspected to have COPD for spirometry is 
more effective than more widespread, public invitation for screening. Indirect 
comparisons suggest that uptake of screening is likely to be higher with opportunistic 
than postal invitation, and that targeting ever smokers with a history of respiratory 
symptoms may improve the yield. Screening with either questionnaires or handheld 
flow meters prior to diagnostic spirometry may uncover a similar proportion of 
patients with undiagnosed COPD compared to direct invitation for diagnostic 
spirometry but may reduce the number of diagnostic assessments needed.  
Conclusions 
There is extensive heterogeneity in studies evaluating case finding strategies for 
COPD, with few RCTs. There is a need for well conducted RCTs comparing case 
finding approaches to help identify the most effective target population, recruitment 
strategy and use of screening and diagnostic tests, that use a clinical definition of 
COPD, and address the limitations highlighted in this review. 
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3.2 Introduction 
COPD is the third leading cause of mortality,(1) is an important cause of disability,(2) 
and is a source of significant healthcare expenditure.(3) However, much of the 
disease burden remains undiagnosed with estimates as high as 70-90%.(4) People 
with undiagnosed COPD often under-recognise the significance of their 
symptoms,(5) and there is poor awareness of the condition among the general 
public.(6, 7) Clinicians in primary care also frequently miss opportunities to diagnose 
COPD.(8) Although undiagnosed patients are more likely to have  mild-to-moderate 
airflow obstruction, there are likely to be a significant number with more severe 
disease and symptom burden who would benefit from symptomatic or disease 
modifying therapies.(9) Furthermore, a higher prevalence of undiagnosed COPD has 
been associated with higher rates of COPD-related hospitalisations (10) and patients 
with undiagnosed COPD often receive their diagnosis during an acute hospital 
admission following an exacerbation.(11) There is now a policy drive to identify 
undiagnosed COPD earlier in the course of the disease in order to initiate secondary 
prevention,(12, 13) particularly smoking cessation support,(14) and to offer 
symptomatic relief through pulmonary rehabilitation,(15) and pharmacological 
therapies.(16) However, the optimal strategy for achieving this remains unknown.(17) 
A systematic review published in 2008 evaluated the effectiveness of population-
based screening for COPD using spirometry but concluded that this would identify 
many asymptomatic individuals with mild-to-moderate airflow obstruction, for whom 
there are limited therapeutic options.(18) However since then there have been a 
large number of studies conducted in primary care evaluating the effectiveness of a 
variety of potentially more efficient approaches for identifying undiagnosed COPD, 
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including the use of screening questionnaires (19) and handheld flow meters (e.g. 
Piko-6® or COPD-6®).(20)  The accuracy of screening tests for COPD was reviewed 
in the previous chapter but this did not consider the full screening process which 
depends also on the target population, method of recruitment, response rates, and 
uptake (Figure 3.1).  
This chapter reports a systematic review and meta-analysis to identify and compare 
the effectiveness (yield) of alternative case-finding approaches for COPD in primary 
care.  
  
Eligible population 
identified 
Complete screening test(s)  
 
Positive screening test(s) 
 
Invited for screening test  
 
Complete diagnostic 
test/assessment  
 
New cases of COPD 
 
Invited for diagnostic 
test/assessment  
 
Some studies perform 
diagnostic spirometry 
without applying an 
intermediate screening 
test 
 
Figure 3.1 Case finding pathway 
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3.3 Methods 
3.3.1 Protocol and registration 
The protocol for this review was previously published (21) and registered on the 
PROSPERO register of systematic reviews (CRD42012002074).(22)  
3.3.2 Eligibility criteria 
Since RCTs were known to be rare, primary studies of any design were sought that 
were conducted in primary care (including general practices and community 
pharmacies), and recruited individuals aged ≥35 years with no prior diagnosis of 
COPD, and aimed to detect undiagnosed COPD confirmed by pre- or post-
bronchodilator spirometry. Eligible screening tests included questionnaires, clinical 
examination, handheld flow meters, peak flow meters, decision aids/risk prediction 
models, and chest radiography, either alone or in combination.  
3.3.3 Search strategy 
The same search strategy was used to identify articles for both systematic reviews in 
this thesis. See section 2.3.4 and Table 2.1. 
3.3.4 Study selection and data extraction 
Titles and abstracts were screened independently by two reviewers. Full text papers 
were obtained for all potentially relevant studies and the eligibility criteria applied 
independently with disagreements resolved through discussion. Data were extracted 
on the characteristics of the selected population, approaches to recruitment, method 
of screening, number of participants newly diagnosed with COPD, and numbers who 
were eligible, participated in screening, and underwent diagnostic spirometry. Where 
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these data were not provided, where possible we used information provided in the 
paper to derive them.  
3.3.5 Methodological quality assessment 
Included studies were assessed independently by two reviewers against criteria 
adapted from the QUADAS-1  (23) and QUADAS-2  (24) checklists, and the 
Cochrane risk of bias assessment tool for RCTs.(25) Disagreements were resolved 
through discussion. 
3.3.6 Statistical analysis 
Results from comparative studies were described but not suitable for synthesis. We 
therefore used data from individual study arms of the trials together with the non-
comparative studies to summarise uptake of tests and yields. The yield was 
calculated as the proportion of all eligible subjects who were newly diagnosed with 
COPD. Where there was sufficient methodological homogeneity these were 
combined using random effects meta-analyses to estimate the uptake of screening 
and diagnostic tests and the proportion diagnosed with COPD for each case finding 
approach. Forest plots were constructed to visually explore between-study 
heterogeneity in the yield, including differences in population characteristics, 
screening tests, diagnostic criteria, and study design. All analyses were performed 
using Stata version 13.1 (Stata-Corp, College Station, Texas, USA) and StatsDirect 
version 2.7.9. 
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3.4 Results 
3.4.1 Study selection 
After removing duplicates, 2605 citations were identified and 266 full-text articles 
assessed for eligibility (Figure 3.2). 39 studies were finally selected from which 18 
were included in meta-analyses. Studies that did not exclude patients with previously 
known COPD, or did not provide sufficient data to separate out new from existing 
diagnoses of COPD, were excluded.  
  
Records identified through database 
searching 
(n = 3299) 
Additional records identified through 
other sources 
(n = 0) 
Records screened 
(n = 2605) 
Records excluded 
(n = 2339) 
Full-text articles assessed for 
eligibility  
(n = 266) 
Full-text articles excluded 
(n=227) 
Reasons for exclusion: 
Not a case finding study (14) 
Ineligible population/setting 
(64) 
Not a primary study (42) 
Inadequate outcome 
ascertainment (7) 
Primarily focused on 
detecting conditions other 
than COPD (15) 
Unclear population (7) 
Included subjects with known 
COPD (47) 
No relevant outcomes (16) 
Insufficient data (4) 
Unable to acquire full text 
article (11) 
 
Studies included  
(n = 39) 
Studies included in 
quantitative synthesis (meta-
analysis) 
(n = 18) 
Duplicates removed 
(n = 686) 
Figure 3.2 Article selection 
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3.4.2 Overall study characteristics  
Of the 39 included studies, there were two individually randomised controlled trials 
(RCTs), one cluster RCT, one non-randomised controlled trial, 25 single arm before-
after studies and ten cross-sectional test accuracy studies (Table S3.1). Most were 
conducted in general practices (n=34) and two were conducted in community 
pharmacies. They evaluated the use of screening questionnaires (n=13), handheld 
flow meters (n=5), and diagnostic spirometry (n=30). No studies evaluating other 
screening tests met the inclusion criteria.  
3.4.3 Comparative studies  
The comparative studies were highly heterogeneous with major differences in trial 
design (individually randomised controlled trials, cluster RCT, and non-randomised 
controlled trial) and comparators (usual care, invitation of high risk patients for 
spirometry, and screening with questionnaires; Table 3.1). An RCT of nurse-led case 
finding using written invitations to attend post-bronchodilator spirometry among 
eligible patients in four general practices in Australia showed this to have a 2.3% 
(95%CI 0.7 to 3.9%) higher yield of new cases than usual care.(26) A cluster RCT in 
the Netherlands found that a practice-managed approach to scoring a respiratory 
screening questionnaire and arranging follow-up was more effective than leaving 
patients to score their own questionnaires and request a spirometry assessment 
(difference in yield 0.9% [0.5 to 1.3%]).(27) Our own pilot trial of postal versus 
opportunistic invitation for screening using a respiratory questionnaire prior to pre-
bronchodilator diagnostic spirometry indicated that a postal questionnaire might lead 
to higher yield though the study lacked sufficient power to detect a significant 
difference.(28) Finally, a non-randomised trial comparing public invitation for 
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spirometry for people with chronic respiratory symptoms (cough, sputum production, 
wheeze, or dyspnoea) to offering pre-/post-bronchodilator spirometry to patients 
attending primary care suspected by their GP to have COPD, found that the latter 
approach resulted in a significantly higher yield (difference in yield 18.6% (95% CI 
12.6 to 24.6%]).(29) These comparative studies suffered from methodological 
problems but the main risks of bias arose from problems of randomisation, 
inadequate blinding of assessors to intervention arms and insufficient clarity about 
whether the populations in trial arms were comparable (Table 3.2). There was too 
much heterogeneity in their design and outcomes to combine their results. 
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Table 3.1 Comparative studies 
Study Study design & 
setting 
Eligibility criteria Intervention Comparator COPD definition COPD1/eligible2 Limitations 
Bunker  
2009 (26) 
RCT: nurse-led 
case finding 
using spirometry 
versus usual 
care in four 
practices 
(recruitment 
dates not 
reported) 
Inclusion criteria 
Ever smokers 
aged 40-80 years  
Exclusion criteria 
Known diagnosis 
of COPD, cognitive 
impairment, non-
English speaking, 
and <2 visits to 
practice in 
preceding year 
Case finding 
arm 
Spirometry 
(unclear whether 
pre- or post-BD) 
performed by 
practice nurses 
Routine care FEV1/FVC<70% 
(unclear whether 
pre- or post-BD) 
Case finding 
10/400 (2.5%) 
Routine care  
1/408 (0.2%) 
Difference in 
yield=2.3% (95% 
CI 0.7 to 3.9%) 
Method of 
randomisation 
not described. 
Inadequate 
outcome 
ascertainment. 
Outcome 
assessors not 
blinded. 
Unclear whether 
intervention 
groups 
comparable. 
Dirven 
2013 (30) 
Cluster RCT: 
patient versus 
practice-
managed 
scoring of a 
screening 
questionnaire in 
16 general 
practices from 
May to 
September 2012 
Inclusion criteria 
Age 40-70 years 
Exclusion criteria 
Previous diagnosis 
of asthma, COPD 
or significant lung 
disease. Also 
excluded patients 
using oxygen 
supplementation 
and with impaired 
mobility. 
Patient-
managed arm 
Stage 1 
 Patients mailed 
Respiratory 
Health Screening 
Questionnaire, 
self-calculated 
risk of COPD and 
advised to 
consult GP if 
score >19.5 
Stage 2: 
Post-BD 
spirometry for 
subjects scoring 
>19.5 
Practice-
managed arm 
Stage 1 
 Patients were 
mailed the 
questionnaire but 
scoring 
performed by 
healthcare staff 
Stage 2: 
Post-BD 
spirometry on 
subjects scoring 
>19.5 
Post-BD 
FEV1/FVC<0.7  & 
physician’s clinical 
evaluation 
Patient-managed  
25/6393 (0.4%) 
Practice-
managed 
48/3715 (1.3%) 
Difference in 
yield=0.9% (95% 
CI 0.5 to 1.3%) 
Unclear whether 
intervention 
groups 
comparable 
(although 
practices were 
stratified by 
socioeconomic 
status). 
Unclear whether 
outcome 
assessors were 
blinded. 
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Study Study design & 
setting 
Eligibility criteria Intervention Comparator COPD definition COPD1/eligible2 Limitations 
Haroon 
2013 (28) 
RCT: active 
versus 
opportunistic 
case finding in 
two general 
practices from 
May 2010 to 
January 2011 
Inclusion criteria 
Ever smokers 
aged 35-79 years.   
Exclusion criteria 
Prior diagnosis of 
COPD or asthma. 
Active arm 
Stage 1  
Postal screening 
questionnaire 
Stage 2  
Pre-BD 
spirometry in 
subjects with 
symptoms 
Opportunistic 
arm 
Stage 1  
Opportunistic 
screening 
questionnaire 
provided at 
routine primary 
care visits 
Stage 2  
Pre-BD 
spirometry in 
subjects with 
symptoms 
Pre-BD 
FEV1/FVC<0.7 with 
FEV1<80% 
predicted, lack of 
reversibility 
(reversibility 
defined as increase 
in FEV1 of 200mL 
and 15% from pre-
BD FEV1) and 
presence of 
respiratory 
symptoms. 
Active  
10/815 (1.2%) 
Opportunistic  
6/819 (0.7%) 
Difference in 
yield=0.5% (95% 
CI -0.5 to 1.5%) 
Unclear whether 
outcome 
assessors were 
blinded. 
Poor spirometry 
attendance. 
Konstantikaki 
2011 (29) 
Non-randomised 
controlled trial: 
open spirometry 
programme 
versus case 
finding strategy 
in 24 semirural 
general 
practices  from 
November 2008 
to October 2009 
Inclusion criteria 
>30 years 
Exclusion criteria 
History of 
respiratory tract 
infection in 
previous four 
weeks and inability 
to perform 
spirometry 
Open 
spirometry arm 
Public invitation 
through local 
advertisements 
offering free 
spirometry to 
people with 
chronic 
respiratory 
symptoms  
Case finding 
strategy 
Primary care 
physicians 
identified patients 
with a probable 
diagnosis of 
COPD in their 
daily practice and 
spirometry 
performed by 
research team. 
History of exposure 
to noxious particles 
or gases, 
particularly 
smoking, 
compatible 
symptoms, and 
post-BD 
FEV1/FVC<0.7 
Open spirometry  
76/1084 (7.0%) 
Case-finding  
56/219 (25.6%) 
Difference in 
yield=18.6% 
(95% CI 12.6 to 
24.6%) 
No 
randomisation. 
Poor description 
of recruitment, 
selection criteria 
and spirometry. 
1. Subjects newly diagnosed with COPD, 2. Eligible subjects  
BD=bronchodilator, NR=not reported, FEV1=forced expiratory volume in 1 second, FVC=forced vital capacity, RCT=randomised controlled trial 
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Table 3.2 Quality assessment of randomised controlled trials 
 Bunker 2009 (26) Haroon 2013 (28) Dirven 2013a (27) 
Adequate description of method of randomisation No Yes Yes 
Adequate description of method of allocation 
concealment 
No No No 
Comparison groups similar except for intervention 
received 
Unclear Yes Unclear 
Participants blinded to intervention arm Yes Yes Yes 
Outcome assessors blinded to intervention arm No No Unclear 
Outcome data completeness described for each 
outcome, including attrition and exclusions from the 
analysis 
No Yes Yes 
Evidence of selective outcome reporting No No No 
Other sources of bias  Inadequate outcome 
ascertainment in control group 
Poor spirometry 
attendance in both 
arms 
Did not report number of spirometry 
procedures that were of acceptable 
quality 
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3.4.4 Estimating the effect of different case-finding approaches using all 
data from uncontrolled studies and single arms of trials 
3.4.4.1 Methodological quality  
The majority of included studies were uncontrolled single-arm studies and were 
highly heterogeneous. They generally provided a clear description of recruitment, 
selection criteria, characteristics of screened and clinically assessed participants, and 
how spirometry was performed. Most used standard diagnostic criteria for COPD or 
airflow obstruction as the outcome. However there were deficiencies in the reporting 
of eligible populations (the complete targeted population), withdrawals, 
uninterpretable and indeterminate test results, participant flow, and spirometry quality 
control procedures (Figure 3.3, and Tables S3.2a/b). 
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Figure 3.3 Quality assessment  
*Only studies evaluating screening questionnaires and/or handheld flow meters  
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Uninterpretable, indeterminate or intermediate results reported
Clinical data available representative of routine practice
Intervention described in sufficient detail to permit its replication
All/random sample with +ve screening result underwent spirometry*
Spirometry performed within 6 months of index test*
Quality diagnostic spirometry as reference standard*
Standard diagnostic criteria
Spirometry quality control
Participant flow diagram
Clear description of withdrawals
Representative spectrum of patients
Clear description of participants
Clear description of selection criteria
Clear description of recruitment
Yes
No
Unclear
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3.4.4.2 Recruitment and population selection 
Participants were actively recruited through postal invitations, telephone calls, and 
advertisements (n=17 studies), opportunistically invited at primary care consultations 
(n=17), or recruited through a combination of both approaches (n=2; Table S3.1). 
Age (usually ≥40 years) and a positive smoking history were the main eligibility 
criteria although more than half of studies included never-smokers. A small number 
of studies specified additional eligibility criteria including presence of respiratory 
symptoms,(31-34) or recent acute respiratory infections.(35)   
3.4.4.3 Screening tests and diagnosis of COPD  
Strategies for targeting those at high risk included using basic patient characteristics 
only (e.g. age and smoking status (n=30)), use of respiratory screening 
questionnaires (n=13), and administration of handheld flow meters (n=5) prior to 
diagnostic spirometry. Only nine studies included a clinical component to the case 
definition of COPD, requiring reporting of relevant symptoms and exposures, or 
clinical judgment. All other studies used a purely physiological definition of COPD 
based on airflow limitation, most commonly a forced expiratory volume in one second 
to forced vital capacity ratio of less than 70% (FEV1/FVC<0.7; n=30). In addition, 13 
used pre-bronchodilator spirometry only for diagnosis. 
3.4.4.4 Yield of new COPD cases with different approaches 
Table 3.3 summarises the characteristics and yield of all of the included studies for 
each case finding approach. With direct invitation for diagnostic spirometry, the 
overall proportion of all eligible subjects newly diagnosed with COPD (as defined by 
each study), ranged from 1.7 to 30.5% (18 studies; Tables 3.4 and S3.3). Most had 
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mild-to-moderate disease although in some studies, a significant proportion (up to 
37.2%) had severe disease (FEV1<50% predicted).  Studies with the highest yields 
were mainly test accuracy studies and those that limited recruitment to symptomatic 
patients. 
Among 13 studies that used screening questionnaires prior to diagnostic spirometry 
(Tables 3.3, 3.5 and S3.4), the COPD Diagnostic Questionnaire (19) (CDQ- also 
referred to as the International Primary Airways Group Questionnaire, and the 
Respiratory Health Screening Questionnaire) was the most widely evaluated (n=5 
studies). Overall, new cases of COPD ranged from 0.4% to 22.3% of those eligible, 
again with the highest yields found in test accuracy studies.  
Five (mostly test accuracy) studies evaluated screening with handheld flow meters 
prior to diagnostic spirometry (Tables 3.3, 3.5, and S3.5). Overall, the yield (new 
cases of COPD) ranged from 6-20% of those eligible and all but one recruited 
patients only opportunistically. 
From this overview, because of the huge heterogeneity of methodology and 
participants it was not possible to determine which of the approaches had greater 
yield. However with an initial screening test (either a screening questionnaire or 
handheld flow meter) the yield from the final diagnostic assessment (i.e. the 
proportion of those diagnosed with COPD out of all those who underwent spirometry) 
seemed higher (19-94% when using handheld flow meters, 14.3-42.1% when using 
screening questionnaires, and 4.1-40.2% when directly inviting patients for diagnostic 
spirometry). 
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Table 3.3 Studies evaluating spirometry, screening questionnaires and handheld flow meters  
  Diagnostic spirometry 
(n=30) 
Screening questionnaires 
(n=13) 
Handheld flow meters 
(n=5) 
Study design RCT 1 1 0 
 Cluster RCT 0 1 0 
 Non-randomised trial 1 0 0 
 Test accuracy study 7 8 4 
 Single arm study 21 3 1 
Participants* Screened - 18,932 4759 
 Performed spirometry 63,087 8845 568 
 Diagnosed with COPD 10,428 1996 346 
Mean age (years)  47.9-65.3 52.3-65.3 52-65 
Male (%)  19.6-100 38.1-69 37.7-99.7 
Required smoking status Current/ex-smokers 11 7 2 
 Inc. never smokers 19 6 3 
Required respiratory symptoms 5 0 0 
Setting General practice(s) 24 12 5 
 Pharmacies 1 1 0 
 Other 3 0 0 
 Not reported 2 0 0 
Number of centres  1-821 1-36 3-25 
 Multicentre 24 12 5 
 Single centre 2 1 0 
 Not reported 4 0 0 
Recruitment strategy Active 13 6 1 
 Opportunistic 14 4 3 
 Active & opportunistic 1 2 1 
 Not reported 2 1 0 
Questionnaires CDQ1 - 6 - 
 LFQ - 2 - 
 Not named - 5 - 
Common items Age - 11 - 
 Smoking status - 12 - 
 Respiratory symptoms - 13 - 
 Allergies - 7 - 
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  Diagnostic spirometry 
(n=30) 
Screening questionnaires 
(n=13) 
Handheld flow meters 
(n=5) 
Handheld spirometers     
Device Piko-6® - - 4 
 COPD-6® - - 1 
Operator Nurse - - 3 
 GP - - 1 
 Not reported - - 1 
Use of bronchodilator Pre-bronchodilator - - 3 
 Post-bronchodilator - - 2 
Test threshold FEV1/FEV6<0.7 - - 3 
 FEV1/FEV6<0.75 - - 1 
 FEV1/FEV6<0.8 - - 1 
Spirometry Post-bronchodilator 15 10 5 
 Pre-bronchodilator 13 3 0 
 Not reported 2 0 0 
Definition of airflow obstruction Post-BD FEV1/FVC<0.7 12 9 3 
 Pre-BD FEV1/FVC<0.7 9 2  
 Post-BD FEV1/FVC<LLN 1   
 Pre-BD FEV1/FVC<LLN 1   
 Other 7 2 2 
Symptoms in definition of COPD 4 3 0 
Spirometry quality control Yes 22 11 2 
 No 4 2 1 
 Unclear 4 0 2 
Range of results     
New COPD cases/eligible subjects* 1.7-30.5% (19) 0.4-22.3% (8) 6-20% (3) 
New COPD cases/no. screened  - 1.5-30.0% (12) 3-20% (5) 
New COPD cases /no. assessed with spirometry 4.1-40.2% (30) 14.3-42.1% (13) 19-94% (5) 
Severity of new cases 
(FEV1 % predicted)** 
≥80% 11.5-86.7% 11.5-51.1% 33.3-64.3% 
50-80% 12.9-68.2% 42.8-87.5% 35.7-61.4% 
<50% 0-37.2% 5.3-37.2% 0-16.2% 
BD=bronchodilator, CDQ=COPD Diagnostic Questionnaire (also referred to as the Respiratory Health Screening Questionnaire and the International Primary 
Airways Group Questionnaire), FEV1=forced expiratory volume in 1 second, FVC=forced vital capacity, LFQ=Lung Function Questionnaire, LLN=lower limit of 
normal, RCT=randomised controlled trial. 
*A number of studies did not report the total eligible population  **Restricted to studies that reported severity staging according to the GOLD strategy.(16) 
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Table 3.4 Yield from case finding with spirometry (30 studies) 
Study Recruitment strategy Mean age  
(years) 
Male (%) Smoking  
status 
Population Diagnosed  
with COPD 
New diagnoses of COPD  
as a percentage of those: 
Eligible Spirometry** Eligible Spirometry** 
Al Ghobain 2011 Opportunistic 47.9 89.6 Smokers 1380 1380 71 5.1 5.1 
Bednarek 2008 Active 56.7 39.0 Any 2250 1986 149 6.6 7.5 
Broekhuizen* Opportunistic 63 45 Any NR 353 102 NR 28.9 
Bunker 2009 Active 62.4 57 Smokers 400 79 10 2.5 12.7 
Clotet 2004 NR 54 80 Smokers 177 155 36 20.3 23.2 
DeJong 2004 Active 55 49 Smokers NR 243 43 NR 17.7 
Freeman 2005 Active 61.7 52 Smokers 1195 369 62 5.2 16.8 
Frith 2011 Active & opportunistic 61 69 Smokers 233 233 57 24.5 24.5 
Fuller 2012 Active 55 40 Any NR 185 16 NR 8.6 
Geijer 2005 Active 50 100 Smokers 918 805 210 22.9 26.1 
Hanania 2010 Opportunistic NR 38.1 Any NR 937 156 NR 16.6 
Kimura 2011a Active 63.3 33.7 Any 839 814 59 7.0 7.2 
Kimura 2011b Active NR NR Any 1300 363 22 1.7 6.1 
Kögler 2010* Opportunistic NR 62.2 Smokers NR 1282 516 NR 40.2 
Konstantikaki 20111 Active 62.5 64 Any 1084 1084 76 7.0 7.0 
Konstantikaki 20112 Active 63.5 19.6 Any NR 219 56 NR 25.6 
Kotz 2008 Active 52.3 58.7 Smokers 1052 826 278 26.4 33.7 
Leuppi 2010 Opportunistic 51.6 58.6 Smokers 26400 24995 4231 16.0 16.9 
Lokke 2012* Opportunistic 57.5 51 Smokers 4000 4049 878 22.0 21.7 
Price 2006 Active 58.2 49.3 Smokers NR 898 155 NR 17.3 
Queiroz 2012 Opportunistic 65 NR Smokers NR 214 45 NR 21.0 
Sandelowsky 2011* Active 55 44.2 Smokers 250 150 38 15.2 25.3 
Sichletidis 2011 Opportunistic 65.3 57.1 Any 1250 1250 111 8.9 8.9 
Stratelis 2004 Active 48 43 Smokers 5332 512 141 2.6 27.5 
Takahashi 2003 NR 63.1 76.3 Any NR 1168 281 NR 24.1 
Takemura 2005 Opportunistic 49.8 69.3 Any NR 10256 425 NR 4.1 
Thorn 2012 Opportunistic 61.2 43.3 Smokers NR 305 77 NR 25.2 
Ulrik 2011* Opportunistic  58 49 Smokers 10050 3095 1079 10.7 34.9 
Vandevoorde 2007 Opportunistic 52.3 42.5 Smokers 141 129 43 30.5 33.3 
Vrijhoef 2003 Opportunistic 53.5 48.5 Smokers NR 231 17 NR 7.4 
Van Schayck Opportunistic NR NR Smokers 229 201 30 13.1 14.9 
1. Open spirometry programme, 2. Case-finding programme, NR=not reported 
*Only recruited subjects complaining of respiratory symptoms or an acute respiratory infection 
**Received a spirometry assessment 
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Table 3.5 Yield from case finding with screening questionnaires and/or handheld flow meters 
Study Recruitment  
strategy 
Mean age  
(years) 
Male (%) Smoking  
status 
Population COPD Subjects diagnosed with COPD 
as a percentage of those: 
Eligible Screened Received 
spirometry 
Eligible Screened Received  
spirometry 
Screening questionnaires 
CDQ (≥19.5) 
Dirven 2013a1 Active 53.5 51 Any 6393 1715 140 25 0.4 1.5 17.9 
Dirven 2013a2 Active 53.7 49.7 Any 3715 1855 135 48 1.3 2.6 35.6 
Dirven 2013b Active NR NR Any 849 293 39 9 1.1 3.1 23.1 
Frith 2011 Combined 61 69 Smokers 233 233 107 40 17.2 17.2 37.4 
Kotz 2008 Active  52.3 58.7 Smokers 1052 1052 554 233 22.1 22.1 42.1 
Price 2006 Active 58.2 49.3 Smokers NR 898 243 91 NR 10.1 37.4 
CDQ (≥16.5) 
Frith 2011 Combined 61 69 Smokers 233 233 163 52 22.3 22.3 31.9 
Kotz 2008 Active 52.3 58.7 Smokers 1052 1052 844 316 30.0 30.0 37.4 
Price 2006 Active 58.2 49.3 Smokers NR 898 406 125 NR 13.9 30.8 
Sichletidis 2011 Opportunistic 65.3 57.1 Any 1250 1250 693 103 8.2 8.2 14.9 
All other questionnaires 
Buffels 2004 Opportunistic NR 45 Any 3158 3158 703 126 4.0 4.0 17.9 
Castillo 2009 Opportunistic 55 42 Any NR 161 96 21 NR 13.0 21.9 
Freeman 20053 Active 61.7 52 Smokers 1195 369 121 47 3.9 12.7 38.8 
Freeman 20054 Active 61.7 52 Smokers 1195 369 142 54 4.5 14.6 38.0 
Hanania 2010 Opportunistic  NR 38.1 Any NR 937 537 129 NR 13.8 24.0 
Haroon 2013 Opportunistic 55.3 67.6 Smokers 819 111 28 6 0.7 5.4 21.4 
Haroon 2013 Active 53.0 60.8 Smokers 815 212 70 10 1.2 4.7 14.3 
Laniado-Laborin 2011 Active 57.6 39.8 Any NR NR 2617 472 NR NR 18.0 
Mintz 2011 NR 53.9 51.2 Smokers NR 1575 1225 315 NR 20.0 25.7 
 
Handheld flow meter 
Duong-Quy 2009 Active 52 99.7 Smokers 2464 2464 144 136 5.5 5.5 94.4 
Frith 2011 Combined 61 69 Smokers 233 233 97 46 19.7 19.7 47.4 
Kaufmann 2009 Opportunistic 54.8 37.7 Any NR 507 74 14 NR 2.8 18.9 
Sichletidis 2011 Opportunistic 65.3 57.1 Any 1250 1250 147 89 7.1 7.1 60.5 
Thorn 2012 Opportunistic 61.2 43.3 Smokers NR 305 106 61 NR 20.0 57.5 
 
CDQ & handheld flow meter 
Sichletidis 2011 Opportunistic 65.3 57.1 Any 1250 1250 111 82 6.6 6.6 73.9 
1. Patient-managed arm, 2. Practice-managed arm, 3. Multiple response questions, 4. Binary response questions  
CDQ=COPD Diagnostic Questionnaire (score threshold), Combined=active and opportunistic, NR=not reported
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3.4.4.5 Exploring the effect of different target populations and recruitment 
strategies 
It was only possible to combine the results using meta-analyses in a selection of 
studies that had apparent homogeneity as described below. Studies among ever 
smokers were chosen, and a further subset among those already reporting 
respiratory symptoms. 
3.4.4.6 Uptake of screening/diagnostic tests 
A meta-analysis of studies among ever smokers invited for diagnostic spirometry 
showed that opportunistic invitation at routine primary care attendances was 
associated with a significantly higher uptake of spirometry (97% [95% CI 90 to 
100%]; n=5 studies (33, 36-39)) than when actively inviting patients by post (47% [16 
to 80%]; n=6 studies (26, 35, 40-43)), although confidence intervals for the latter 
were wide. Meta-analysis of the proportion responding to postal questionnaires (n=4 
studies (27, 28, 40, 44)) showed an average response of 30% (95% CI 20 to 41%). 
There were insufficient data to estimate the response when questionnaires were 
distributed opportunistically at primary care attendances. 
3.4.4.7 Target populations 
From four similar studies, where ever smokers aged ≥40 years were opportunistically 
invited directly for diagnostic spirometry, 20% (95% CI 7 to 37%; n=4 studies (36, 38, 
45, 46)) were diagnosed with airflow obstruction (Figure 3.4) although the confidence 
intervals were wide and not all of these subjects would necessarily have clinical 
symptoms. Restricting recruitment to ever smokers reporting a history of respiratory 
symptoms/infections provided a higher yield of 32% (95% 21 to 44%; n=3 studies 
(32, 33, 47)) and these would constitute new clinical diagnoses of COPD, although 
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again these confidence intervals were wide and overlap with the yield from inviting 
ever smokers.  Note that these studies were limited to those where patients attended 
primary care and were opportunistically invited to participate and did not include 
active written invitation to patients. 
  
Figure 3.4 Random effects meta-analysis of the proportion of eligible ever smokers diagnosed 
with COPD when opportunistically invited for spirometry (restricted to studies that defined 
airflow obstruction as FEV1/FVC<0.7)
Proportion meta-analysis plot [random effects]
0.0 0.2 0.4 0.6
combined 0.20 (0.07, 0.37)
Vandevoorde 2007 0.33 (0.25, 0.42)
Thorn 2012 0.25 (0.20, 0.31)
Queiroz 2012 0.21 (0.16, 0.27)
Al Ghobain 2011 0.05 (0.04, 0.06)
proportion (95% confidence interval)
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3.5 Discussion 
3.5.1 Main findings 
This review incorporated evidence from 39 primary studies and summarised the 
effectiveness of case finding using a number of approaches. The few comparative 
studies had a number of methodological limitations and were highly heterogeneous. 
Their findings suggest that active case finding in primary care is likely to identify a 
greater number of patients with undiagnosed COPD compared to usual care, that 
arrangement of follow-up should be performed by practices rather than by patients, 
and that assessment of patients clinically suspected to have COPD is likely to be 
more effective than widespread invitation of the general public for screening. The 
majority of studies found were non-comparative and also highly heterogeneous, with 
significant limitations in study design and the reporting of eligible populations, 
withdrawals, indeterminate results and spirometry quality control procedures. The 
lack of direct comparisons and the heterogeneity in populations, study design, 
definition of COPD and methods for estimating the yield limited the ability to combine 
results and to draw conclusions about the most effective case finding approach.  
Indirect comparisons suggest that uptake for spirometry is higher when patients are 
invited opportunistically at routine primary care visits than with active written invitation 
by post and response to mailed screening questionnaires is likely to be around 30%. 
Studies that opportunistically invited patients with a history of respiratory symptoms 
to undertake spirometry seemed to have a higher yield than those that invited ever 
smokers without first eliciting a history of relevant symptoms, although the difference 
in the yields for both groups was not statistically significant. The yields from the 
different approaches (direct invitation for spirometry, and screening with a postal 
89 
 
questionnaire or handheld flow meter) were highly heterogeneous and no approach 
was clearly associated with a higher overall yield. However studies that first screened 
patients using either a questionnaire or handheld flow meter seemed to achieve a 
higher yield at the diagnostic assessment, suggesting that fewer diagnostic 
assessments may be needed per case detected. However, this would be at the 
expense of applying screening tests to the target population prior to referral for 
diagnostic assessment. Again these estimates were highly heterogeneous and 
comparisons were indirect, so these findings could be biased by differences in study 
design and population characteristics. Finally, case finding is likely to uncover a 
significant burden of disease, and although the majority of this will be of mild-to-
moderate severity, a significant proportion will have severe airflow obstruction. 
3.5.2 Relationship to existing reviews 
The UK National Screening Committee recently recommended against screening for 
COPD due to a lack of relevant RCTs, and insufficient evidence on the optimal 
approach and the benefits of early treatment.(17) They also concluded that case-
finding among symptomatic individuals with more developed COPD is likely to be 
cost-effective and should continue. A systematic review on the use of diagnostic 
spirometry for population screening similarly concluded that it could not be 
recommended on the basis that it would require a large number of assessments to 
prevent a single COPD exacerbation and would largely unveil patients with 
asymptomatic airflow obstruction for whom there are limited therapeutic options.(18) 
Our findings agree that there are currently few RCTs but also highlight several 
important methodological limitations that should be addressed in future trials 
evaluating case finding strategies. Our review also agrees that targeting symptomatic 
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individuals may increase the efficiency of case finding but also shows that while the 
majority of patients found have mild disease (which is arguably when secondary 
prevention may be most effective), a significant proportion of those diagnosed are 
likely to have moderate-to-severe disease that would most likely benefit from 
recommended therapies for COPD.(9)  
Jithoo and colleagues recently compared alternative case finding strategies using 
data from the Burden of Obstructive Lung Disease Study and concluded that peak 
flow meters were a cost-effective screening test for COPD.(48) However the peak 
expiratory flow rate was derived from quality-controlled spirometry measurements 
and may not necessarily reflect the accuracy of actual peak flow meters used in 
everyday clinical practice. Our search strategy did not identify any studies directly 
evaluating peak flow meters for case finding. RCTs comparing the effectiveness of 
screening with peak flow meters against other screening tests such as 
questionnaires and handheld flow meters should therefore be considered. 
3.5.3 Strengths and limitations 
We performed an extensive review of the literature and incorporated detailed 
evidence on 39 primary studies. However there was extensive heterogeneity, which 
limited the quantitative synthesis. There were also very few RCTs and those that 
were identified were highly heterogeneous, preventing direct comparison. We 
therefore mainly relied on indirect comparisons, which may potentially be biased 
because of differences in study design and population characteristics. The size of 
eligible populations was often not reported which limited estimates of the uptake of 
screening tests and could potentially bias estimates obtained from the meta-
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analyses. Furthermore many of the combined results had wide confidence intervals 
and should be interpreted with caution. 
Another important limitation was that most studies used a purely physiological 
definition of COPD without clearly specifying the requirement for relevant symptoms, 
associated risk factors or compatible clinical history. Use of a physiological definition 
of COPD is likely to overestimate the effectiveness of case finding- an analysis of the 
Health Survey for England (49) I conducted found that only about half of individuals 
with undiagnosed airflow obstruction have chronic respiratory symptoms in keeping 
with a clinical diagnosis of COPD. Identification of individuals with asymptomatic 
airflow obstruction is problematic in the absence of evidence-based 
recommendations to guide their management.(18)  
3.5.4 Implications for practice, research and policy 
Case finding through any approach is likely to uncover a substantial number of 
patients with undiagnosed COPD. Primary care services wishing to identify patients 
with undiagnosed COPD are likely to achieve a higher uptake for spirometry by 
offering this opportunistically to high risk patients at routine primary care visits than 
by using postal invitations. However it is unclear which approach results in a higher 
overall yield. Targeting patients with a history of respiratory symptoms or infections 
may improve the case finding yield and screening using either a respiratory 
questionnaire such as the CDQ or handheld flow meter followed by diagnostic 
assessment in those with a positive screening test may reduce the number of 
diagnostic assessments needed compared to directly inviting all high risk patients for 
diagnostic spirometry. However it is unclear whether screening with a handheld flow 
meter would actually reduce the overall number of clinical contacts or improve the 
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use of healthcare resources. While the majority of patients identified through case 
finding will have mild-to-moderate disease, around one in five is likely to have severe 
disease requiring more extensive management.       
There is extensive heterogeneity in the literature on evaluations of case finding 
strategies for COPD with few RCTs, making comparative assessments on the 
effectiveness of different approaches, in terms of yield, highly problematic. Future 
studies should directly compare alternative approaches, particularly addressing the 
most effective patient population to target (e.g. smokers with a history of respiratory 
symptoms or those identified as at high risk by prediction models), the recruitment 
strategy (opportunistic invitation at primary care attendance versus a more active 
approach using written [mailed/emailed/texted] invitations) and use of screening tests 
(e.g. screening questionnaires, handheld flow meters, peak flow meters, risk 
prediction models, alone and in combination).  
A high yield at the diagnostic assessment (i.e. a high proportion of subjects attending 
a spirometry assessment receiving a diagnosis of COPD) does not necessarily imply 
a high yield for the case finding process as a whole. This is particularly the case if a 
large proportion of eligible subjects did not attend a screening or diagnostic 
assessment. Studies evaluating case finding strategies should thus consider the 
whole targeted population when considering the overall yield of that strategy in terms 
of the proportion of that population who are subsequently identified with COPD. 
Future studies should also use a clinical definition of COPD that aligns with current 
recommendations, requiring the presence of both relevant symptoms and clinical 
features in addition to airflow limitation (50) using a standardised definition so that 
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findings across studies can be compared. They should also report withdrawals and 
indeterminate results and present this in a participant flow chart, including a 
description of the size and characteristics of the eligible population as well as those 
who received a screening and diagnostic assessment. They should also employ strict 
quality control procedures for spirometry to avoid misdiagnosis. The findings of these 
studies will be important to enable economic evaluations of alternative case finding 
strategies in order to aid policy makers to make appropriate decisions on the most 
cost-effective approach.  
3.5.5 Conclusion 
There is extensive heterogeneity and few RCTs among studies evaluating case 
finding strategies for COPD in primary care. Uptake for spirometry assessments may 
be higher when opportunistically inviting patients at routine primary care visits than 
active written invitations, though it is unclear which approach has the higher overall 
yield. Targeting ever smokers with a history of respiratory symptoms may improve 
the yield and using screening tests such as questionnaires may reduce the number 
of diagnostic assessments needed to identify a patient with COPD. High quality 
RCTs are needed to make direct comparisons of alternative case finding strategies, 
including the target population, recruitment strategy and screening tests, using a 
standardised clinical definition of COPD, and taking into consideration the 
methodological limitations of previous studies highlighted in this review. 
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3.6 Supplementary Tables 
Table S3.1 Study characteristics 
Study Country Study design Setting Recruitment method Eligibility criteria Screening & diagnostic test(s) 
Al Ghobain 
2011 (36) 
Saudi 
Arabia 
Single arm 
before-after 
study  
60 primary healthcare 
clinics 
Invited patients routinely 
attending private primary 
healthcare clinics. Dates of 
recruitment not reported. 
Inclusion criteria 
Age ≥40 years  & 
current/ex-smoker of >5 years 
duration  
Exclusion criteria 
Known lung disease, upper 
respiratory tract infection or 
spirometry contraindications  
Pre-/post-BD  spirometry 
Bednarek 
2008 (51) 
Poland Single arm 
before-after 
study 
Single primary care practice Personalised letter from primary 
care physician. Dates of 
recruitment not reported. 
Inclusion criteria 
Age ≥40 years 
Exclusion criteria 
None 
Pre-/post-BD  spirometry 
Broekhuizen 
2010 (31) 
Netherlands Single arm 
before-after 
study 
73 general practitioners Invited patients visiting their GP 
for persistent cough lasting ≥14 
days during the winter period 
from January 2006-April 2009 
Inclusion criteria 
Age >50 years & persistent 
cough lasting ≥14 days 
Exclusion criteria 
Known COPD or asthma, 
suspected pneumonia, severe 
psychiatric symptoms, or 
terminal illness 
Extensive diagnostic work-up 90 
days after presentation, including 
pre- /post-BD  spirometry 
Buffels  
2004 (52) 
Belgium Cross-sectional 
test accuracy 
study 
20 general practitioners Invited patients routinely 
attending general practice over 
a 12 week period in 1999 
Inclusion criteria 
Age 35-70 years 
Exclusion criteria 
Receiving bronchodilators and/or 
inhaled corticosteroids 
Stage 1  
Screening questionnaire 
Stage 2  
Pre-BD spirometry in all subjects 
with respiratory symptoms and 
10% sample of asymptomatic 
subjects 
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Study Country Study design Setting Recruitment method Eligibility criteria Screening & diagnostic test(s) 
Bunker  
2009 (26) 
Australia RCT (case 
finding vs. 
usual care) 
4 general practices Postal invitation with two 
reminder letters. Dates of 
recruitment not reported. 
Inclusion criteria 
Current/ex-smokers aged 40-80 
years  
Exclusion criteria 
Known diagnosis of COPD, 
cognitive impairment, non-
English speaking, <2 visits to 
practice in preceding year 
Spirometry (unclear whether pre- 
or post-BD)  
Castillo  
2009 (53) 
Spain Single arm 
before-after 
study 
13 community pharmacies Invited subjects visiting 
participating pharmacies in 
April/May 2007 
Inclusion criteria 
Age >40 years 
Exclusion criteria 
History of lung disease or use of 
inhalers 
Stage 1  
Screening questionnaire 
Stage 2  
Pre-BD spirometry for those with 
≥3 positive answers 
Clotet  
2004 (54) 
Spain Single arm 
before-after 
study 
NR NR Inclusion criteria 
Age 40-76 years & active smoker 
for ≥10 years with no or only mild 
respiratory symptoms 
Exclusion criteria 
Previous diagnosis of COPD, 
asthma, bronchiectasis, cystic 
fibrosis, tuberculosis, chronic 
bronchitis, restrictive pulmonary 
disease or receiving 
bronchodilators 
Pre-BD spirometry 
DeJong  
2004 (55) 
US Single arm 
before-after 
study 
Range of settings – unclear Direct mailing to 1500 
individuals who were coded as 
being a current/ex- smoker 
within a large primary care clinic 
system. 
Advertised via article in the 
local newspaper and posters 
placed in 6 physician offices 
and 1 hospital. (Dates not 
reported) 
Inclusion criteria 
Age 40-60 years (although no 
subjects were turned away) 
Exclusion criteria 
None 
Pre-BD spirometry 
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Study Country Study design Setting Recruitment method Eligibility criteria Screening & diagnostic test(s) 
Dirven  
2013a (30) 
Netherlands Cluster RCT 
(patient vs. 
practice-
managed 
screening 
approach) 
16 general practices in four 
cities 
The COPD Diagnostic 
Questionnaire (referred to as 
the “Respiratory Health 
Screening Questionnaire”) was 
posted to all eligible patients 
registered at participating 
practices from May to 
September 2012 
Inclusion criteria 
Age 40-70 years 
Exclusion criteria 
Previous diagnosis of asthma, 
COPD or significant lung disease 
such as lung cancer, 
pneumoconiosis, tuberculosis, 
bronchiectasis and 
pneumonectomy. Also excluded 
patients using oxygen 
supplementation and with 
impaired mobility. 
Stage 1 
In the “patient-managed” arm 
subjects were asked to calculate 
their risk of COPD using a 
screening questionnaire (COPD 
Diagnostic Questionnaire) and 
advised to consult their GP if 
their score was >19.5. In the 
“practice-managed” arm the 
scoring was performed by the 
practice and subjects with a 
score >19.5 were invited for 
spirometry. 
Stage 2: 
Post-BD spirometry for subjects 
with a score >19.5 
Dirven  
2013b (44) 
Netherlands Single arm 
before-after 
study 
10 general practices in two 
cities (five low 
socioeconomic status (SES) 
practices and five 
moderate-to-high SES) 
The COPD Diagnostic 
Questionnaire (referred to as 
the “Respiratory Health 
Screening Questionnaire”) was 
posted to all eligible patients 
registered at participating 
practices from May-July 2012. 
Inclusion criteria 
Age 40-70 years 
Exclusion criteria 
As above (Dirven 2013a) 
Stage 1: 
Screening questionnaire (COPD 
Diagnostic Questionnaire; score 
completed by practice assistant) 
Stage 2: 
Post-BD spirometry for subjects 
with a score ≥19.5 
Duong-Quy 
2009 (56) 
Vietnam Cross-sectional 
test accuracy 
study 
12 primary care medical 
centres in one city 
Broadcast an advertisement on 
the local television daily for one 
week. A recruitment company 
was used to help with recruiting 
participants (details not 
reported). Eligible subjects 
expressing an interest in 
participating were advised to 
attend one of the twelve primary 
care centres from January 
2007- February 2008. 
Inclusion criteria 
Current/ex-smokers aged >40 
years with >10 pack-years  
Exclusion criteria 
Previously diagnosed respiratory 
disease (asthma, COPD and 
tuberculosis) 
Stage 1 
Pre-BD handheld flow meter 
(Piko-6®) 
Stage 2 
Full medical assessment 
including clinical examination, 
pulmonary radiology, ECG, and 
post-BD spirometry for subjects 
with FEV1/FEV6<0.7 and a 
sample of subjects with 
FEV1/FEV6≥0.7 
Freeman  
2005 (40) 
UK Cross-sectional 
test accuracy 
study 
One general practice Postal invitation from October 
1997-April 2002 
Inclusion criteria 
Current/ex-smokers aged ≥40 
years & had either received 
respiratory medications in the 
preceding two years or history of 
asthma  
Stage 1  
Screening questions 
Stage 2  
Pre-/ post-BD spirometry on all 
subjects 
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Study Country Study design Setting Recruitment method Eligibility criteria Screening & diagnostic test(s) 
Frith  
2011 (20) 
Australia Cross-sectional 
test accuracy 
study 
Four primary care practices Recruited during routine 
practice visits, invitation to 
study days, and via local 
newspaper advertisement 
between August-December 
2006 
Inclusion criteria 
Current/ex-smokers aged ≥50  
years with no prior diagnosis of 
obstructive lung disease (COPD, 
emphysema, chronic bronchitis, 
asthma) & no treatment for 
obstructive lung disease in past 
12 months 
Exclusion criteria 
Refusal or inability to give 
consent, pre-existing non-
obstructive lung disease, 
symptoms suggestive of unstable 
heart disease, and spirometry 
contraindications  
Stage 1:  
Pre-BD Piko-6® & screening 
questionnaire (COPD Diagnostic 
Questionnaire) 
Stage 2:  
Pre-/ post-BD spirometry on all 
subjects 
 
Fuller  
2012 (57) 
US Single arm 
before-after 
study 
Four community 
pharmacies and offsite 
screening events. Each 
pharmacy was an 
established patient care 
centre which had a clinical 
pharmacist and provided 
services such as 
immunisation, medication 
therapy management and 
smoking cessation 
counselling 
Screening was offered to any 
interested subjects fulfilling the 
eligibility criteria. Participation 
was encouraged by in-store 
advertising, brochures, 
prescription bag ties and fliers. 
Recruitment took place from 
March-June 2010 
Inclusion criteria 
Age ≥35 years 
Exclusion criteria 
History of lung cancer, 
pregnancy at time of screening, 
previous diagnosis of COPD, 
lung surgery or resection, recent 
abdominal or thoracic surgery, 
respiratory infection within the 
previous 3 weeks, uncontrolled 
hypertension (>160/90 mm 
Hg),and  inability to produce 
three acceptable tracings during 
spirometry 
Pre-BD spirometry 
Geijer  
2005 (41) 
Netherlands Single arm 
before-after 
study 
Primary care (otherwise 
unspecified) 
Mailed invitation ascertaining 
smoking status, only inviting  
current smokers in 1998 with 
follow-up measurements in 
2003 
Inclusion criteria 
Males aged 40-65 years who had 
smoked ≥1 cigarette per day 
during previous  12 months 
Exclusion criteria 
Prior history of lung disease, ex-
/non-/pipe/cigar smokers  
Pre-/post-BD spirometry (post-
BD spirometry only performed if 
pre-BD FEV1 % predicted<85%) 
Hanania  
2010 (58) 
US Cross-sectional 
test accuracy 
study 
Two family physician group 
offices 
Invited patients visiting the 
practices from March-May 2008 
Inclusion criteria 
Age ≥40 years 
 
Exclusion criteria: 
None 
Stage 1 
Screening questionnaire (Lung 
Function Questionnaire) 
Stage 2  
Pre-BD spirometry in all subjects 
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Study Country Study design Setting Recruitment method Eligibility criteria Screening & diagnostic test(s) 
Haroon  
2013 (28) 
UK RCT (targeted 
vs. 
opportunistic 
case finding) 
Two general practices Postal invitation (“targeted”) vs. 
invitation to patients routinely 
attending primary care 
(“opportunistic”) from May 
2010-January 2011 
Inclusion criteria 
Current/ex-smokers aged 35-79 
years   
Exclusion criteria 
Prior diagnosis of COPD or 
asthma 
Stage 1  
Screening questionnaire 
Stage 2  
Pre-BD spirometry in subjects 
with symptoms 
Kaufmann 
2009 (59) 
Austria Single arm 
before-after 
study 
Three general practices Invited patients who attended 
participating practices from 
May-June 2005 
Inclusion criteria 
NR 
Exclusion criteria 
Known lung or psychiatric 
disease  
Stage 1  
Pre-BD handheld flow meter 
(Piko-6®) 
Stage 2  
Post-BD spirometry 
Kimura  
2011 (60) 
Japan Repeated 
single arm 
before-after 
studies 
(reported two 
separate  
studies) 
Community health centre Personalised postal invitation 
from the local government to 
the general population from 
2004-2007. COPD was 
described in a newsletter and a 
lecture was delivered by one of 
the authors before the study, 
emphasizing the prevention of 
severe life-threatening disease 
Inclusion criteria 
Age >40 years (study 1). 
Inclusion criteria not specified for 
study 2 
Exclusion criteria 
Illiteracy 
Pre-BD spirometry 
Kögler  
2010 (32) 
Germany Single arm 
before-after 
study 
684 urban and rural primary 
care practices and 137 
respiratory physicians 
Invited consecutive patients 
routinely attending primary care 
(dates not reported) 
Inclusion criteria 
Age ≥40 years with no prior 
diagnosis of lung disease. 
Subjects were then selected 
either if they had ever smoked or 
regularly suffered from cough 
and/or breathlessness. 
Assessment by a pulmonologist, 
including spirometry (unclear 
whether pre- or post-BD) 
Konstantikaki 
2011 (29) 
Greece Non-
randomised 
controlled trial 
24 semirural primary care 
practices  
Public invitation with local 
advertisement offering free 
spirometry to individuals with 
chronic respiratory symptoms 
(open spirometry programme) 
from November 2008-October 
2009. 
 
Primary care physicians 
identified patients with a 
probable diagnosis of COPD in 
their daily practice (case finding 
strategy). 
Inclusion criteria 
>30 years 
Exclusion criteria 
History of respiratory tract 
infection in previous four weeks 
and inability to perform 
spirometry 
Post-BD spirometry 
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Study Country Study design Setting Recruitment method Eligibility criteria Screening & diagnostic test(s) 
Kotz  
2008 (42) 
Netherlands Cross-sectional 
test accuracy 
study  
General population and 
primary care practices 
  
Advertisements in a local 
newspaper, flyers, posters, 
mailings to households and 
invitation during primary care 
consultations from 
January 2005-December 2006 
Inclusion criteria 
Current smokers aged 40-70 
years with ≥10 pack years & 
motivated to stop smoking, able 
to read and speak Dutch & 
reporting a respiratory symptom 
(cough, phlegm or dyspnoea) 
Exclusion criteria: 
Prior respiratory diagnosis, 
spirometry in previous 12 months 
or contraindications to smoking 
cessation therapy 
Stage 1  
Questionnaire (COPD Diagnostic 
Questionnaire) 
Stage 2  
Pre-/post-BD spirometry in all 
participants 
Laniado-
Laborin 
2011 (61) 
Mexico Single arm 
before-after 
study 
Primary care practices in 27 
cities from March-October 
2008 
 
Received phone call from family 
physician to schedule an 
assessment from March-
October 2008 
Inclusion criteria 
Age ≥40 years 
Exclusion criteria 
None 
Stage 1 
Screening questionnaire 
Stage 2 
Subjects with risk factors or 
symptoms proceeded to post-BD 
spirometry  
Leuppi 
2010 (37) 
Switzerland Single arm 
before-after 
study 
Primary care practices with 
440 GPs 
Invited patients attending 
primary care (dates not 
reported) 
Inclusion criteria 
Current smokers aged ≥40 years  
Exclusion criteria 
None 
Pre-BD spirometry 
Løkke 
2012 (33) 
Denmark Single arm 
before-after 
study 
Primary care practices with 
241 GPs 
Invited consecutive patients 
attending practices during 
March-August 2010 
Inclusion criteria 
Age ≥35 years & current/ex-
smoker or relevant occupational 
exposure & ≥1 respiratory 
symptom (dyspnoea, cough, 
wheeze, sputum  and/or 
recurrent chest infections) 
Exclusion criteria 
Unable to perform spirometry or 
previous diagnosis of chronic 
respiratory disease 
Pre-BD spirometry with 
bronchodilator reversibility for 
patients with airway obstruction 
and corticosteroid reversibility 
test for subjects with an increase 
in FEV1 between 200-500mL 
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Study Country Study design Setting Recruitment method Eligibility criteria Screening & diagnostic test(s) 
Mintz  
2011 (62) 
US Cross-sectional 
test accuracy 
study 
36 primary care centres  NR. 
Study took place from 18th 
February to 29th May 2009. 
Inclusion criteria 
Current/ex-smokers aged ≥30 
years old with ≥10 pack years  
Exclusion criteria 
Regular use of respiratory 
medication within 4 weeks of 
study, known diagnosis of 
substantial lung conditions with 
regular use of respiratory 
medication. 
Stage 1 
Screening questionnaire (Lung 
Function Questionnaire) 
Stage 2 
Pre-/post-BD spirometry on 
subjects with LFQ ≤18 & first two 
subjects with LFQ ≥18 at each 
site 
Price  
2006 (19) 
UK & US Cross-sectional 
test accuracy 
study 
Two primary care practices Postal invitation (dates not 
reported) 
Inclusion criteria 
Current/ex-smokers aged ≥40 
years  
Exclusion criteria 
Refusal to consent, history of 
non-obstructive lung disease, 
use of respiratory medications in 
previous year, and acute 
symptoms of unstable heart 
disease 
Stage 1 
Screening questionnaire (COPD 
Diagnostic Questionnaire) 
Stage 2 
Pre-/post-BD spirometry  on all 
subjects 
de Queiroz 
2012 (45) 
Brazil Single arm 
before-after 
study 
Three primary healthcare 
clinics 
Invited individuals routinely 
attending primary healthcare 
clinics between May-September 
2011 
Inclusion criteria 
Age ≥40 years & ≥20 pack-years 
smoking or ≥80 hour-year history 
of exposure to biomass smoke 
Exclusion criteria 
Acute respiratory symptoms, 
previous history of bronchial 
asthma, allergic rhinitis, chronic 
lung diseases other than COPD, 
extra-pulmonary disease 
potentially affecting lung function 
and not meeting the criteria for 
spirometry 
Pre-/post-BD spirometry 
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Study Country Study design Setting Recruitment method Eligibility criteria Screening & diagnostic test(s) 
Sandelowsky 
2011 (35) 
Sweden Single arm 
before-after 
study 
Primary healthcare centre 
and urgent primary care unit 
Patients meeting the inclusion 
criteria were telephoned from 
January-March 2005. 
Telephone conversations were 
followed by formal written 
invitations. 
Inclusion criteria 
Current/ex-smokers aged 40-75 
years & visited a primary 
healthcare centre or urgent 
primary care unit & diagnosed 
with acute respiratory infection 
(confirmed with a review of the 
medical records). 
Exclusion criteria 
Poor knowledge of Swedish, 
severe cardiac, psychiatric or 
multi-organ disease, prior history 
of lung disease (except asthma), 
or on beta-blockers 
Pre-/post-BD spirometry  
Sichletidis 
2011 (63) 
Greece Cross-sectional 
test accuracy 
study 
25 general practices Invited first 50 patients meeting 
the inclusion criteria who 
attended each participating GP 
from March-May 2009 
Inclusion criteria 
Age >40 years 
Exclusion criteria 
Confirmed diagnosis of lung 
disease, thoracic surgery in 
previous six months, acute 
respiratory infection, uncontrolled 
cardiac disease, or could not 
perform acceptable spirometry 
Stage 1 
Screening questionnaire 
(International Primary Airways 
Group [IPAG] questionnaire, also 
known as COPD Diagnostic 
Questionnaire) 
Stage 2 
Post-BD Piko-6® (using 400µg 
salbutamol) 
Stage 3  
Pre-/post-BD spirometry  
Stratelis 
2004 (43) 
Sweden Single arm 
before-after 
study 
Primary care centres 
(number of centres not 
reported) 
Placards advertising the study 
displayed in each healthcare 
centre and advertisement in 
local newspaper (dates not 
reported) 
Inclusion criteria 
Current smokers aged 40-55 
years (or had stopped smoking 
within 3 months of the study) 
Exclusion criteria 
None 
Pre-BD spirometry 
 
Takahashi 
2003 (64) 
Japan Single arm 
before-after 
study 
56 primary care facilities (23 
hospitals and 33 general 
practices) 
Not reported Inclusion criteria 
Considered to be high risk for 
COPD (not otherwise defined) 
Exclusion criteria 
Established diagnosis of COPD, 
asthma or other chronic 
respiratory disease 
Pre-BD spirometry 
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Study Country Study design Setting Recruitment method Eligibility criteria Screening & diagnostic test(s) 
Takemura 
2005 (65) 
Japan Single arm 
before-after 
study 
Health screening clinic Invited patients attending a 
medical check-up from 1997-
2001 
Inclusion criteria 
Age >30 years 
Exclusion criteria 
Established diagnosis of chronic 
respiratory disease, 
abnormalities on chest X-ray and 
unknown smoking status 
Pre-BD spirometry 
Thorn 
2012 (46) 
Sweden Cross-sectional 
test accuracy 
study 
21 primary healthcare 
centres 
Invited patients attending 
participating primary healthcare 
centres over a five month 
period (dates not reported) 
Inclusion criteria 
Current/ex-smokers aged 45-85 
years with ≥15 pack years 
Exclusion criteria 
None 
Stage 1  
Pre-BD handheld spirometer 
(COPD-6®) 
Stage 2  
Pre-/post-BD spirometry  
Ulrik 
2011 (34) 
Denmark Single arm 
before-after 
study 
Primary care practices 
involving 335 GPs 
Invited consecutive patients 
routinely attending primary care 
(dates not reported)  
Inclusion criteria 
Age ≥35 years old 
& current/ex- smoker or relevant 
occupational exposure & 
≥1 respiratory symptom 
(dyspnoea, cough, wheeze, 
sputum or recurrent chest 
infections) 
Exclusion criteria 
Unable to perform spirometry or 
previous diagnosis of chronic 
respiratory disease 
Pre-BD spirometry  
van Schayck 
2002 (66) 
Netherlands Single arm 
before-after 
study 
Two semirural primary care 
practices 
Randomly invited patients 
routinely attending primary care 
(dates not reported) 
Inclusion criteria 
Current smokers aged 35-70 
years 
Exclusion criteria 
Use of respiratory medication 
Pre-BD spirometry 
Vandevoorde 
2007 (38) 
Belgium Single arm 
before-after 
study 
Six primary care practices, 
involving  eight GPs 
Invited patients routinely 
attending primary care over a 
two month period (dates not 
reported) 
Inclusion criteria 
Current smokers aged 40-70 
years with ≥15 pack-years 
Exclusion criteria 
History of asthma or COPD 
Pre-BD spirometry 
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Study Country Study design Setting Recruitment method Eligibility criteria Screening & diagnostic test(s) 
Vrijhoef  
2003 (67) 
Netherlands Single-arm 
before-after 
study 
Eight primary care practices Invited patients attending 
primary care for reasons 
unrelated to respiratory disease 
from September 1998-July 
1999 
Inclusion criteria 
Current/ex-smokers aged 40-70 
years 
Exclusion criteria 
Receiving respiratory medication, 
known diagnosis of asthma, 
COPD or chronic bronchitis, or 
significant co-morbidity 
Stage 1 
Pre-/ post-BD spirometry 
performed by medical 
undergraduates 
Stage 2:  
Pre-/post-BD spirometry 
performed by specialist 
respiratory nurse 
ATS=American Thoracic Society, BD=bronchodilator, ERS=European Respiratory Society, NR=not reported, RCT=randomised controlled trial 
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Table S3.2a Quality assessment of studies evaluating direct invitation for spirometry 
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Clear description of recruitment Y Y Y Y N Y Y Y Y Y N N Y Y Y Y N N Y Y Y Y 
Clear description of selection criteria Y Y Y Y Y N Y Y N Y N Y Y Y Y Y N Y Y Y Y Y 
Clear description of participants Y Y Y N N Y Y Y N Y Y N Y N Y Y Y Y Y N Y Y 
Representative spectrum of patients Y Y Y U U Y Y N U Y N Y Y U Y N Y Y Y U Y Y 
Clear description of withdrawals N Y U N N N N N N Y Y N N Y Y N N N N Y U Y 
Participant flow diagram N N N Y Y N Y N Y N Y N N Y Y N N N N N N Y 
Spirometry quality control Y Y U Y N N Y Y Y U Y Y U N U Y Y Y N Y Y Y 
Standard diagnostic criteria Y Y Y Y Y Y Y Y N Y Y Y Y Y Y Y Y Y Y Y Y N 
Intervention described in sufficient 
detail to permit its replication 
Y Y Y Y N N Y Y Y Y N Y Y Y Y Y Y Y N Y Y Y 
Clinical data available representative 
of routine practice 
Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
Uninterruptable, indeterminate or 
intermediate results reported  
Y Y N N N N Y Y Y N Y Y N Y Y N Y N N Y Y N 
Y=yes, N=no, U=unclear  
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Table S3.2b Quality assessment of studies evaluating screening questionnaires and/or handheld flow meters 
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Spirometry quality control Y Y N N N Y Y Y Y U Y Y Y Y Y U 
Standard diagnostic criteria Y Y Y Y Y Y Y Y Y U Y Y Y Y Y Y 
Quality diagnostic spirometry as reference standard Y Y Y U Y Y Y Y Y U Y Y Y Y Y Y 
Spirometry performed within 6 months of index test Y Y U U U Y Y Y Y U U Y Y Y U Y 
All or random selection of participants with positive screening test 
result underwent spirometry 
Y Y N Y N Y Y Y N Y Y Y N Y Y Y 
Intervention described in sufficient detail to permit its replication Y Y Y Y Y Y Y Y Y N Y Y Y Y Y Y 
Clinical data available representative of routine practice Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
Uninterpretable, indeterminate or intermediate results reported  N Y N N N N Y N N U Y Y Y Y Y N 
Y=yes, N=no, U=unclear  
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Table S3.3 Results: studies evaluating spirometry 
Study Population Spirometry Spirometry Definition of COPD New cases of COPD1 
Al Ghobain  
2011 (36) 
Eligible: 1380 
Invited: 1380 
Subjects with 
acceptable 
spirometry: 
Mean age: 47.9  
Male: 89.6% 
Smoking status 
Current: 82.6%  
Former:  17.4%  
Device: NR 
Bronchodilator: 200µg salbutamol 
Operator: Physicians trained in the research 
methods 
Standard: ATS standards 
Quality control: Two investigators 
independently assessed the quality of 
spirometry tests according to ATS criteria. 
Total: 1380 
Acceptable: 501  
Post-BD FEV1/FVC<0.7 with no history of 
asthma or atopy, and with a smoking history 
of ≥5 years 
71 cases 
FEV1 % predicted  
>70%: 0  
50-70%: 40 (56.3%) 
<50%: 31 (43.6%) 
Bednarek 
2008 (51) 
Eligible: 2250 
Invited: NR 
Subjects with 
acceptable 
spirometry 
Mean age: 56.7  
Male: 39.0%  
Smoking status 
Current: 29.6%  
Former: 24.9%  
Never: 45.5%  
Device: EasyOne Diagnostic (ndd Medical) 
Bronchodilator: 200µg salbutamol 
Operator: Primary care nurses who had 
attended two four hour training sessions in a 
reference lung function laboratory 
Standard: ATS standards 
Quality control: Spirometry tests were sent to 
one of the authors for quality assessment, 
reviewed according to ATS criteria 
Total: 1986 
Acceptable: 1960 
Post-BD FEV1/FVC<5th percentile of normal 
(using ECCS predicted values) & compatible 
clinical presentation (excluding asthma 
based on case notes review) 
149 cases 
FEV1 % predicted 
>70%: 56 (30.6%) 
50-69%: 94 (51.4%) 
35-49%: 28 (15.3%) 
<35%: 5 (2.7%) 
Broekhuizen 
2010 (31) 
Eligible: NR 
Invited: NR 
Subjects 
analysed: 
Mean age: 63  
Male: 45%  
Smoking status 
Current/ex: 74% 
Never: 26%  
Device: NR 
Bronchodilator: 400µg salbutamol 
Operator: Lung function technicians 
Standard: NR 
Quality control: Tests performed in a secondary 
care lung function laboratory 
Total: 353 
Acceptable: NR 
Consensus panel diagnosis with two 
physicians. Diagnosis based on recurrent 
respiratory symptoms & post-BD 
FEV1/FVC<0.7 & clinical judgement 
102 cases 
FEV1 % predicted 
>80%: 71 (69.7%) 
50-80%: 29 (28.4%) 
30-50%: 2 (2.0%) 
<30%: 0  
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Study Population Spirometry Spirometry Definition of COPD New cases of COPD1 
Bunker 
2009 (26) 
Eligible: 400 
Invited: NR 
Subjects who 
performed 
spirometry: 
Mean age: 62.4*  
Male: 57.0%  
Smoking status 
Current: 32.9%  
Former: 67.1%  
Device: NR 
Bronchodilator: NR 
Operator: practice nurses who had attended a 
two hour training session on performance and 
interpretation of spirometry 
Standard: GOLD strategy 
Quality control: 25% of spirometry results were 
reviewed by a member of the study team. 
Total: 79 
Acceptable: NR 
FEV1/FVC<70% (unclear whether pre- or 
post-BD) 
10 cases 
FEV1 % predicted 
>80%: 5 (31.3%) 
50-80%: 9 (56.3%) 
30-50%: 2 (12.5%) 
<30%: 0 
NB. FEV1 % predicted 
includes cases that were 
later deemed not to have 
COPD. 
 
Clotet 
2004 (54) 
Eligible: 177 
Invited: 177 
Subjects with 
spirometry: 
Mean age: 54  
Male: 80% 
Smoking status 
Current: 100%  
Device: DATOSPIR 100 spirometer  
Bronchodilator: None 
Operator: NR 
Standard: Spanish Society of Pulmonology and 
Thoracic Surgery (SEPAR) 
Quality control: NR 
Total: 155 
Acceptable: NR 
Pre-BD FEV1<80% predicted & 
FEV/FVC<70% 
36 cases 
FEV1 % predicted  
NR 
 
DeJong 
2004 (55) 
Eligible: NR 
Invited: NR 
Subjects who 
performed 
spirometry: 
Mean age: 55 
Male: 49%  
Smoking status 
Current: 49%  
Former: 37% 
Never: 14% 
Spirometer: Jones handheld spirometer 
Bronchodilator: NR 
Operator: Trained respiratory therapist 
Standard: NR 
Quality control: NR 
Total: 243 
Acceptable: NR 
Pre-BD FEV1/FVC<0.7 43 cases 
FEV1 % predicted:  
>80%: 15 (34.9%) 
50-80%: 28 (65.1%) 
30-50%: 0 
<30%: 0 
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Study Population Spirometry Spirometry Definition of COPD New cases of COPD1 
Freeman 
2005 (40) 
Eligible: 1195 
Invited: 1195 
Consented: 624 
Subjects who 
performed 
spirometry 
Mean age: 61.7  
Male: 52%  
Smoking status 
Current: 54.1%  
Former: 45.9% 
Spirometer: Micro-Med handheld spirometer 
with Spida software 
Bronchodilator: 5mg salbutamol for those with 
prior respiratory medication/history of 
asthma/FEV1<80% predicted 
Operator: Trained respiratory nurse 
Standard: ATS standards. Minimum of 3 tests 
or until results within 5%. 
Quality control: All spirometry results were 
reviewed by a physician to ensure compliance 
with ATS standards 
Total: 369 
Acceptable: NR 
Post-BD FEV1/FVC<0.7 and lack of 
reversibility (reversibility defined as increase 
in FEV1 ≥200mL and 15% from pre-BD FEV1 
(not clear if all were post-BD) 
62 cases 
FEV1 % predicted  
NR 
 
Frith 
2011 (20) 
Eligible: 233 
Invited: 237 
Subjects with 
acceptable 
spirometry: 
Mean age:  61  
Male: 69%  
Smoking status 
Current: 45%  
Former: 55%  
Never: <1% 
Device: EasyOne spirometer (ndd Medical) 
Bronchodilator: 360mcg salbutamol 
Operator: trained operators using ATS/ERS 
guidelines 
Standard: ATS/ERS standards. At least 3 
adequate baseline and post-BD FVC 
manoeuvres performed. 
Quality control: spirometry quality monitored by 
a respiratory physiologist blinded to the 
questionnaire and Piko-6® results 
Total: 233 
Acceptable: 204 
Post-BD FEV1/FVC<0.7 57 cases 
FEV1 % predicted 
>80%: 19 (33.3%) 
50-80%: 35 (61.4%) 
30-50%: 3 (5.3%) 
<30%: 0  
Fuller 
2012 (57) 
Eligible: NR 
Invited: NR 
Subjects with 
acceptable 
spirometry: 
Mean age: 55 
Male: 40% 
Smoking status 
Current: 12% 
Former: 34% 
Never: 54% 
Device: EasyOne spirometer (ndd Medical) 
Bronchodilator: None 
Operator: 3 pharmacy residents and 5 clinical 
pharmacists who had participated in 16 hours 
of training from a pulmonary physician 
experienced in lung function testing. 
Standard: ATS standards 
Quality control: All spirometry results were 
reviewed independently by two study 
pulmonologists. 
Total: 185 
Acceptable: 174 
Pre-BD FEV1/FVC<LLN  (using NHANES III) 
reference equations 
16 cases 
FEV1 % predicted 
NR 
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Study Population Spirometry Spirometry Definition of COPD New cases of COPD1 
Geijer 
2005 (41) 
Eligible: 918 
Invited: NR 
Subjects with 
acceptable 
spirometry: 
Mean age: 50  
Male: 100% 
Smoking status 
Current: 100%  
Device: Vitalograph 2170 with Spirotrack 
software 
Bronchodilator: 250µg terbutaline 
Operator: Trained nurse practitioner 
Standard: Each subject had to perform at least 
three acceptable FVC manoeuvres according 
to ATS standards. 
Quality control: Two investigators 
independently assessed quality of spirometry 
curves according to ATS criteria. Where there 
was disagreement a final assessment was 
made by a lung physiologist. 
Total: 805 
Acceptable: 702 
FEV1/FVC<0.7 (unclear whether pre- or 
post-BD) 
210 cases 
FEV1 % predicted 
≥80%: 182 (86.7%) 
50-80%: 27 (12.9%) 
30-49%: 1 (0.5%) 
<30%: 0 
 
Hanania 
2010 (58) 
Eligible: NR 
Invited: NR 
Subjects with 
spirometry: 
Mean age: NR 
Male: 38.1% 
Smoking status  
NR 
 
Device: EasyOne spirometers (ndd Medical 
Technologies) 
Bronchodilator: None 
Operator: NR 
Standard: NR 
Quality control: Investigators rated spirometry 
quality based on reliability and reproducibility 
and only included traces that were considered 
reliable. 
Total: 937  
Acceptable:  NR 
Pre-BD FEV1/FVC<0.7 156 cases 
FEV1 % predicted 
≥80%: 17 (11.5%) 
50-80%: 76 (51.4%) 
30-50%: 44 (29.7%) 
<30%: 11 (7.4%) 
NB. Reported numbers 
do not summate to 156. 
Kimura 
2011 (60) 
(Study 1) 
Eligible: 839 
Invited: NR 
Eligible subjects: 
Mean age: 63.3  
Male: 33.7%  
Smoking status 
NR 
 
Device: Chestgraph Jr. H1-101 (Chest Co., 
Japan) 
Bronchodilator: None 
Operator: trained examiners 
Standard: ATS standards 
Quality control: All spirometry data were 
checked by two study authors. Only tests with 
at least two manoeuvres with FEV1 within 0.2L 
were included in the analysis.  
Total: 814  
Acceptable: 630   
 
 
 
  
Pre-BD FEV1/FVC<0.7 59 cases 
FEV1% predicted 
≥80%: 29 (49.2%) 
50-80%: 27 (45.8%) 
30-50%: 3 (5.1%) 
<30%: 0 
 
 
Kimura 
2011 (60) 
(Study 2) 
Eligible:1300 
Invited:363 
Mean age: NR 
Male: NR 
Smoking status 
NR 
As above  Total: 363  
Acceptable: 254  
Pre-BD FEV1/FVC<0.7 22 cases 
FEV1% predicted 
≥80%: 6 (27.3%) 
50-80%: 15 (68.2%) 
30-50%: 1 (4.5%) 
<30%: 0 
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Study Population Spirometry Spirometry Definition of COPD New cases of COPD1 
Kögler 
2010 (32) 
Eligible: NR 
Invited: 2276 
Subjects with 
complete data: 
Mean age: NR 
Male: 62.2%* 
Smoking status  
Current/ex: 100% 
Device: NR 
Bronchodilator: NR 
Operator: Pulmonologist 
Standard: NR 
Quality control: NR 
Total: 1282 
Acceptable: NR 
Physician diagnosis (physicians were 
advised to follow the GOLD strategy) 
516 cases 
FEV1% predicted: 
≥80%: 137 (12.6%) 
50-80%: 290 (26.7%) 
<50%: 89 (8.2%) 
 
Konstantikaki 
2011 (29) 
- Open 
spirometry 
programme 
Eligible: NR  
Invited: NR 
Subjects with 
acceptable 
spirometry: 
Mean age: 62.5  
Male: 64% 
Smoking status 
Current: 36.2% 
Former: 27.1% 
Never: 36.7% 
Device: dry spirometer (Koko Legend, Ferraris, 
UK) 
Bronchodilator: 400 µg salbutamol 
Standard: ATS standards 
Operator: Physicians who had undergone 
training by two chest physicians 
Quality control: three experienced chest 
physicians evaluated the quality of all 
spirometry readings 
Total:1084  
Acceptable: 905 
 
History of exposure to noxious particles or 
gases, particularly smoking, compatible 
symptoms, and post-BD FEV1/FVC<0.7 
76 cases 
FEV1% predicted: 
≥80%: 34 (44.7%) 
50-80%: 32 (42.1%) 
30-50%: 8 (10.5%) 
<30%: 2 (2.6%) 
Konstantikaki 
2011 (29) 
- Case-finding 
programme 
Eligible: NR 
Invited: NR 
Mean age: 63.5  
Male: 19.6% 
Smoking status 
Current: 68.7% 
Former: 22.9% 
Never: 8.5% 
As above Total: 219  
Acceptable: 201 
As above 56 cases 
FEV1% predicted 
≥80%: 18 (32.1%) 
50-80%: 32 (57.1%) 
30-50%: 4 (7.1%) 
<30%: 2 (3.6%) 
Kotz 
2008 (42) 
Eligible: 1052 
Invited: 1052 
Subject who 
performed 
spirometry: 
Mean age: 52.3  
Male: 58.7% 
Smoking status 
Current: 100% 
Device: Vitalograph 2120  
Bronchodilator: 500µg terbutaline 
Operator: Two qualified research assistants 
under the supervision of a pulmonologist 
Standard: ATS/ERS standards 
Quality control: All spirometry results were 
validated by a pulmonologist and specialised 
lung function laboratory assistant not involved 
in the trial- both were blinded to the 
questionnaire scores 
Total: 826  
Acceptable: 716 
Post-BD FEV1/FVC<0.7 278 cases 
FEV1 % predicted 
≥80%: 142 (51.1%) 
50-80%: 119 (42.8%) 
<50%: 17 (6.1%) 
 
111 
 
Study Population Spirometry Spirometry Definition of COPD New cases of COPD1 
Leuppi 
2010 (37) 
Eligible: 26,400 
Invited: NR 
Subjects aged ≥40 
years who 
performed 
spirometry: 
Mean age: 51.6 
Male: 58.6% 
Smoking status 
Current: 100% 
Device: EasyOne spirometer (ndd Medical 
Technologies) 
Bronchodilator: None 
Operator: GPs and practice nurses provided 
with 1-2 hours training 
Standard: ATS standards 
Quality control: spirometry quality assessed 
automatically by the spirometer. Only 
spirometry results in the top three quality 
grades were included in the analysis. 
Total: 24,995 
Acceptable: 15,084 
Pre-BD FEV1/FVC<0.70 in subjects <70 
years 
Pre-BD FEV1/FVC<0.65 in subjects aged 70-
80 years 
Pre-BD FEV1/FVC<0.60 in subjects aged 
>80 years 
4231 cases 
FEV1 % predicted 
≥80%: 951 (22.5%) 
50-80%: 2217 (52.4%) 
30-50%: 818 (19.3%) 
<30%: 245 (5.8%) 
Løkke 
2012 (33) 
Eligible: 4000 
Invited: NR 
Data on 4049 
subjects with 
complete data 
Mean age: 57.5%* 
Male: 51% 
Smoking status 
Current: 59% 
Former: 37% 
Never: 4% 
Device: NR 
Bronchodilator: 0.4mg salbutamol for those 
with initial airflow obstruction 
Operator: NR 
Standard: Danish Respiratory Society 
guidelines. Aimed to achieve at least three 
forced expiratory manoeuvres and at least two 
measurements differing <5% 
Quality control: NR 
Total: 4049 
Acceptable: NR 
Pre-BD FEV1/FVC≤0.7 & post-BD FEV1 
showing <200mL improvement or a negative 
corticosteroid reversibility test (spirometry 
performed 6 weeks after administration of 
1600ug budesonide daily or 37.5mg oral 
prednisolone daily for 14 days) for those with 
an FEV1 improvement of 200-500mL 
878 cases 
FEV1 % predicted 
≥80%: 307* (35%) 
50-79%: 439* (50%) 
<50%: 132* (15%) 
 
Price 
2006 (19) 
Eligible: NR 
Invited: 17,361 
Subjects with 
acceptable 
spirometry: 
Mean age: 58.2 
Male: 49.3% 
Smoking status 
Current: 44.5% 
Former: 55.5% 
Device: EasyOne spirometer (ndd Medical 
Technologies) 
Bronchodilator: 2.5mg salbutamol/albuterol 
Operator: NR 
Standard: ATS standards 
Quality control: Principal investigators 
conducted blinded review of all spirometry 
loops. A pulmonologist not associated with the 
study reviewed all loops on which there was 
disagreement. 
Total: 898 
Acceptable: 818 
 
Post-BD FEV1/FVC<0.7 155 cases 
FEV1 % predicted 
NR 
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Study Population Spirometry Spirometry Definition of COPD New cases of COPD1 
de Queiroz  
2012 (45) 
Eligible: NR 
Invited: 350 
Subjects with 
acceptable 
spirometry: 
Mean age: 65 
Male: NR 
Smoking status 
NR  
Device: Spirotrac® (Vitalograph) 
Bronchodilator: NR 
Operator: NR 
Standard: Brazilian Thoracic Association 
Quality control: NR  
Total: 214 
Acceptable: 200 
 
Post-BD FEV1/FVC<0.7 45 cases 
FEV1% predicted:  
≥80%: 22 (48.9%) 
50-80%: 17 (37.8%) 
30-50%: 6 (13.3%) 
<30%: 0 
Sandelowsky 
2011 (35) 
Eligible: 250 
Invited: 190 
Subjects with 
acceptable 
spirometry: 
Mean age: 55 
Male: 44.2% 
Smoking status 
Current: 52.9% 
Former: 47.1% 
Device: Vitalograph Alpha® 
Bronchodilator: 8µg formoterol 
Operator: NR 
Standard: NR 
Quality control: NR 
Total: 150 
Acceptable: 138 
Post-BD FEV1/FVC<0.7 
(Used ECCS reference equations for 
disease severity) 
38 cases 
FEV1% predicted: 
≥80%: 17 (44.7%) 
50-80%: 20 (52.6%) 
30-50%: 1 (2.6%) 
<30%: 0 
Sichletidis 
2011 (63) 
Eligible: 1250 
Invited: 1250 
Subjects with 
acceptable 
spirometry 
Mean age: 65.3  
Male: 57.1% 
Smoking status 
Current/ex: 48.8% 
Never: 51.2% 
Device: Vitalograph 
Bronchodilator:400µg salbutamol 
Operator: Pulmonary specialists 
Standard: ATS/ERS standards 
Quality control: Spirometry performed and 
interpreted by pulmonary specialists according 
to ATS/ERS standards 
Total: 1250 
Acceptable: 1078 
Post-BD FEV1/FVC<0.7 111 cases 
FEV1 % predicted 
≥80%:40 (36.0%) 
50-80%:53 (47.7%)  
30-50%:16 (14.4%) 
<30%:2 (1.8%) 
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Study Population Spirometry Spirometry Definition of COPD New cases of COPD1 
Stratelis 
2004 (43) 
Eligible: 5332 
Invited: 5332 
Subjects who 
performed 
spirometry: 
Mean age: 48  
Male: 43% 
Smoking status  
NR 
 
Device: Flowscreen version 3.10gb, 
Vitalograph Compact II, Vitalograph Alpha, 
Vicatest P2a 
Bronchodilator: None 
Operator: Trained COPD nurses 
Standard: ATS standards 
Quality control: Spirometry results were re-
evaluated by an experienced physician. 
Spirometry judged not to be optimal or showing 
evidence of obstruction was performed again 
by the physician. 
Total: 512 
Acceptable: NR 
Pre-BD FEV1/VCmax<88% predicted for 
males and <89% predicted for females 
141 cases 
FEV1% predicted: 
≥80%: 95 (63.3%) 
50-80%: 52 (34.7%) 
30-50%: 3 (2.0%) 
<30%: 0 
(NB. Reported numbers 
do not summate to 141) 
Takahashi  
2003 (64) 
Eligible: NR 
Invited: NR 
Subjects with 
acceptable 
spirometry: 
Mean age: 63.1 
Male: 76.3% 
Smoking status 
Current: 41.7% 
Former: 29.8% 
Never: 28.5% 
Device: Peakman-8, Chest Corp 
Bronchodilator: None 
Operator: Trained physician 
Standard: Subjects were asked to perform at 
least three forced expiratory manoeuvres. No 
standard reported.  
Quality control: Spirometry data were reviewed 
by pulmonary specialists 
Total: 1168 
Acceptable: 1040 
Pre-BD FEV1/FVC<0.7 
 
281 cases 
FEV1% predicted: 
≥80%: 62 (22.1%) 
50-80%: 60 (21.4%) 
30-50%: 30 (10.7%) 
<30%: 6 (2.1%) 
 
Takemura 
2005 (65) 
Eligible: NR 
Invited: NR 
Subjects aged ≥40 
years who 
performed 
spirometry: 
Mean age: 49.8*  
Male: 69.3% 
Smoking status 
Current: 38.2%  
Former: 18.7% 
Never: 43.1%  
Device: Autospiro AS-505 
Bronchodilator: None 
Operator: Trained laboratory technologist 
Standard: ATS standards 
Quality control: Spirometry performed 
according to ATS standards. No other quality 
control measures reported. 
Total: 10,256 
Acceptable: NR 
NB. Only including 
subjects aged 
≥40years (80.4% of 
all subjects) 
Pre-BD FEV1/VC<0.7 425 cases* 
FEV1% predicted 
NR 
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Study Population Spirometry Spirometry Definition of COPD New cases of COPD1 
Thorn 
2012 (46) 
Eligible: NR 
Invited: NR 
Subjects who 
performed 
spirometry: 
Mean age: 61.2  
Male: 43.3% 
Smoking status 
Current/ex: 100%  
Device: NR 
Bronchodilator: 0.5mg terbutaline 
Operator: Nurses 
Standard: ATS standards 
Quality control: NR 
 
Total: 305 
Acceptable: NR 
 
Post-BD FEV1/FVC<0.7 77 cases 
FEV1 % predicted 
≥80%: 35 (45.5%) 
50-80%: 41 (53.2%) 
30-50%: 1 (1.3%) 
<30%: 0 
 
Ulrik 
2011 (34) 
Eligible: 10,050 
Invited: NR 
Subjects with 
complete data 
(n=3097): 
Mean age: 58 
Male: 49% 
Smoking status 
Current: 65%  
Former: 32% 
Never:3% 
Device: NR 
Bronchodilator: NR 
Operator: NR  
Standard: NR 
Quality control: NR 
Total: 3095 
Acceptable: NR 
Pre-BD FEV1/FVC<0.7  1079 cases 
FEV1% predicted 
≥80%: 302 (28%)* 
50-80%: 550 (51%)* 
30-50%: 194 (18%)* 
<30%: 22 (2%)* 
 
 
van Schayck 
2002 (66) 
Eligible: 229 
Invited: 201 
Subjects who 
performed 
spirometry: 
Mean age: NR 
Male: NR 
Smoking status 
Current: 100%  
 
Device: MicroMedical 3300  
Bronchodilator: None 
Operator: Trained practice assistants with at 
least three years’ experience (received two 4 
hour sessions by a lung function laboratory 
assistant) 
Standard: ATS standards 
Quality control: Performance of practice 
assistants monitored by study author 
Total: 201 
Acceptable: 169 
Pre-BD FEV1% predicted<80% 30 cases 
FEV1% predicted  
NR 
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Study Population Spirometry Spirometry Definition of COPD New cases of COPD1 
Vandevoorde 
2007 (38) 
Eligible: 141 
Invited: 141 
Subjects meeting 
inclusion criteria 
(n=146): 
Mean age:52.3 
Male:42.5% 
Smoking status 
Current: 100% 
Device: Spirobank S, One Flow FVC 
Bronchodilator: None 
Operator: Participating GPs received 
spirometry training consisting of a theoretical 
course followed by two practical sessions in a 
lung function laboratory. 
Standard: ERS standards 
Quality control: All spirometry curves were 
assessed by two study authors. Two other 
study authors reviewed spirometry curves 
where there was disagreement. 
Total: 129 
Acceptable: 121 
Pre-BD FEV1/FVC<0.7  43 cases 
FEV1% predicted 
≥80%:18 (41.9%) 
50-80%:21 (48.8%) 
30-50%:4 (9.3%) 
<30%:0 
 
Vrijhoef  
2003 (67) 
Eligible: NR 
Invited: NR 
Subjects who 
performed 
spirometry: 
Mean age: 53.5  
Male: 48.5% 
Smoking status 
Current: 62% 
Former: 38% 
Device: Vitalograph 2120, Microlab 3300 
Bronchodilator: 500µg terbutaline 
Operator: Initial spirometry performed by four 
medical undergraduates trained for a day at a 
lung function laboratory. Subsequent 
spirometry performed by a respiratory nurse 
practitioner. 
Standard: ERS standards. 
Quality control: NR 
Total: 231 
Acceptable: NR 
Post-BD FEV1/FVC<0.65 of predicted ratio 
or FEV1<84% predicted following course of 
oral prednisolone 
17 cases 
FEV1% predicted 
NR 
 
*Value computed from available data 
NR=not reported, Age in years 
  
116 
 
 
Table S3.4 Results: studies evaluating screening questionnaires 
Study Population Questionnaire  Spirometry Screened Definition of COPD New cases of 
COPD 
Buffels 
2004 (52) 
Eligible: 3158 
Invited: 3158 
Data on subjects 
with spirometry 
Mean age: NR 
Male: 45% 
Smoking status 
Current: 30.7%  
Former: 18.1% 
Never: 50.1%  
 
Items: 
Cough >2 weeks 
Dyspnoea during mild 
exercise or at night 
Nasal allergy or hay fever 
Visit to doctor for wheeze 
or chronic cough 
Threshold: 
≥1 symptom 
Device: Spirobank spirometer with 
Winspiro software 
Bronchodilator: None 
Operator: GPs who had received 12 hours 
of training 
Standard: NR 
Quality control: Technical support 
provided to GPs throughout the study. 
Accuracy of GP-performed spirometry for 
a patient was compared to result from a 
lab technician. 
Questionnaire 
Total: 3158 
Positive: 728 
Spirometry 
Total: 703  
Acceptable: 
NR 
Pre-BD FEV1/FVC<88.5% predicted 
for men & <89.3% for women  
With symptoms 
and airflow 
obstruction: 
126 cases 
FEV1 % predicted 
(all spirometry 
tests) 
>80%: 53 (39%) 
50-80%: 69 
(51%) 
30-50%: 12 (9%) 
≤30%: 1 (<1%) 
 
Castillo 
2009 (53) 
Eligible: NR 
Invited: 254 
Data on subjects 
who completed 
questionnaire 
Mean age: 55  
Male: 42%  
Smoking status 
Current/ex: 77%  
Never: 23% 
Items: 
More breathlessness 
than people of same age 
Chronic cough 
Chronic sputum 
Age >40 years 
Smoking 
Threshold: 
 ≥3 positive items 
Device: EasyOne Spirometer (ndd 
Medical Technologies) 
Bronchodilator: None 
Operator: Pharmacists who had attended 
a four-day spirometry training course. 
Standard: ERS/ATS standards 
 
Quality control: All spirometry curves 
reviewed by a lung function expert. 
Subjects with FEV1/FVC<0.7 referred to 
lung function unit for spirometry. 
Questionnaire 
Total: 161 
Positive: 100 
Spirometry 
Total: 96 
Acceptable: 86 
Pre-BD FEV1/FVC<0.7 21 cases 
Severity: 
Mild: 13 (61.9%) 
Moderate: 7 
(33.3%) 
Severe: 1 (4.8%) 
(Severity grading 
criteria not 
reported) 
Dirven 
2013a (30)  
-Patient-
managed 
arm 
Eligible: 6,393 
Invited: 6,393 
Data on subjects 
who completed 
questionnaire 
Mean age: 53.5 
Male: 51.0% 
Smoking status 
Current: 40% 
Former: 12% 
Never: 48% 
 
COPD Diagnostic 
Question (referred to as 
“Respiratory Health 
Screening 
Questionnaire”) 
Items: 
See Price 2006 
Threshold: 
Score >19.5 
Device: NR 
Bronchodilator: NR 
Operator: NR 
Standard: Dutch College of General 
Practitioners 
Quality control: NR 
Questionnaire 
Total: 1715 
Positive: 186 
Spirometry 
Total: 140 
Acceptable: 
NR 
Post-BD FEV1/FVC<0.7  & physician’s 
clinical evaluation 
25 cases 
FEV1 % predicted 
NR 
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Study Population Questionnaire  Spirometry Screened Definition of COPD New cases of 
COPD 
Dirven 
2013a (30)  
-Practice-
managed 
arm 
Eligible: 3,715 
Invited: 3,715 
Data on subjects 
who completed 
questionnaire 
Mean age: 53.7 
Male: 49.7% 
Smoking status 
Current: 44% 
Former: 14% 
Never: 42% 
 
As above As above Questionnaire 
Total: 1855 
Positive: 251 
Spirometry 
Total: 135 
Acceptable 
quality: NR 
As above 48 cases 
FEV1 % predicted 
NR 
Dirven 
2013b (44) 
Eligible: 849 
Invited: 831 
Mean age: NR 
Male: NR 
Smoking status: 
Current: NR 
Former: NR 
Never: NR 
 
As above (Dirven 2013a) Device: NR 
Bronchodilator: NR  
Operator: NR 
Standard: NR 
Quality control: NR 
Questionnaire 
Total: 293 
Positive: 50 
Spirometry 
Total: 39 
Acceptable: 
NR 
Post-BD FEV1/FVC<0.7  & physician’s 
clinical evaluation 
9 cases 
FEV1 % predicted 
NR 
Freeman 
2005 (40) 
 
Eligible: 1195 
Invited: 1195 
Data on subjects 
with spirometry 
Mean age: 61.7  
Male: 52%  
Smoking status 
Current: 54.1%  
Former: 45.9% 
Multiple response 
questionnaire 
Items: 
Age 
Smoking status 
Pack-years 
Cough 
Dyspnoea 
Wheeze 
Threshold:  
NR (included only “best” 
reported) 
 
Spirometer: Micro-Med handheld 
spirometer with Spida software 
Bronchodilator: 5mg salbutamol for those 
with prior respiratory medication/history of 
asthma/FEV1<80% predicted 
Operator: Trained respiratory nurse 
Standard: ATS standards. Minimum of 3 
tests or until results within 5%. 
Quality control: All spirometry results 
reviewed by a physician to ensure 
compliance with ATS standards 
Questionnaire 
Total: 369 
Positive: 121*  
Spirometry 
Total: 369 
Acceptable: 
NR 
Post-BD FEV1/FVC<0.7 and lack of 
reversibility (reversibility defined as 
increase in FEV1 of ≥200mL and 15% 
from pre-BD FEV1 
(not clear if all were post-BD) 
47 cases* 
FEV1 % predicted 
NR 
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Study Population Questionnaire  Spirometry Screened Definition of COPD New cases of 
COPD 
Freeman 
2005 (40) 
 
Eligible: 1195 
Invited: 1195 
Data on subjects 
with spirometry 
Mean age: 61.7  
Male: 52%  
Smoking status 
Current: 54.1%  
Former: 45.9% 
Binary response 
questionnaire 
As above 
 
As above Questionnaire 
Total: 369 
Positive: 142*  
Spirometry 
Total: 369 
Acceptable: 
NR 
As above 54 cases* 
FEV1 % predicted 
NR 
Frith 
2011 (20) 
Eligible: 233 
Invited: 237 
Data on subjects 
with acceptable 
spirometry: 
Mean age:  61  
Male: 69%  
Smoking status 
Current: 45%  
Former: 55%  
Never: <1% 
COPD Diagnostic 
Questionnaire 
Items: 
See Price 2006 
Threshold: 
≥19.5 
Device: EasyOne spirometer (NDD) 
Bronchodilator: 360mcg salbutamol 
Operator: trained operators using 
ATS/ERS guidelines 
Standard: ATS/ERS standards. At least 3 
adequate baseline and post-BD FVC 
manoeuvres performed. 
Quality control: spirometry quality 
monitored by a respiratory physiologist 
blinded to the questionnaire and Piko-6® 
results 
Questionnaire 
Total: 233 
Positive: 107*  
Spirometry 
Total: NR 
Acceptable: 
204 
Post-BD FEV1/FVC<0.7 40 cases* 
FEV1 % predicted 
see table S3.3 
Frith 
2011 (20) 
As above As above 
Threshold: 
≥16.5 
As above Questionnaire 
Total: 233 
Positive: 163*  
Spirometry 
As above 
As above 52 cases* 
FEV1 % predicted 
see table S3.3 
 
Hanania 
2010 (58) 
Eligible: NR 
Invited: NR 
Data on 837 
subjects with 
spirometry: 
Mean age: NR 
Male: 38.1%  
Smoking status 
NR 
Lung Function 
Questionnaire 
Items: 
Age 
Cough 
Wheeze 
Dyspnoea 
Smoking 
Threshold:  
Score ≤18 
Device: EasyOne spirometers (ndd 
Medical Technologies) 
Bronchodilator: None 
Operator: NR 
Standard: NR 
Quality control: Investigators rated 
spirometry quality based on reliability and 
reproducibility. Only included traces 
considered reliable. 
Questionnaire 
Total: 937 
Positive: 537* 
Spirometry 
Total: 937  
Acceptable: 
NR 
Analysed: 837 
Pre-BD FEV1/FVC<0.7 129 cases* 
FEV1 % predicted 
See table S3.3 
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Study Population Questionnaire  Spirometry Screened Definition of COPD New cases of 
COPD 
Haroon 
2013 (28)  
Eligible: 815 
Invited: 813 
Data on subjects 
who returned 
questionnaire 
Mean age: 53.0  
Male: 60.8% 
Smoking status 
Current: 62.3%  
Former: 45.8%  
Postal questionnaire 
Items  
Cough 
Wheeze 
Sputum 
Dyspnoea 
Smoking 
Occupational exposures 
Demographics 
Threshold 
≥1 chronic respiratory 
symptom 
Device: Microloop and Micro GP 
spirometers with Spida 5 software 
Bronchodilator: None 
Operator: Trained practice nurses  
Standard: ATS/ERS standards 
Quality control: First five spirometry 
results were quality checked by a 
respiratory scientist 
Questionnaire 
Total: 212 
Positive: 166 
Spirometry 
Total: 70 
Acceptable: 
NR 
Pre-BD FEV1/FVC<0.7 with 
FEV1<80% predicted, lack of 
reversibility (reversibility defined as 
increase in FEV1 of 200mL and 15% 
from pre-BD FEV1) and presence of 
respiratory symptoms. 
10 cases 
FEV1 % predicted 
50-80%: 14 
(87.5%) 
30-50%: 2 
(12.5%) 
<30%: 0 (0%) 
(NB. FEV1 % 
predicted 
includes results 
from both study 
arms) 
Haroon 
2013 (28)  
Eligible: 819 
Invited: 258 
Mean age: 55.3  
Male: 67.6%  
Smoking status 
Current: 55.9%  
Former: 54.1%  
Opportunistic 
questionnaire 
As above 
As above Questionnaire 
Total: 111 
Positive: 81 
Spirometry 
Total: 28 
Acceptable: 
NR 
As above 6 cases 
FEV1 % predicted  
As above 
 
Kotz  
2008 (42) 
Eligible: 1052 
Invited: 1052 
Data on subjects 
with spirometry: 
Mean age: 52.3  
Male: 58.7% 
Smoking status 
Current: 100% 
COPD Diagnostic 
Questionnaire (CDQ)  
Items: 
See Price 2006 
Threshold 
≥19.5 
Device: Vitalograph 2120 
Bronchodilator: 500 µg terbutaline  
Operator: Two qualified research 
assistants under supervision of a 
pulmonologist. 
Standard: ATS/ERS standards 
Quality control: All spirometry results were 
validated by a pulmonologist and 
specialised lung function laboratory 
assistant not involved in the trial- both 
were blinded to questionnaire scores. 
Questionnaire 
Total: 1052 
Positive: 554*  
Spirometry 
Total: 826  
Acceptable: 
716 
Post-BD FEV1/FVC<0.7 233 cases* 
FEV1 % predicted 
See table S3.3 
Kotz  
2008 (42) 
As above As above 
Threshold 
≥16.5 
As above Questionnaire 
Total: 1052 
Positive: 844*  
Spirometry 
As above 
As above 316 cases* 
FEV1 % predicted 
See table S3.3 
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Study Population Questionnaire  Spirometry Screened Definition of COPD New cases of 
COPD 
Laniado-
Laborin 
2011 (61) 
Eligible: NR 
Invited: NR 
Data on 2293 
subjects with 
acceptable 
spirometry: 
Mean age: 57.6  
Male: 39.8% 
Smoking status 
Current: 42.1%* 
Former: NR 
Never: NR 
Items 
Smoking 
Exposure to biomass 
smoke and/or dusts 
Cough 
Sputum production 
Dyspnoea 
Threshold 
 ≥1 symptom or risk 
factor 
Device: EasyOne spirometer (ndd Medical 
Technologies) 
Bronchodilator: NR 
Operator: Certified respiratory therapist 
Standard: ATS/ERS standards 
Quality control: Poor quality results were 
excluded from analysis. 
Questionnaire 
Total: NR 
Positive: NR 
Spirometry 
Total: 2617 
Acceptable: 
2293 
Post-BD FEV1/FVC<0.7 
(Used reference equations from 
NHANES III for Mexican Americans) 
472 cases  
FEV1 % predicted 
≥80%: 96 
(20.3%) 
50-79%: 217 
(46.0%) 
30-49%: 123 
(26.1%) 
<30%: 36 (7.6%) 
 
Mintz  
2011 (62) 
Eligible: NR 
Invited: 4956 
Data on subjects 
who completed 
questionnaire: 
Mean age: 53.9* 
Male: 51.2% 
Smoking status 
Current: 57.6% 
Former: 42.4% 
Lung Function 
Questionnaire 
Items 
See Hanania 2010 
Threshold  
Score ≤18 
Device: Biomedical Systems, St Louis, 
MO 
Bronchodilator: 360µg albuterol 
Operator: Trained site staff 
Standard: ATS standards 
Quality control: Only data collected from 
acceptable spirometry manoeuvres were 
included. Patients producing unacceptable 
spirometry were allowed to repeat this 
within seven days of study visit. 
Questionnaire 
Total: 1575 
Positive: 1228* 
Spirometry  
Total: 1225 
Acceptable: 
849 
LFQ≤18 & post-BD FEV1/FVC<0.7 315 cases* 
NB. restricted to 
subjects ≥40 
years 
FEV1 % predicted 
NR 
Price 
2006 (19) 
Eligible: NR 
Invited: 17,361 
Data on subjects 
with acceptable 
spirometry 
Mean age: 58.2  
Male: 49.3% 
Smoking status 
Current: 44.5% 
Former: 55.5% 
COPD Diagnostic 
Questionnaire 
Items 
Age 
Smoking pack-years 
Weather-affected cough 
Cough up phlegm in 
absence of a cold 
Early morning cough 
Wheeze  
Allergies 
Threshold 
≥19.5 
Device: EasyOne spirometer (NDD) 
Bronchodilator:2.5mg salbutamol/albuterol 
Operator: NR 
Standard: ATS standards 
Quality control: Principal investigators 
conducted blinded review of all spirometry 
loops. A pulmonologist not associated 
with the study reviewed all loops on which 
there was disagreement. 
Questionnaire 
Total: 898 
Positive: 243* 
Spirometry 
Total: 898 
Acceptable: 
818 
 
Post-BD FEV1/FVC<0.7 91 cases* 
FEV1 % predicted 
See table S3.3 
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Study Population Questionnaire  Spirometry Screened Definition of COPD New cases of 
COPD 
Price 
2006 (19) 
As above As above 
Threshold 
≥16.5 
As above Questionnaire 
Total: 898 
Positive: 406*  
Spirometry 
As above 
As above 125 cases* 
FEV1 % predicted 
NR 
 
Sichletidis 
2011 (63) 
Eligible: 1250 
Invited: 1250 
Data on subjects 
with acceptable 
spirometry: 
Mean age: 65.3  
Male:57.1% 
Smoking status 
Current/ex: 48.8% 
Never: 51.2% 
COPD Diagnostic 
Questionnaire (referred 
to as “International 
Primary Airways Group 
Questionnaire”) 
Items 
See Price 2006 
Threshold 
Score ≥17 
 
Device: Vitalograph 
Bronchodilator:400µg salbutamol 
Operator: Pulmonary specialists 
Standard: ATS/ERS standards 
Quality control: Spirometry performed and 
interpreted by pulmonary specialists 
according to ATS/ERS standards 
Questionnaire 
Total: 1250 
Positive: 693* 
Spirometry 
Total: NR 
Acceptable: 
1078 
Post-BD FEV1/FVC<0.7 103 cases * 
FEV1 % predicted 
See table S3.3 
 
ATS=American Thoracic Society, ERS=European Respiratory Society, LFQ=Lung Function Questionnaire 
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Table S3.5 Results: studies evaluating handheld flow meters 
Study Population Handheld spirometer Spirometry Screened Definition of COPD New cases of COPD 
Duong-Quy 
2009 (56) 
Eligible: 2464 
Invited: NR 
Data on 2397 
screened subjects  
Mean age: 52 
Male: 99.7% 
Smoking status 
Current: 88.9% 
Former: 11.1% 
Pre-BD Piko-6® 
Best of three manoeuvres 
selected. 
All measures where 
FEV1/FEV6>1 were 
excluded. 
Operator: NR 
Threshold 
FEV1/FEV6<0.7 
Device: SpiroLab II 
Bronchodilator: short-acting β2-agonist 
(specific drug not specified) 
Operator: NR 
Standard: ATS/ERS standards. 
Quality control: Required at least three 
measures and at least two within 150mL 
Handheld flow 
meter 
Total: 2464 
Positive: 324 
Spirometry 
Total:144 
Acceptable: NR 
Post-BD FEV1/FVC<0.7 
with <200mL or 12% 
reversibility 
136 cases 
FEV1 % predicted 
<80%: 65 
50-79%: 63 
30-49%: 8 
<30%: 0 
Frith 
2011(20) 
Eligible: 233 
Invited: 237 
Data on subjects 
with acceptable 
spirometry: 
Mean age:  61  
Male: 69%  
Smoking status 
Current: 45%  
Former: 55%  
Never: <1% 
Pre-BD Piko-6®  
Operator: Study nurse or 
GP 
Threshold:  
FEV1/FEV6<0.75 (optimal 
cut-point) 
 
Device: EasyOne spirometer (ndd 
Medical Technologies) 
Bronchodilator: 360mcg salbutamol 
Operator: trained operators  
Standard: ATS/ERS standards. At least 
3 adequate baseline and post-BD FVC 
manoeuvres performed. 
Quality control: spirometry quality 
monitored by a respiratory physiologist 
blinded to the questionnaire and Piko-
6® results 
Handheld flow 
meter 
Total: 233 
Positive: 97* 
Spirometry 
Total: NR 
Acceptable: 204 
Post-BD FEV1/FVC<0.7 46 cases* 
FEV1 % predicted: see 
table S3.3 
Kaufmann 
2009 (59) 
Eligible: NR  
Invited: NR 
Data on subjects 
who used 
handheld flow 
meter: 
Mean age: 54.8* 
Male: 37.7%  
Smoking status 
Current: 30.4%  
Former: 4.1%  
Never: 65.5%  
Pre-BD Piko-6®  
Operator: trained study 
nurses  
Threshold: 
FEV1/FEV6<80% 
Device: NR 
Bronchodilator: Combivent (dose not 
reported) 
Operator: Trained study nurses 
Standard: NR 
Quality control: Study nurses were 
trained in a pulmonary function 
laboratory 
Handheld flow 
meter 
Total: 507 
Positive: 106 
Spirometry 
Total: 74 
Acceptable: NR 
Reversibility of 
FEV1≤200mL or <15% after 
administration of 
Combivent (dose NR) 
14 cases 
FEV1 % predicted 
≥80%: 9 (64.3%) 
50-80%: 5 (35.7%) 
<50%: 0 
(NB. Study also 
included five patients 
with normal spirometry 
as having COPD) 
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Study Population Handheld spirometer Spirometry Screened Definition of COPD New cases of COPD 
Sichletidis 
2011 (63) 
Eligible: 1250 
Invited: 1250 
Data on subjects 
with acceptable 
spirometry: 
Mean age:65.3 
Male:57.1% 
Smoking status 
Current/ex: 48.8% 
Never: 51.2% 
Post-BD Piko-6® 
Operator: GPs who had 
two hours training 
Bronchodilator: 400µg 
salbutamol 
Threshold 
Post-BD FEV1/FEV6<0.7 
Device: Vitalograph 
Bronchodilator:400µg salbutamol 
Operator: Pulmonary specialists 
Standard: ATS/ERS standards 
Quality control: Spirometry performed 
and interpreted by pulmonary specialists 
according to ATS/ERS standards 
Handheld flow 
meter 
Total: 1250 
Positive: 147*  
Spirometry 
Total: NR 
Acceptable: 1078 
Post-BD FEV1/FVC<0.7 89 cases* 
FEV1 % predicted 
See table S3.3 
Sichletidis 
2011 (63) 
As above Post-BD Piko-6® and 
COPD Diagnostic 
Questionnaire (see table 
3) 
As above Handheld flow 
meter & screening 
questionnaire 
Total: 1250 
Positive: 111*  
Spirometry: 
As above 
As above 82 cases* 
FEV1 % predicted 
See table S3.3 
Thorn  
2012 (46) 
Eligible: NR 
Invited: NR 
Data on subjects 
with spirometry: 
Mean age: 61.2  
Male:43.3% 
Smoking status  
Current/ex: 100% 
Pre-BD COPD 6® 
Operator: Nurses 
Threshold 
FEV1/FVC<0.73 
Device: NR 
Bronchodilator: 0.5mg terbutaline 
Operator: Nurses 
Standard: ATS standards 
Quality control: NR 
Handheld flow 
meter 
Total: 305 
Positive: 106* 
Spirometry 
Total: 305 
Acceptable: NR 
 
Post-BD FEV1/FVC<0.7 61 cases* 
FEV1 % predicted 
See table S3.3 
ATS=American Thoracic Society, ERS=European Respiratory Society, NR=not reported 
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CHAPTER 4: PREDICTING RISK OF 
COPD IN PRIMARY CARE: 
DEVELOPMENT AND VALIDATION 
OF A CLINICAL RISK SCORE  
This chapter is based on a paper currently in press: Haroon S, Adab P, Riley RD, 
Marshall T, Lancashire R, Jordan RE. Predicting risk of COPD in primary care: 
development and validation of a clinical risk score. BMJ Open Respiratory Research. 
2014.  
4.1 Abstract 
Objectives 
To develop and validate a clinical risk score to identify patients at risk of chronic 
obstructive pulmonary disease (COPD) using clinical factors routinely recorded in 
primary care. 
Design 
Case-control study of patients containing one incident COPD case to two controls 
matched on age, sex, and general practice. Candidate risk factors were included in a 
conditional logistic regression model to produce a clinical score. Accuracy of the 
score was estimated on a separate external validation sample derived from 20 
purposively selected practices. 
Setting 
UK general practices enrolled in the Clinical Practice Research Datalink (1st January 
2000 to 31st March 2006). 
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Participants 
The development sample included 340 practices containing 15,159 newly diagnosed 
COPD cases and 28,296 controls (mean age 70 years, 52% male). The validation 
sample included 2,259 cases and 4,196 controls (mean age 70 years, 50% male).  
Main outcome measures 
Area under the receiver operator characteristic curve (c-statistic), sensitivity, and 
specificity in the validation practices.  
Results 
The final model included four variables including smoking status, history of asthma, 
and lower respiratory tract infections, and prescription of salbutamol in the previous 
three years. It had a high average c-statistic of 0.85 [95% CI 0.83 to 0.86]) and 
yielded a sensitivity of 63.2% (95% CI 63.1 to 63.3) and specificity of 87.4% (95% CI 
87.3 to 87.5).  
Conclusions 
Risk factors associated with COPD and routinely recorded in primary care have been 
used to develop and externally validate a new COPD risk score. This could be used 
to target patients for case finding.  
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4.2 Introduction 
Chronic obstructive pulmonary disease (COPD) is the third leading cause of 
mortality.(1) However, population studies suggest that 50-90% of the disease burden 
remains undiagnosed.(2) A recent analysis of UK primary healthcare records showed 
that opportunities to diagnose COPD are frequently missed with up to 85% of 
patients presenting within five years of their diagnosis with indicative symptoms and 
clinical events.(3) There is now a drive to identify such patients in order to instigate 
early management and reduce disease progression.(4) A variety of screening tools 
have been proposed and evaluated including symptom-based questionnaires,(5) and 
use of handheld and diagnostic spirometry.(6) Although a variety of screening tools 
for COPD have been evaluated, as summarised in Chapters 2 and 3, mass 
screening is likely to be costly and a more targeted approach is required to improve 
their efficiency.  
One potential way to achieve this is through the use of clinical prediction models. 
Several have already been developed to identify individuals at risk of undiagnosed 
COPD. These include two developed in the USA using administrative claims data,(7, 
8) one in Denmark using primary and secondary care data,(9) and most recently in 
Scotland using routine primary healthcare data.(10) The first three models are 
unlikely to be implementable in a UK or similar primary care setting because of 
differences in healthcare structures as well as the included predictor variables, many 
of which are not routinely recorded. The Scottish model, while likely to be 
implementable, only considered a very limited number of potential risk factors, was 
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not externally validated, and used a country-specific index of socioeconomic 
deprivation as a predictor, which limits its use outside the UK.(10)  
This chapter reports the development and external validation of a clinical prediction 
model that provides a score for identifying patients at high risk of undiagnosed COPD 
in primary care.   
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4.3 Methods 
4.3.1 Study design 
Electronic primary care records were available from a matched case-control dataset 
obtained from the General Practice Research Database (GPRD; now the Clinical 
Practice Research Datalink). Cases with incident COPD were matched by age, sex 
and general practice with controls without COPD (1:2).  
4.3.2 Description of dataset 
The GPRD is a computerised database of longitudinal anonymised patient records 
from a representative sample of 480 general practices across the UK, covering 
approximately 6% of the population.(11)  
4.3.3 Selection of cases and controls 
Cases consisted of all patients aged ≥35 years on 1st April 2006 with a new diagnosis 
of COPD recorded between 1st January 2000 and 1st April 2006 (see Table S4.1 for 
clinical codes). Cases had at least three years of up-to-standard data (i.e. data entry 
meeting set quality standards) prior to the date of COPD diagnosis (index date). 
Controls had no diagnosis of COPD, were registered on the index date and also had 
at least three years of up-to-standard data. 
4.3.4 Identification of candidate risk factors 
Risk factors associated with newly diagnosed COPD were identified from published 
epidemiological studies. Studies were identified from Medline, Embase and Google 
Scholar using “COPD” (and relevant synonyms) and “risk factor” as Medical Subject 
Headings and free text (Appendix 4). From 544 articles 46 candidate risk factors 
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were identified that were likely to be routinely recorded in primary care (Table 4.1). 
The final list included smoking history, comorbidities (including asthma, ischaemic 
heart disease and depression), lower and upper respiratory tract infections (LRTIs, 
URTIs), respiratory symptoms (including cough, dyspnoea, wheeze, and sputum 
production), systemic symptoms (including unintentional weight loss, chronic fatigue, 
and poor sleep), body mass index, and health service use including medication 
prescriptions (salbutamol, oral prednisolone, and antibiotics for a LRTI) and number 
of previous primary care consultations.  
4.3.5 Data extraction 
Clinical codes for each variable were identified using the CPRD medical and product 
dictionaries and the NHS Clinical Terminology Browser version 1.04.(12) Data on 
demographic characteristics, smoking, comorbidities, respiratory symptoms and 
health service use were extracted over the specified period (Table 4.1). Data 
recorded within 60 days prior to the index date were excluded since a clinical 
suspicion of COPD could have influenced clinical activity during this period.(7) 
Smoking status closest to the COPD diagnosis date (or matched time point) was 
used to reflect likely clinical practice.  
4.3.6 Sample size and creation of derivation and validation datasets 
The dataset was split into a development and external validation sample (whilst 
preserving matching of cases and controls) by purposively selecting 20 general 
practices that reflected the full range of practice and population characteristics where 
the risk score would be applicable. These practices each had at least 200 individuals 
to ensure validation statistics were estimated with high precision.  
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Table 4.1 Risk factors associated with COPD extracted for analysis 
Category Variable Restriction*1 
Demographic 
information 
Age At diagnosis 
Sex N/A 
Socioeconomic status*2  N/A 
Smoking history Current smoker Last recorded before diagnosis  
Ex-smoker Last recorded before diagnosis  
Never smoked Last recorded before diagnosis  
Comorbidities Asthma Before diagnosis 
Ischaemic heart disease*3 Before diagnosis 
Heart failure Before diagnosis 
Stroke Before diagnosis 
Hyperlipidaemia Before diagnosis 
Anaemia Before diagnosis 
Polycythaemia Within 3 years of diagnosis 
Pulmonary embolus Within 3 years of diagnosis 
Deep vein thrombosis Within 3 years of diagnosis 
Atrial fibrillation Before diagnosis 
Lung cancer Before diagnosis 
Cancer (excluding lung cancer) Before diagnosis 
Depression  Within 3 years of diagnosis 
Anxiety  Within 3 years of diagnosis 
Allergic rhinitis Before diagnosis 
Tuberculosis Before diagnosis 
Obstructive sleep apnoea Before diagnosis 
Gastric ulcer Before diagnosis 
Helicobacter pylori Before diagnosis 
Gastro-oesophageal reflux disease Before diagnosis 
Osteoporosis Before diagnosis 
Fractures Before diagnosis 
Diabetes Before diagnosis 
Rheumatoid arthritis Before diagnosis 
Chronic kidney disease Before diagnosis 
Underweight Within 3 years of diagnosis 
Cachexia Within 3 years of diagnosis 
Overweight Within 3 years of diagnosis 
Obesity Within 3 years of diagnosis 
Lower respiratory tract infection Within 3 years of diagnosis 
Upper respiratory tract infection Within 3 years of diagnosis 
Common cold Within 3 years of diagnosis 
Allergies Before diagnosis 
Symptoms Cough  Within 3 years of diagnosis 
Dyspnoea Within 3 years of diagnosis 
Wheeze Within 3 years of diagnosis 
Sputum Within 3 years of diagnosis 
Unintentional weight loss  Within 3 years of diagnosis,  
Chronic fatigue or tiredness Within 3 years of diagnosis 
Insomnia/poor sleep Within 3 years of diagnosis 
Clinical 
measurements and 
tests 
Height  Last recorded before diagnosis 
Weight  Last recorded before diagnosis 
Body mass index  Last recorded before diagnosis 
Sputum culture Within 3 years of diagnosis 
Chest X-ray Within 3 years of diagnosis 
Medications Salbutamol  Within 3 years of diagnosis,  
Oral prednisolone  Within 3 years of diagnosis 
 Antibiotics*4 Within 3 years of diagnosis 
Consultations GP consultations Within 3 years of diagnosis 
Emergency hospital referrals Within 3 years of diagnosis 
*1. Excluding 60 days prior to COPD diagnosis or equivalent matched time point for controls. 
*2. Socioeconomic status of general practice as measured by the Index of Multiple Deprivation Score. 
*3. Including myocardial infarction, angina & coronary artery bypass graft. 
*4. Antibiotics (combined): amoxicillin, clarithromycin, doxycyclin, benzylpenicillin, co-amoxiclav, cefuroxime, or rifampicin 
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4.3.7 Model development 
Both the unadjusted and adjusted association between each factor and COPD were 
estimated using conditional logistic regression (to account for matching of cases and 
controls). Risk factors were included in the model based on statistical significance 
(adjusted odds ratio ≥1.5 and p-value <0.05) and clinical understanding, with the aim 
to achieve a parsimonious and clinically acceptable model (Figure 4.1). The final 
model was simplified by including only four risk factors that had the highest adjusted 
odds ratios and were most likely to be recorded in a range of primary care settings. 
Missing smoking status was accounted for by including a missing value category in 
the regression model. Patients in primary care may have unknown smoking status 
and the model in practice may be applied to such patients. Missing data for other 
factors was assumed indicative of their true absence.  Risk scores were computed 
for each individual by combining the estimated regression log odds ratios (beta 
coefficients) from the final model with the individual's risk factor values.  
4.3.8 External validation and model performance 
The accuracy of the risk score was evaluated in each of the 20 validation practices 
by producing the corresponding receiver operator characteristic (ROC) curve and 
estimating the area under it (c-statistic). To summarise the average performance 
across the 20 practices, the c-statistic estimates were synthesised in a random 
effects meta-analysis. The heterogeneity in performance was also summarised by 
estimating a 95% interval for the range of potential c-statistics.(13) 
A score cut-point to define 'high risk' was selected by optimising the balance between 
the sensitivity and positive predictive value (PPV), assuming a prevalence of 
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undiagnosed COPD of 5.5% in the general population.(14) The total number 
screened was divided by the number of true positives to derive the number-needed-
to-screen (NNS) to detect a single case of COPD. The number of diagnostic 
assessments needed to detect a single case of COPD (NND) was estimated as the 
reciprocal of the PPV.  
 
Figure 4.1 Model building strategy 
 
Step 5: The final multivariable model was estimated by including all risk factors remaining after 
step 4. Missing data was only a concern for smoking status and was accounted for by including 
a “missing value” in the regression model (but multiple imputation was not used).  
Step 4: Finally risk factors that had an adjusted OR<1.5 in the model from step 3 were 
excluded to achieve a more parsimonious model that could be practically used in a brief 
general practice consultation. 
Step 3: Any risk factors that had initially been excluded on the basis of their unadjusted OR 
were then individually added to the model from step 2, to assess whether they improved the fit 
using likelihood ratio tests. Risk factors that did not improve the fit of the model were excluded.  
Step 2: The multivariable model containing risk factors from step 1 was then estimated, and 
any risk factors with a p-value >0.05 for the adjusted OR were then individually removed from 
the model. The fit of each reduced model was tested against the model witht the risk factor 
included using likelihood ratio tests. Risk factors that did not significantly contribute to the 
overall fit of the model were excluded unless they were considered to be clinically significant. 
Step 1: Risk factors were initially included if the p-value of the unadjusted OR was <0.2 or if 
they were considered clinically important (based on face validity). 
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4.4 RESULTS 
4.4.1 Development sample: population characteristics 
15,159 newly diagnosed COPD cases and 28,296 controls from 340 general 
practices were included in the development sample (Tables 4.2 and 4.3). Mean age 
was 70 years and 52% were male. Cases and controls were matched and therefore 
identical in age, sex, and socioeconomic status of registered practice. 27% were 
current smokers, 25% ex-smokers and 40% had never smoked. A significantly higher 
proportion of cases than controls had a positive smoking history (77% vs. 38%, 
respectively). All co-morbidities except hyperlipidaemia and diabetes mellitus were 
more common in cases than in controls. This was also true for respiratory and 
systemic symptoms, including fatigue and poor sleep, as well as health service use. 
4.4.2 Model results 
Details of the selection of predictors are shown in Table S4.2. The final model 
included history of smoking, asthma, and salbutamol prescriptions and number of 
lower respiratory tract infections (LRTIs) in the previous three years (Table 4.4). 
There was a significant drop in the model fit when removing asthma, salbutamol and 
LRTIs. The model was used to derive a clinical score ranging from 0 to 6.5 as shown 
below Table 4.4. This had a c-statistic in the development sample of 0.85 (95% CI 
0.845 to 0.853). A more comprehensive model that incorporates additional variables, 
including symptoms, is provided in Table 4.5. 
4.4.3 External validation sample: population characteristics  
2259 newly diagnosed cases and 4196 controls from 20 general practices were 
included in the validation sample (Table 4.6). The mean age was 70 years, 50% were 
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male, and 26.6% were current smokers. A greater proportion of subjects in the 
validation sample than the development sample were from practice in the lowest 
socioeconomic quintile (42.4% vs. 26.8%, respectively).  
4.4.4 External validation: discriminative ability 
The final risk score had a c-statistic of 0.84 (95% CI 0.83 to 0.85) in the validation 
sample when analysing the data from all 20 practices combined (ignoring clustering 
of patients within practices; Figure 4.2). The c-statistic in each of the validation 
practices separately was consistently high (Figure 4.3) and a random effects meta-
analysis (which takes into account clustering) produced a similar summary c-statistic 
of 0.85 (95% CI 0.83 to 0.86), with a 95% prediction interval of 0.80 to 0.90. The 
more comprehensive score had a marginally higher c- statistic (0.87, 95% CI 0.86 to 
0.87). 
Table 4.7 summarises the performance of the final score across a range of 
thresholds in the validation sample. A score threshold of ≥2.5 yielded a sensitivity of 
63.2% (95% CI 63.1 to 63.3) and specificity of 87.4% (95% CI 87.3 to 87.5). 
Assuming a prevalence of undiagnosed COPD of 5.5%,(14) the score at the 
suggested threshold would have a PPV of 22.6%, NPV of 97.6%, and an overall 
screening yield of 3.5% when applied to patients over the age of 35 years. At this 
threshold the score would need to be applied to 29 patients, 5 of whom would require 
a clinical assessment, to identify one with COPD (Figure 4.4).  
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Table 4.2 General characteristics of subjects in the development sample 
  Controls 
(n=28,296) 
Cases 
(n=15,159) 
Unadjusted  
OR 
(95% CI) 
  N (%) N (%)    
Mean age (standard deviation)  69.7 (10.8) 69.7 (10.9) -   
Males  14,655 (51.8) 7,849 (51.8) -   
Socioeconomic quintile*1 1 5,035 (17.8) 2,698 (17.8) -   
 2 4,156 (14.7) 2,237 (14.8) -   
 3 5,079 (17.9) 2,733 (18.0) -   
 4 6,386 (22.6) 3,429 (22.6) -   
 5 7,640 (27.0) 4,062 (26.8) -   
Smoking status*2 Never 14,693 (51.9) 2,758 (18.2) 1   
 Former 6,013 (21.3) 4,671 (30.8) 4.79 (4.49, 5.10) 
 Current 4,831 (17.1) 6,961 (45.9) 8.99 (8.43, 9.59) 
 Missing 2,759 (9.8) 769 (5.1) 1.37 (1.23, 1.51) 
BMI*2 <18.5 5,810 (20.5) 2,917 (19.2) 0.80 (0.76, 0.85) 
 18.5-25 8,651 (30.6) 5,232 (34.5) 1   
 25-30 9,299 (32.9) 4,475 (29.5) 0.79 (0.75, 0.83) 
 >30 4,536 (16.0) 2,535 (16.7) 0.93 (0.87, 0.98) 
Unadjusted odds ratio (OR) for association with COPD. 
NB. Unadjusted ORs for age, sex and socioeconomic status of general practice were not estimated as cases and 
controls were matched on these variables. 
*1. 1=least deprived, 5=most deprived. Based on Index of Multiple Deprivation score of general practice electoral 
ward. 
*2. Closest to diagnosis 
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Table 4.3 Comorbidities, symptoms, and healthcare use (development sample) 
   Controls 
(n=28,296) 
Cases 
(n=15,159) 
Unadjusted 
OR 
(95% CI) 
   N (%) N (%)    
C
om
or
bi
di
tie
s1
 
Asthma  2,438 (8.6) 5,669 (37.4) 6.61 (6.23, 7.02) 
Ischaemic heart disease 5,572 (19.7) 3,560 (23.5) 1.31 (1.25, 1.38) 
Heart failure 687 (2.4) 847 (5.6) 2.50 (2.24, 2.77) 
Stroke  850 (3.0) 539 (3.6) 1.23 (1.10, 1.37) 
Hyperlipidaemia 3,327 (11.8) 1,660 (11.0) 0.93 (0.87, 1.00) 
Anaemia  1,554 (5.5) 859 (5.7) 1.04 (0.95, 1.14) 
Pulmonary embolism 50 (0.2) 71 (0.5) 2.72 (1.89, 3.91) 
Deep vein thrombosis 139 (0.5) 107 (0.7) 1.44 (1.12, 1.86) 
Atrial fibrillation 980 (3.5) 690 (4.6) 1.37 (1.24, 1.51) 
Lung cancer 35 (0.1) 68 (0.4) 3.68 (2.45, 5.55) 
Cancer  3,805 (13.4) 2,098 (13.8) 1.05 (0.99, 1.11) 
Depression2 967 (3.4) 630 (4.2) 1.24 (1.12, 1.38) 
Anxiety2  2,056 (7.3) 1,816 (12.0) 1.77 (1.65, 1.90) 
Allergic rhinitis 1,917 (6.8) 1,152 (7.6) 1.13 (1.05, 1.22) 
Tuberculosis 421 (1.5) 365 (2.4) 1.66 (1.44, 1.91) 
Pulmonary tuberculosis 371 (1.3) 344 (2.3) 1.77 (1.52, 2.06) 
Chronic kidney disease 56 (0.2) 45 (0.3) 1.69 (1.11, 2.60) 
Helicobacter pylori 188 (0.7) 139 (0.9) 1.45 (1.16, 1.81) 
Gastric ulcer 545 (1.9) 472 (3.1) 1.63 (1.43, 1.85) 
Gastro-oesophageal reflux disease 1,897 (6.7) 1,229 (8.1) 1.25 (1.16, 1.35) 
Osteoporosis 713 (2.5) 569 (3.8) 1.58 (1.41, 1.78) 
Fractures  3,862 (13.6) 2,547 (16.8) 1.30 (1.23, 1.38) 
Diabetes  2,167 (7.7) 1,015 (6.7) 0.87 (0.81, 0.94) 
Rheumatoid arthritis 462 (1.6) 369 (2.4) 1.52 (1.32, 1.75) 
Lower respiratory tract infections2 0 25,128 (88.8) 9,344 (61.6) 1   
 1 2,205 (7.8) 2,947 (19.4) 4.02 (3.76, 4.29) 
 >1 963 (3.4) 2,868 (18.9) 9.76 (8.93, 10.7) 
Upper respiratory tract infections2 0 22,355 (79.0) 10,623 (70.1) 1   
 1 3,917 (13.8) 2,702 (17.8) 1.47 (1.39, 1.56) 
 >1 2,024 (7.2) 1,834 (12.1) 1.98 (1.85, 2.13) 
Allergy  7,614 (26.9) 5,045 (33.3) 1.40 (1.34, 1.46) 
S
ym
pt
om
s*
2  
Presentations with cough 0 23,470 (82.9) 8,180 (54.0) 1   
 1 3,072 (10.9) 3,130 (20.6) 3.14 (2.96, 3.34) 
 >1 1,754 (6.2) 3,849 (25.4) 7.12 (6.64, 7.63) 
Presentations with dyspnoea 0 26,789 (94.7) 11,294 (74.5) 1   
 1 1,014 (3.6) 2,220 (14.6) 5.57 (5.12, 6.06) 
 >1 493 (1.7) 1,645 (10.9) 9.01 (8.05, 10.1) 
Wheeze  456 (1.6) 1,860 (12.3) 8.89 (7.96, 9.94) 
Sputum production 245 (0.9) 609 (4.0) 5.32 (4.52, 6.26) 
Weight loss 211 (0.7) 306 (2.0) 2.74 (2.30, 3.28) 
Fatigue  1,550 (5.5) 1,215 (8.0) 1.53 (1.42, 1.66) 
Poor sleep 977 (3.5) 810 (5.3) 1.59 (1.44, 1,75) 
H
ea
lth
 s
er
vi
ce
 u
se
*2
 
Antibiotic courses 0 18,799 (66.4) 5,150 (34.0) 1   
 1 5,361 (18.9) 3,313 (21.9) 2.34 (2.21, 2.47) 
 2 2,127 (7.5) 2,267 (15.0) 4.04 (3.76, 4.34) 
 >2 2,009 (7.1) 4,429 (29.2) 8.64 (8.07, 9.25) 
Salbutamol 2,492 (8.8) 7,723 (50.9) 11.5 (10.8, 12.2) 
Prednisolone 1,800 (6.4) 4,358 (28.7) 6.17 (5.78, 6.58) 
GP consultations <5 5,162 (18.2) 1,156 (7.6) 1   
 5-10 4,618 (16.3) 1,734 (11.4) 1.81 (1.66, 1.98) 
 10-20 7,677 (27.1) 3,745 (24.7) 2.55 (2.36, 2.77) 
 20-40 7,610 (26.9) 5,136 (33.9) 3.99 (3.68, 4.32) 
 >40 3,229 (11.4) 3,388 (22.3) 6.91 (6.31, 7.57) 
Hospital referrals 703 (2.5) 687 (4.5) 2.08 (1.85, 2.34) 
Unadjusted odds ratio (OR) for association with COPD. 
1. Ever previously diagnosed 
2. Within 3 years of COPD diagnosis or equivalent matched time point for controls 
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Table 4.4 Adjusted odds ratios (OR) and regression coefficients (β) for risk factors included in 
the final risk model 
  OR* (95% CI) β (95% CI) 
Smoking status Never 1   0   
 Former 4.72 (4.35, 5.12) 1.55 (1.47, 1.63) 
 Current 11.7 (10.7, 12.7) 2.46 (2.37, 2.54) 
 Missing 2.44 (2.16, 2.76) 0.89 (0.77, 1.02) 
Asthma  2.11 (1.93, 2.31) 0.75 (0.66, 0.84) 
Lower respiratory tract infection (LRTI)** 0 1   0   
 1 2.57 (2.36, 2.81) 0.94 (0.86, 1.03) 
 >1 4.29 (3.83, 4.80) 1.46 (1.34, 1.57) 
Salbutamol**  6.91 (6.33, 7.55) 1.93 (1.85, 2.02) 
As this model was developed using case-control data, the intercept term is not applicable and has 
therefore not been presented. 
*Estimated using a multivariable conditional logistic regression model 
**Within 3 years of COPD diagnosis or equivalent matched time point for controls 
Risk score=(former smoker*1.55)+(current smoker*2.46)+(unknown smoking 
status*0.89)+(asthma*0.75)+(1 episode of LRTI*0.94)+(>1 episode of LRTI*1.46)+(salbutamol*1.93) 
NB. Each variable can either take the value 0 (not present) or 1 (present) 
e.g. A former smoker with a history of asthma who presented with more than one lower respiratory 
tract infection in the last three years, and received salbutamol in the last three years would have the 
following risk score:  
(1*1.55)+(0*2.46)+(0*0.89)+((1*0.75)+(0*0.94)+(1*1.46)+(1*1.93)=5.69 
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Table 4.5 Adjusted odds ratios (OR) and regression coefficients (β) for variables included in a 
more comprehensive risk score 
  OR* (95% CI) β (95% CI) 
Smoking status Never 1   0   
 Former 4.36 (4.00, 4.75) 1.47 (1.39, 1.56) 
 Current 12.0 (10.97, 13.12) 2.48 (2.40, 2.57) 
 Missing 2.87 (2.52, 3.26) 1.05 (0.92, 1.18) 
Asthma  1.89 (1.71, 2.08) 0.64 (0.54, 0.73) 
Lower respiratory tract infection (LRTI)** 0 1   0   
 1 1.81 (1.64, 1.99) 0.59 (0.49, 0.69) 
 >1 2.23 (1.96, 2.54) 0.80 (0.67, 0.93) 
Presentations with cough** 0 1   0   
 1 1.42 (1.30, 1.56) 0.35 (0.26, 0.44) 
 >1 1.77 (1.59, 1.97) 0.57 (0.46, 0.68) 
Presentations with dyspnoea** 0 1   0   
 1 3.17 (2.82, 3.57) 1.16 (1.04, 1.27) 
 >1 4.53 (3.89, 5.28) 1.51 (1.36, 1.66) 
Wheeze**  1.86 (1.60, 2.17) 0.62 (0.47, 0.77) 
Sputum production**  1.49 (1.17, 1.90) 0.40 (0.16, 0.64) 
Unintended weight loss**  1.75 (1.33, 2.31) 0.56 (0.29, 0.84) 
Antibiotic courses for a LRTI** 0 1   0   
 1 1.33 (1.23, 1.44) 0.29 (0.21, 0.37) 
 2 1.53 (1.38, 1.70) 0.43 (0.32, 0.53) 
 >2 1.80 (1.62, 2.01) 0.59 (0.48, 0.70) 
Salbutamol**  4.19 (3.81, 4.61) 1.43 (1.34, 1.53) 
Prednisolone**  1.53 (1.38, 1.69) 0.42 (0.32, 0.52) 
As this model was developed using case-control data, the intercept term is not applicable and has 
therefore not been presented. The c statistic for this model in the external validation sample was 0.87 
(95% CI 0.86 to 0.87). 
*Estimated using a multivariable conditional logistic regression model 
**Within 3 years of COPD diagnosis or equivalent matched time point for controls 
Risk score=(former smoker*1.47)+(current smoker*2.48)+(unknown smoking 
status*1.05)+(asthma*0.64)+(1 episode of LRTI*0.59)+(>1 episode of LRTI*0.80)+(1 episode of 
cough*0.35)+(>1 episode of cough*0.57)+(1 episode of dyspnoea*1.16)+(>1 episode of 
dyspnoea*1.15)+(wheeze*0.62)+(sputum*0.40)+(unintended weight loss*0.56)+(1 antibiotic 
course*0.29)+(2 antibiotic course*0.43)+(>2 antibiotic 
courses*0.59)+(salbutamol*1.43)+(prednisolone*0.42) 
NB. Each variable can either take the value 0 (not present) or 1 (present) 
e.g. A former smoker with a history of asthma who presented with more than one lower respiratory 
tract infection and episode of cough in the last three years, complained of unintended weight loss and 
received salbutamol and 2 course of antibiotics for a LRTI in the last three years would have the 
following risk score:  
(1*1.47)+(0*2.48)+(0*1.05)+(1*0.64)+(0*0.59)+(1*0.80)+(0*0.35)+(1*0.57)+(0*1.16)+(0*1.15)+(0*0.62)
+(0*0.40)+(1*0.56)+(0*0.29)+(1*0.43)+(0*0.59)+(1*1.43)+(0*0.42)=5.9 
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Table 4.6 Characteristics of subjects in the external validation sample (derived from 20 general 
practices) 
  Controls 
(n=4196) 
Cases 
(n=2259) 
  N (%) N (%) 
Mean age (SD)  69.8 (11.0) 70.0 (11.1) 
Males  2,110 (50.3) 1,133 (50.2) 
Socioeconomic quintile* 1 (least deprived) 475 (11.3) 258 (11.4) 
 2 561 (13.4) 313 (13.9) 
 3 1,072 (25.5) 574 (25.4) 
 4 308 (7.3) 159 (7.0) 
 5 (most deprived) 1,780 (42.4) 955 (42.3) 
Smoking status Never 1,858 (44.3) 374 (16.6) 
 Former 799 (19.0) 674 (29.8) 
 Current 751 (17.9) 966 (42.8) 
 Missing 788 (18.8) 245 (10.8) 
Body mass index <18.5 1,234 (29.4) 623 (27.6) 
 18.5-25 1,098 (26.2) 643 (28.5) 
 25-29 1,246 (29.7) 624 (27.6) 
 ≥30 618 (14.7) 369 (16.3) 
* Based on the Index of Multiple Deprivation score of electoral ward. 
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Table 4.7 Test accuracy of the final risk score in the external validation sample 
 Discrimination characteristics Application of the score assuming a 
5.5% prevalence of undiagnosed COPD  
Score  
cut-point 
Sensitivity 
(%) 
Specificity 
(%) 
Correctly  
Classified (%) 
LR+ LR- PPV (%) NPV (%) Screening 
Yield (%) 
NNS NND 
≥0 100 0 35.0 1 - 5.5 - 5.50 19 19 
≥0 .5 96.1 34.7 56.2 1.47 0.11 7.9 99.3 5.29 19 13 
≥1.0 90.6 51.9 65.5 1.88 0.18 9.9 99.0 4.98 21 11 
≥1.5 89.4 55.1 67.1 1.99 0.19 10.4 98.9 4.92 21 10 
≥2.0 81.2 71.9 75.2 2.89 0.26 14.4 98.5 4.47 23 7 
≥2.5 63.2 87.4 79.0 5.02 0.42 22.6 97.6 3.48 29 5 
≥3.0 55.8 91.9 79.3 6.89 0.48 28.6 97.3 3.07 33 4 
≥3.5 47.6 94.6 78.1 8.80 0.55 33.9 96.9 2.62 39 3 
≥4.0 40.4 95.8 76.4 9.57 0.62 35.8 96.5 2.22 45 3 
≥4.5 23.2 98.3 72.0 13.5 0.78 44.0 95.6 1.28 79 3 
≥5.0 20.6 98.4 71.2 13.1 0.81 44.3 95.5 1.13 89 3 
≥5.5 11.3 99.5 68.6 21.5 0.89 55.8 95.1 0.62 161 2 
≥6.0 5.53 99.7 66.7 18.9 0.95 50.9 94.8 0.30 329 2 
≥6.5 3.23 99.8 65.0 19.4 0.97 52.5 94.7 0.18 563 2 
Correctly classified= proportion of subjects with disease status correctly classified  
LR= likelihood ratio (i.e. the ratio by which the pre-test probability is altered by a positive or negative test result). 
PPV=positive predictive value (proportion of all subjects with a positive test who have disease) 
NPV=negative predictive value (proportion of all subjects with a negative test who are disease free) 
Screening yield= proportion of all patients subjected to the risk score who would be correctly identified as having COPD 
NNS=number-needed-to-screen (the number of patients or patient records the risk score would need to be applied to) to identify one patient with COPD 
NND=number of diagnostic assessments needed to identify one patient with COPD
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Figure 4.2 Receiver under the operator characteristic (ROC) curve for the test accuracy of the 
final risk score in the entire external validation sample (c-statistic=0.84, 95% CI 0.83 to 0.85), 
ignoring clustering of patients within practices. 
Each point on the graph represents the performance (sensitivity and specificity) of the risk score at 
specific thresholds. 
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Figure 4.3 Random effects meta-analysis of the c statistics obtained for the final risk score 
when applied in each of the 20 validation practices separately. The summary result is the 
estimate of the average c-statistic across the validation practices. 
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Figure 4.4 Screening test accuracy of the final risk score at a threshold of ≥2.5 when applied to 
100 patients aged ≥35 years in primary care with an assumed prevalence of undiagnosed 
COPD of 5%. 
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4.5 DISCUSSION 
4.5.1 Principal findings 
A new clinical prediction model has been developed and validated for identifying 
patients at high risk of COPD in primary care. The clinical score incorporates 
smoking status, previous diagnosis of asthma and LRTIs, and prescriptions for 
salbutamol. The score showed good discrimination characteristics in the external 
validation population and the suggested cut-point to denote high risk yielded a 
relatively high sensitivity and specificity. It can potentially detect about three out of 
every five patients with undiagnosed COPD while also being able to effectively rule 
out patients at low risk of disease. The score cut-point however can be altered to 
either maximise sensitivity or specificity.  
This builds on a previous published model (based on data from the Health Survey for 
England) which would require 19 patients to actively undertake a screening process 
(19 questionnaire responses and 7 clinical assessments) to identify one individual 
with COPD.(14) The new clinical score, which uses routine data from primary care 
health records, would significantly improve the efficiency of this process. 
4.5.2 Comparison with existing literature 
The first published risk model to identify patients with undiagnosed COPD was based 
on managed (predominantly secondary) care administrative claims data in the 
USA.(7) Using a case-control design, 19 health service utilisation characteristics 
were included, many of which are unlikely to be routinely recorded in primary care. In 
the current study a more parsimonious model was developed that uses data routinely 
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recorded in primary care and the study population had more complete data on 
smoking history. A further model was developed in the USA using outpatient 
pharmacy data.(8) This incorporated respiratory and cardiovascular medications and 
antibiotics, and had a sensitivity of 60.6% and specificity of 70.5% when externally 
validated. The risk score developed in the current study similarly included prior 
prescription of salbutamol as an important predictor. However the ROC curve and c-
statistic for both US models were not reported, which makes it impossible to evaluate 
their discriminatory accuracy. 
In Denmark, Smidth and colleagues used administrative data on hospital admissions 
for lung disorders, respiratory prescriptions and lung function tests to develop a 
model to identify COPD.(9) This had a much lower sensitivity (29.7-44.8%) but higher 
specificity (98.9%) than the score developed in the current study. While it had a high 
PPV in the Dutch population (65.0-72.9%; based on an overall COPD prevalence of 
9%), it would be difficult to administer in a UK or similar primary care setting where 
primary and secondary care data are currently poorly linked. This model also relies 
on prior diagnoses of emphysema and chronic bronchitis at hospital admissions and 
would miss a significant number of patients due to the low sensitivity and high 
proportion of false negative results.  
Kotz and colleagues recently developed and internally validated a COPD risk model 
using routine longitudinal data from primary care in Scotland,(10) including a very 
large (n=480,903 in the development cohort) and relatively young population (mean 
age 55.6 years). Their model demonstrated similar discrimination characteristics to 
that shown in the current study (c-statistic 0.85 [95% CI 0.84 to 0.85] in females and 
0.83 [95% CI 0.83 to 0.84] in males), with good calibration. However this has only 
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been internally validated since the study population was randomly split into derivation 
and validation samples. Furthermore only a very limited range of risk factors were 
considered (age, sex, smoking status, socioeconomic status and history of asthma) 
and potentially important predictors such as respiratory infections were not. They 
constructed separate models for males and females since they found an interaction 
between smoking status and sex. We also stratified our model by sex and repeated 
our analysis but found the odds ratios to be broadly similar to those in the non-
stratified model.  
As described in Chapter 2, a variety of screening questionnaires have also been 
evaluated. For example Price and colleagues assessed the accuracy of a case 
finding questionnaire which included items on respiratory symptoms, smoking, and 
allergies and showed good discrimination characteristics.(15) This and other 
questionnaire-based tools can only be used in either face-to-face consultations or 
distributed by mail or online. If used in a population with a 5.5% prevalence of 
undiagnosed COPD, 26 patients would need to be screened to identify one case of 
COPD. The model developed in the current study has the advantage of being 
applicable in both face-to-face consultations as well as integrated with clinical 
information systems and used at a practice level to identify whole groups of high risk 
patients who could be invited to screening sessions. With the latter approach, only 
five patients would need to be invited for assessment to identify one case of COPD, 
thus improving its efficiency fivefold over the use of current screening questionnaires. 
4.5.3 Strengths 
Data were used from a large primary care population and a wide range of risk factors 
were explored, focusing on those routinely recorded in primary care. Both aspects 
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help ensure this clinical score will be widely applicable in primary care in the UK and 
other similar health systems. The score was also validated in a number of non-
randomly selected practices allowing for assessment of the heterogeneity of its 
performance.  
4.5.4 Weaknesses 
Ideally previously undiagnosed COPD cases identified by case-finding/screening 
would have been used to derive the risk score since their characteristics may differ 
from incident cases identified through routine clinical practice. A coded diagnosis of 
COPD was used for the case definition. Given that the data are from a UK primary 
care setting, the diagnosis of COPD is likely to be based on NICE guidance. GPs 
would be expected to take a clinical history, perform a clinical examination, have the 
patient undertake pre- and post-bronchodilator spirometry as well as other clinical 
investigations (e.g. chest radiography) prior to making the diagnosis. Spirometry 
should be performed before and after the administration of a bronchodilator to help 
differentiate COPD from asthma and the diagnosis should be based on the presence 
of post-bronchodilator airflow obstruction.(16) However there is good evidence that 
COPD is both misdiagnosed and under-diagnosed in primary care,(2) a proportion of 
patients are likely to have undergone spirometry of variable quality,(17) and this may 
have led to some misclassification of cases and controls. Unfortunately there was 
insufficient spirometry data in the dataset to validate the diagnosis.  
The analysis was performed on data that mostly preceded the Quality and Outcomes 
Framework, which is a pay-for-performance initiative in England that was introduced 
to the national GP contract in 2004. A number of COPD-related performance 
indicators were introduced into QOF, one of which requires post-bronchodilator 
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spirometry.(18) The quality of spirometry data for COPD diagnosis is thus likely to be 
of higher quality in more recent primary care data. Quint and colleagues recently 
demonstrated that clinical codes specific for COPD and emphysema have a high 
positive predictive value for validated COPD.(19) Clinical codes for COPD that were 
recommended by the GPRD (now CPRD) at the time of this analysis were used. 
Although these largely overlapped with those recommended by Quint et al. they also 
included codes specific for chronic bronchitis, which would not necessarily constitute 
a diagnosis of COPD (although may increase the likelihood of the development of 
airflow obstruction and risk of mortality.(20) 
The mean age of the study population (70 years) was older than patients who would 
typically be targeted for case finding.  Age and sex, which are likely to be predictors 
of COPD, could not be incorporated in the model because of the matched case-
control data. This also prevented evaluation of the calibration of the model in the 
validation practices. 18.2% of cases were classed as never smokers. This was 
significantly higher than the proportion of never smokers among patients with 
diagnosed COPD (6.9%) but similar to the proportion of never smokers among 
patients with undiagnosed COPD (16.8%) in an analysis of the Health Survey for 
England.(14) Anecdotally the quality of smoking status coding in primary can be quite 
variable and often misclassified and it is likely that the proportion of never smokers 
among incident cases may in fact be lower than suggested in the current analysis. 
Another limitation of the matched case-control design is that c-statistics are generally 
downwardly biased when estimated in such data.(21, 22) Therefore, it is possible the 
true c-statistic may be closer to 1 upon application.  
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Some of the variables explored, such as hospitalisations were poorly recorded, and 
may actually be significant predictors of COPD. In addition the absence of a risk 
factor could be secondary to under-recording. However the aim was to produce a 
model that would be implementable in a common primary care setting drawing on 
routinely recorded data. If clinical coding improves over time some of these variables 
may need to be revisited as potential predictors and considered for inclusion in future 
revised models. Finally, the clinical score may not be applicable in health settings 
where exposure to risk factors other than cigarette smoking (e.g. biomass fuels) is a 
significant cause of COPD. 
4.5.5 Implications for clinicians, policymakers and research 
The newly developed clinical score once further validated, could be used by 
clinicians in primary care to stratify patients by risk of COPD. This could be achieved 
primarily with the aid of developed software applications that would automate the 
calculations. Since the model was based entirely on routinely collected data it could 
also be integrated into primary care clinical information systems to use data on risk 
factors to stratify all eligible patients. Patients predicted to be at high risk of COPD 
could then be referred for a clinical assessment including confirmatory spirometry 
testing.  
However, further work is needed to validate or adapt this preliminary model in other 
populations, notably in case finding trials that have enrolled patients with previously 
undiagnosed COPD.  This includes examining the matching factors (age and sex) as 
potential predictors. The cost-effectiveness of targeting patients at different 
thresholds should also be evaluated.  Future studies should also address the impact 
of this tool on use and outcomes in general practice. 
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4.5.6 Conclusion 
The newly developed risk score shows promising accuracy and increased efficiency 
over current methods for identifying patients with undiagnosed COPD in primary 
care. Use of an externally validated score could be used for risk stratification so that 
high risk patients can be efficiently identified and referred for confirmatory spirometry. 
However evidence that early identification of COPD results in improved patient 
outcomes must be robustly assessed before screening for COPD can be 
recommended as part of routine practice. 
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4.6 Supplementary tables 
Table S4.1. Clinical codes (Read/OXMIS terms) used to define COPD 
GPRD Medical Code Read/OXMIS Code Read/OXMIS Term 
303970 491 Chronic bronchitis 
303973 492 Emphysema pulmonary 
303971 491 AC Bronchitis acute on chronic 
275013 491 BT Bronchitis obstructive 
303972 491 E Chronic bronchitis with emphysema 
306529 491 R Bronchitis recurrent 
265866 492 AB Apical bullae 
265867 492 AC Emphysema apical bullae 
306530 492 CM Hyperinflation compensatory 
256647 492 PP Puffer pink 
304065 5199C Obstructive airways disease 
304067 5199CL Obstructive lung disease 
304071 5199G Obstructive airways disease chronic 
304072 5199GE Exacerbation coad 
304073 5199GL COLD (chronic obstructive lung disease) 
304074 5199GP COPD (chronic obstructive pulmonary disease) 
305740 9906E Radiological emphysema 
280081 H3...00 Chronic obstructive pulmonary disease 
243388 H3...11 Chronic obstructive airways disease 
207194 H31..00 Chronic bronchitis 
280085 H310.00 Simple chronic bronchitis 
261743 H310000 Chronic catarrhal bronchitis 
289195 H310z00 Simple chronic bronchitis NOS 
280086 H311.00 Mucopurulent chronic bronchitis 
252513 H311000 Purulent chronic bronchitis 
271037 H311100 Fetid chronic bronchitis 
225243 H311z00 Mucopurulent chronic bronchitis NOS 
271038 H312.00 Obstructive chronic bronchitis 
280087 H312000 Chronic asthmatic bronchitis 
207195 H312011 Chronic wheezy bronchitis 
261744 H312100 Emphysematous bronchitis 
216142 H312200 Acute exacerbation of chronic obstructive airways disease 
252514 H312z00 Obstructive chronic bronchitis NOS 
261745 H313.00 Mixed simple and mucopurulent chronic bronchitis 
261745 H313.00 Mixed simple and mucopurulent chronic bronchitis 
298476 H31y.00 Other chronic bronchitis 
261746 H31y100 Chronic tracheobronchitis 
225244 H31yz00 Other chronic bronchitis NOS 
261747 H31z.00 Chronic bronchitis NOS 
234374 H32..00 Emphysema 
280088 H320.00 Chronic bullous emphysema 
225245 H320000 Segmental bullous emphysema 
271039 H320100 Zonal bullous emphysema 
225246 H320200 Giant bullous emphysema 
271040 H320300 Bullous emphysema with collapse 
252516 H320311 Tension pneumatocoele 
280089 H320z00 Chronic bullous emphysema NOS 
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GPRD Medical Code Read/OXMIS Code Read/OXMIS Term 
271041 H321.00 Panlobular emphysema 
298477 H322.00 Centrilobular emphysema 
280090 H32y.00 Other emphysema 
280091 H32y000 Acute vesicular emphysema 
225247 H32y100 Atrophic (senile) emphysema 
298478 H32y111 Acute interstitial emphysema 
216143 H32y200 MacLeod's unilateral emphysema 
234375 H32yz00 Other emphysema NOS 
234376 H32yz11 Sawyer - Jones syndrome 
234377 H32z.00 Emphysema NOS 
280094 H36..00 Mild chronic obstructive pulmonary disease 
298483 H37..00 Moderate chronic obstructive pulmonary disease 
289203 H38..00 Severe chronic obstructive pulmonary disease 
207198 H3y..00 Other specified chronic obstructive airways disease 
216150 H3y..11 Other specified chronic obstructive pulmonary disease 
252524 H3y0.00 Chronic obstruct pulmonary disease with acute lower respiratory infection 
252524 H3y0.00 Chronic obstruct pulmonary dis with acute lower respiratory infection 
261758 H3y1.00 Chronic obstruct pulmonary dis with acute exacerbation, unspecified 
216151 H3z..00 Chronic obstructive airways disease NOS 
261759 H3z..11 Chronic obstructive pulmonary disease NOS 
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Table S4.2 Odds ratios (OR) of variables used to derive the risk score at each main step in the model selection process. 
  Unadjusted1  Adjusted2    Adjusted3   Adjusted4   
Variable  OR (95% CI) p OR (95% CI) p OR (95% CI) OR (95% CI)  
Smoking status Never 1    1    1   1   
 Former 4.87 (4.56, 5.20) <0.001 4.50 (4.11, 4.93) <0.001 4.50 (4.11, 4.92) 4.36 (4.00, 4.75) 
 Current 9.25 (8.65, 9.89) <0.001 11.89 (10.8, 13.1) <0.001 11.80 (10.7, 13.0) 12.00 (11.0, 13.1) 
 Missing            2.87 (2.52, 3.26) 
BMI <18.5 0.80 (0.76, 0.85) <0.001 0.94 (0.85, 1.05) 0.296 0.95 (0.85, 1.06)    
 18.5-25 1    1    1      
 25-30 0.79 (0.75, 0.83) <0.001 0.76 (0.70, 0.82) <0.001 0.76 (0.70, 0.82)    
 >30 0.93 (0.87, 0.98) 0.014 0.76 (0.68, 0.84) <0.001 0.76 (0.68, 0.84)    
Asthma  6.61 (6.23, 7.02) <0.001 1.93 (1.74, 2.15) <0.001 1.93 (1.74, 2.15) 1.89 (1.71, 2.08) 
Ischaemic heart disease  1.31 (1.25, 1.38) <0.001 0.99 (0.91, 1.09) 0.907       
Heart failure  2.50 (2.24, 2.77) <0.001 1.35 (1.13, 1.61) 0.001 1.39 (1.17, 1.64)    
Stroke  1.23 (1.10, 1.37) <0.001 1.14 (0.95, 1.37) 0.157       
Hyperlipidaemia  0.93 (0.87, 1.00) 0.039 0.82 (0.73, 0.91) <0.001 0.82 (0.74, 0.91)    
Anaemia  1.04 (0.95, 1.14) 0.368           
Pulmonary embolism  2.72 (1.89, 3.91) <0.001 1.42 (0.75, 2.69) 0.279       
Deep vein thrombosis  1.44 (1.12, 1.86) 0.005 0.78 (0.52, 1.18) 0.245       
Atrial fibrillation  1.37 (1.24, 1.51) <0.001 1.05 (0.88, 1.24) 0.597       
Lung cancer  3.68 (2.45, 5.55) <0.001 1.84 (0.95, 3.55) 0.071       
Cancer  1.05 (0.99, 1.11) 0.121 0.89 (0.81, 0.99) 0.024 0.90 (0.82, 0.99)    
Depression  1.24 (1.12, 1.38) <0.001 0.89 (0.74, 1.07) 0.211       
Anxiety  1.77 (1.65, 1.90) <0.001 1.00 (0.88, 1.12) 0.937       
Allergic rhinitis  1.13 (1.05, 1.22) 0.001 0.65 (0.56, 0.75) <0.001 0.69 (0.60, 0.78)    
Tuberculosis  1.66 (1.44, 1.91) <0.001 1.42 (1.12, 1.80) 0.003 1.43 (1.13, 1.80)    
Pulmonary tuberculosis  1.77 (1.52, 2.06) <0.001           
Chronic kidney disease  1.69 (1.11, 2.60) 0.016 1.18 (0.58, 2.36) 0.65       
Helicobacter pylori  1.45 (1.16, 1.81) 0.001 0.90 (0.63, 1.28) 0.545       
Gastric ulcer  1.63 (1.43, 1.85) <0.001 1.14 (0.94, 1.40) 0.19       
GORD  1.25 (1.16, 1.35) <0.001 0.84 (0.74, 0.96) 0.01 0.85 (0.75, 0.97)    
Osteoporosis  1.58 (1.41, 1.78) <0.001 1.04 (0.86, 1.26) 0.686       
Fractures  1.30 (1.23, 1.38) <0.001 1.12 (1.02, 1.22) 0.021 1.12 (1.02, 1.23)    
Diabetes  0.87 (0.81, 0.94) 0.001 0.74 (0.65, 0.85) <0.001 0.74 (0.65, 0.84)    
Rheumatoid arthritis  1.52 (1.32, 1.75) <0.001 1.19 (0.95, 1.51) 0.137       
LRTI  0 1    1       1   
 1 4.02 (3.76, 4.29) <0.001 1.70 (1.53, 1.89) <0.001 1.72 (1.55, 1.91) 1.81 (1.64, 1.99) 
 >1 9.76 (8.93, 10.7) <0.001 2.08 (1.81, 2.39) <0.001 2.10 (1.83, 2.42) 2.23 (1.96, 2.54) 
URTI  0 1              
 1 1.47 (1.39, 1.56) <0.001 0.94 (0.85, 1.03) 0.184 0.94 (0.85, 1.03)    
 >1 1.98 (1.85, 2.13) <0.001 0.83 (0.73, 0.95) 0.005 0.83 (0.73, 0.94)    
Allergy  1.40 (1.34, 1.46) <0.001 1.09 (1.00, 1.18) 0.055       
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  Unadjusted1  Adjusted2    Adjusted3   Adjusted4   
Variable  OR (95% CI) p OR (95% CI) p OR (95% CI) OR (95% CI)  
Presentations with cough 0 1    1    1   1   
 1 3.14 (2.96, 3.34) <0.001 1.37 (1.25, 1.51) <0.001 1.37 (1.24, 1.50) 1.42 (1.30, 1.56) 
 >1 7.12 (6.64, 7.63) <0.001 1.78 (1.59, 2.00) <0.001 1.78 (1.59, 1.99) 1.77 (1.59, 1.97) 
Presentations with dyspnoea 0 1    1    1   1   
 1 5.57 (5.12, 6.06) <0.001 3.11 (2.74, 3.53) <0.001 3.11 (2.74, 3.52) 3.17 (2.82, 3.57) 
 >1 9.01 (8.05, 10.1) <0.001 4.27 (3.63, 5.02) <0.001 4.28 (3.65, 5.03) 4.53 (3.89, 5.28) 
Wheeze  8.89 (7.96, 9.94) <0.001 1.88 (1.60, 2.21) <0.001 1.85 (1.58, 2.18) 1.86 (1.60, 2.17) 
Sputum production  5.32 (4.52, 6.26) <0.001 1.55 (1.20, 2.00) 0.001 1.56 (1.21, 2.02) 1.49 (1.17, 1.90) 
Weight loss  2.74 (2.30, 3.28) <0.001 1.52 (1.13, 2.03) 0.005 1.53 (1.14, 2.04) 1.75 (1.33, 2.31) 
Fatigue  1.53 (1.42, 1.66) <0.001 1.06 (0.93, 1.22) 0.371       
Poor sleep  1.59 (1.44, 1.75) <0.001 0.87 (0.73, 1.02) 0.086       
Antibiotic courses 0 1    1    1   1   
 1 2.34 (2.21, 2.47) <0.001 1.32 (1.21, 1.44) <0.001 1.31 (1.20, 1.44) 1.33 (1.23, 1.44) 
 2 4.04 (3.76, 4.34) <0.001 1.54 (1.37, 1.73) <0.001 1.54 (1.37, 1.73) 1.53 (1.38, 1.70) 
 >2 8.64 (8.07, 9.25) <0.001 1.91 (1.69, 2.17) <0.001 1.89 (1.67, 2.14) 1.80 (1.62, 2.01) 
Salbutamol  11.45 (10.8, 12.2) <0.001 4.27 (3.86, 4.73) <0.001 4.25 (3.84, 4.71) 4.19 (3.81, 4.61) 
Prednisolone  6.17 (5.78, 6.58) <0.001 1.49 (1.34, 1.67) <0.001 1.51 (1.36, 1.69) 1.53 (1.38, 1.69) 
GP consultations <5 1    1    1      
 5-10 1.81 (1.66, 1.98) <0.001 1.26 (1.10, 1.45) 0.001 1.27 (1.10, 1.45)    
 10-20 2.55 (2.36, 2.77) <0.001 1.27 (1.11, 1.45) <0.001 1.28 (1.13, 1.46)    
 20-40 3.99 (3.68, 4.32) <0.001 1.34 (1.16, 1.54) <0.001 1.37 (1.20, 1.57)    
 >40 6.91 (6.31, 7.57) <0.001 1.31 (1.10, 1.56) 0.002 1.37 (1.17, 1.61)    
Hospital referrals  2.08 (1.85, 2.34) <0.001 1.20 (0.99, 1.46) 0.065       
1. All risk factors 
2. Risk factors with p<0.2 for unadjusted ORs 
3. Risk factors with p<0.05 for adjusted ORs or significantly contributed to the model fit (as defined by statistically significant likelihood ratio tests) 
4. Risk factors with adjusted OR>1.5 
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CHAPTER 5: PREDICTING RISK OF 
UNDIAGNOSED COPD IN PRIMARY 
CARE: DEVELOPMENT AND 
VALIDATION OF THE TARGETCOPD 
MODEL 
5.1 Abstract 
Background 
Previous prediction models have been developed for assessing the risk of 
undiagnosed COPD. These used data from patients who received a diagnosis 
through routine care, which may be inaccurate because of widespread 
underdiagnosis and misdiagnosis. This chapter reports the development and external 
validation of a primary care-based model using data from a unique case finding trial. 
Methods 
Patients aged 40-79 years with no prior diagnosis of COPD received a screening 
questionnaire either by post or opportunistically at primary care attendances through 
a large case finding trial based in primary care in the West Midlands, UK. Those 
reporting chronic respiratory symptoms were assessed with spirometry. COPD was 
defined as presence of respiratory symptoms with post-bronchodilator 
FEV1/FVC<lower limit of normal. A prediction model was then developed using 
logistic regression with predictor variables available from electronic health records 
from subjects who returned a postal questionnaire (n=2398, mean age 59.9 years, 
52% male). The model was internally validated in the development sample, and then 
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externally validated among subjects who returned an opportunistic questionnaire 
(n=1097, mean age 60.1 years, 51.6% male).  
Results 
A model containing age, smoking status, dyspnoea, and prescriptions of salbutamol 
and antibiotics discriminated reasonably well between patients with and without 
undiagnosed COPD (external validation c-statistic 0.74 [95% CI 0.68 to 0.80]), and 
provided predicted risks that calibrate well up to 10%, but slightly overestimate 
observed risks up to 30%. Using a cut-point of ≥7.5% predicted risk to prompt referral 
for diagnostic assessment has a sensitivity of 68.8% (95% CI 57.3 to 78.9%) and a 
specificity of 68.8% (95% CI 65.8.1 to 71.6%), and requires seven diagnostic 
assessments (95% CI 6 to 10) to identify one patient with undiagnosed COPD.  
Conclusion 
A simple and readily applicable risk prediction model that uses routine data from 
electronic health records in primary care has been developed and externally 
validated for undiagnosed COPD. This could improve the efficiency of targeting 
patients for case finding but should be validated in other populations and its impact 
on patient outcomes evaluated in RCTs.  
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5.2 Introduction 
Chronic obstructive pulmonary disease (COPD) is the third leading cause of mortality 
worldwide (1) and it is estimated that 50-90% of the disease burden is 
undiagnosed.(2) Primary care has a key role to play in improving the diagnosis of 
COPD (3) and the clinical strategy is now shifting towards earlier identification to 
improve access to care and prevent disease progression.(4) To achieve this, a 
number of case finding tools have been evaluated including screening questionnaires 
(5) and handheld flow meters.(6) However mass screening with systematic invitation 
of all potentially at-risk individuals has resource implications and is reliant on patient 
response.(7) A more efficient approach is needed. 
A number of risk prediction models have been developed to help identify patients at 
high risk of undiagnosed COPD. This includes the clinical score reported in Chapter 
4 and another developed using longitudinal data from general practices in 
Scotland.(8) Both used a new diagnosis of COPD in primary healthcare records as 
the outcome. The models demonstrated good discrimination characteristics when 
validated but were limited by their case definition, which lacked standardised, 
objective measures. This has two important implications. Firstly, COPD is often both 
underdiagnosed (9) as well as misdiagnosed,(10) so a proportion of patients classed 
as being disease-free in the previous analyses may in fact have had undiagnosed 
COPD, and some patients with a record of COPD may have been misdiagnosed. 
Secondly, the clinical characteristics of patients diagnosed with COPD through case 
finding may differ from incident cases identified through routine care, thus potentially 
differing in their predictors of disease.  
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This chapter reports the development and external validation of a new prediction 
model for identifying patients at high risk of undiagnosed COPD in primary care using 
data from a large cluster randomised controlled case finding trial.(11) 
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5.3 Methods 
5.3.1 Study design 
This is a retrospective cohort analysis of data from the case finding arm of the 
TargetCOPD trial (12) to develop and validate a risk prediction model for 
undiagnosed COPD. TargetCOPD was a pragmatic cluster randomised controlled 
case finding trial for COPD based in primary care that recruited eligible participants 
from August 2012 to June 2014. Subjects within the case finding arm were 
randomised to receive a screening questionnaire (Appendix 6), either 
opportunistically at routine clinical appointments or to additionally receive it by post. 
This captured information on respiratory symptoms, smoking history, occupational 
exposures to vapours, gases, dust, and fumes (VGDF), and demographic 
characteristics. Participants reporting relevant respiratory symptoms were offered a 
diagnostic assessment with post-bronchodilator spirometry. Data were used from 
their primary care health records (recorded at any time prior to the trial start date at 
each practice), and spirometry assessment to develop and validate a risk prediction 
model for undiagnosed COPD.  
5.3.2 Population 
Participants were aged 40 to 79 years with no prior diagnosis of COPD (Table S5.1 
provides the clinical codes used for exclusion). There were no other specific eligibility 
criteria and subjects were excluded at the discretion of their GP. This analysis was 
restricted to participants who returned a screening questionnaire.  
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5.3.3 Setting 
The TargetCOPD trial was based in primary care practices in the West Midlands, 
UK.(11) Data from electronic health records were available for a subset of 13 of the 
26 participating practices allocated to the case finding arm, which broadly reflected 
the diversity of the population in terms of age, ethnicity and socioeconomic status, 
and practice characteristics.  
5.3.4 Outcome 
COPD was defined as the presence of at least one chronic respiratory symptom 
(chronic cough or phlegm for three or more months of the year for two or more years, 
wheeze in the previous 12 months or dyspnoea of MRC grade 2 or higher) together 
with airflow obstruction measured by post-bronchodilator spirometry. Spirometry was 
performed to ERS standards (13) by trained research assistants using EasyOne 
spirometers (ndd Medical Technologies, Zurich) 20 minutes after the inhalation of 
400mcg of salbutamol delivered through a metered dose inhaler and volumatic 
spacer. Spirometers were calibrated on a daily basis and all research assistants were 
trained for one week at a lung function laboratory followed by training days held 
every 3-6 months. All spirometry traces were reviewed by a lung function specialist. 
For this analysis airflow obstruction was defined as a forced expiratory volume in one 
second to forced vital capacity ratio (FEV1/FVC) less than the lower limit of normal 
(<5th percentile) adjusted for age, sex, height, and ethnic group using the Global 
Lung Initiative 2012 equations.(14)  
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5.3.5 Data extraction 
Data (clinical codes) selected for extraction from electronic health records were 
initially based on those predictors identified as important in the previous analysis 
reported in Chapter 4. These included demographic characteristics, smoking status, 
respiratory symptoms, comorbidities, lower respiratory tract infections (LRTIs), and 
respiratory medication prescriptions (see Table S5.2 for the corresponding clinical 
codes). Data from residential postcodes were used to estimate socioeconomic status 
using the Index of Multiple Deprivation (IMD, higher scores represent greater levels 
of socioeconomic deprivation).(15) Data on antibiotics that are indicated for treating 
LRTIs were extracted- this included amoxicillin, clarithromycin, co-amoxiclav, 
erythromycin, doxycycline, and cephalexin. All data were stored on an encrypted 
database. 
5.3.6 Sample size 
Subjects with missing outcome (COPD) status (predominantly those invited but who 
did not attend a spirometry assessment) were excluded from the analysis (n=755) but 
their characteristics were described. Data from 2398 subjects who returned a postal 
questionnaire were used for model development (development sample) and from 
1097 subjects who returned a questionnaire provided opportunistically for external 
validation (external validation sample). This non-random splitting of the data was 
considered important, to ensure the developed model could be checked in new data 
from a different part of the intended population.(16) 7.9% of all subjects were newly 
diagnosed with COPD through the trial (198 in the development and 77 in the 
external validation samples). At least 10 outcome events are recommended per 
candidate predictor considered for inclusion in a logistic regression model.(17) There 
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was therefore sufficient power to consider up to 19 candidate predictors in the 
developed model.   
5.3.7 Model development 
The model was developed using multivariable logistic regression considering the 
following candidate predictors for inclusion: age, sex, latest smoking status, history of 
asthma, and lower respiratory tract infections (LRTIs), complaints of cough, 
dyspnoea, wheeze, and sputum, and prescriptions of salbutamol, prednisolone, and 
antibiotics, within the previous three years. Since there was very little (<1%) missing 
data for these candidate predictors, multiple imputation was not used and a 
complete-case analysis was performed.(18) Interactions were tested for with a 
particular focus on age, sex, and smoking status. The best-fitting terms for 
continuous variables were determined using fractional polynomial regression.(19) 
Predictors that were not statistically significant at the p<0.05 level were removed from 
the model (although age and smoking status were forced in) and the fit of the 
reduced model was compared to that of the full model using a likelihood ratio test. 
To improve the calibration of the model predictions and adjust for over fitting, the 
model’s calibration slope coefficient was estimated in 1000 bootstrap samples to 
determine the shrinkage factor (the average calibration slope), which was multiplied 
against predictor coefficients in the developed model.(20) This produced the final 
model equation. 
5.3.8 Internal validation performance 
To examine the discrimination performance of the final model, the sensitivity and 
specificity of the predicted probabilities from the final model were plotted on a 
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receiver operator characteristic (ROC) curve. The model was internally validated 
using bootstrap resampling (with 1000 replications) to estimate the c-statistic (area 
under the ROC curve) corrected for over-fitting.(21) Calibration was assessed by 
grouping subjects into deciles of predicted risk and comparing the observed with the 
expected number diagnosed with COPD.  
5.3.9 External validation performance 
The c-statistic and calibration of the final model were then assessed in the external 
validation sample. Again, since there was very little missing data, multiple imputation 
was not used for externally validating the model. As a comparator, the discrimination 
performance of the previously developed clinical score (Chapter 4) was assessed in 
the external validation sample.  
5.3.10 Implementation of the model in clinical practice 
For implementation of the model as a screening tool, cut-points were evaluated for 
dichotomising the predicted probabilities into low and high risk. Across a range of cut-
points, the sensitivity and specificity were calculated in the external validation 
sample, alongside the positive and negative predictive values, positive and negative 
likelihood ratios, and number of diagnostic assessments required to identify one 
individual with undiagnosed COPD (NND). All analyses were performed using Stata 
version 13.1 (StataCorp, Texas). 
5.3.11 Ethical approval 
Ethical approval for the TargetCOPD trial was received (IRAS, reference 
11/WM/0403). 
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5.4 Results 
5.4.1 Practice characteristics 
Practices varied in size with the majority having a patient list size below 10,000 
(Table 5.1). Most practices served populations in socioeconomically deprived areas 
with a wide range in the proportion of ethnic minorities. The mean prevalence of 
established COPD was 1.3% (range 0.8 to 2.9%). 
Table 5.1 Practice characteristics 
  N (%) 
Practices  13 (100) 
Patient list size <5000 5 (38.5) 
 5000-10,000 6 (46.2) 
 >10,000 2 (15.4) 
IMD quintile 1 (most deprived) 8 (61.5) 
 2 1 (7.7) 
 3 3 (23.1) 
 4 1 (7.7) 
 5 (least deprived) 0 (0) 
Mean proportion of white patients (range)  71.8% (26.3-98.7%) 
Mean COPD prevalence (range)  1.3% (0.8-2.9%) 
IMD=Index of Multiple Deprivation (measure of socioeconomic deprivation derived from practice 
postcodes) 
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54 practices 
randomised 
Case finding 
(27 practices) 
Routine care 
(27 practices) 
 
13 practices included in 
current study 
14 practices 
excluded due to 
lack of relevant 
data collection  
 
Eligible patients 
(n=16,514) 
Returned postal 
questionnaire 
(n=2,848) 
Returned opportunistic 
questionnaire 
(n=1,402) 
Yes 
(n=1515) 
No  
(No COPD) 
(n=1333) 
Yes 
(n=712) 
Chronic respiratory 
symptoms 
No 
(No COPD) 
(n=690) 
Attended spirometry 
assessment 
(n=1087) 
No spirometry data available: 
Contraindications* (n=8) 
Refused consent* (n=4) 
Inadequate spirometry* (n=4) 
Other* (n=6) 
Attended spirometry 
assessment 
(n=417) 
No spirometry data 
available: 
Contraindications* 
(n=1) 
Refused consent* (n=2) 
Other* (n=7) 
Chronic respiratory 
symptoms 
COPD 
(n=198) 
COPD 
(n=77) 
Did not attend 
spirometry 
assessment* 
(n=295) 
Did not attend spirometry 
assessment* 
(n=428) 
Figure 5.1 Participant selection 
*Disease status unknown 
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5.4.2 Development sample: population characteristics 
The development sample included 2,398 subjects, of whom 198 (8.3%) were 
diagnosed with COPD during the study (Figure 5.1). The mean age was 59.6 years, 
51.6% were male and the majority (85.0%) were of white ethnicity. The severity of 
COPD was: 77.7% mild (FEV1 ≥80% predicted), 21.1% moderate (FEV1 50-79%), 
1.0% severe (FEV1 30-49%), and 0.2% very severe (FEV1 <30%).  
Based on data extracted from electronic health records (Table 5.2), current smoking 
was significantly more common among subjects with COPD than those without 
(32.8% versus 14.1%, respectively). There was also a higher prevalence of asthma 
and a slightly higher prevalence of anxiety and depression among those with COPD 
but the prevalence of other chronic conditions was similar in both groups. Records of 
cough, dyspnoea, sputum production, LRTIs, and respiratory prescriptions were all 
also more common among subjects with COPD. Based on data from returned 
screening questionnaires (Table 5.3), subjects with COPD were also more likely to 
report dyspnoea-related limitation of activities, being unable to lay flat at night, 
symptoms of chronic rhinitis, higher pack years of smoking (median 24.8 versus 12.9, 
respectively) and prior exposure to occupational VGDF (40.4% versus 31.3%).  
There was very little (<1%) missing data for candidate predictors (Table 5.2). 
However there was a large amount of missing data for self-reported characteristics 
including ethnic group (4.7%), smoking pack years (55.3%), and BMI (28.2%; Table 
5.3). It was not possible to quantify the amount of missing data for symptoms or 
comorbidities since these could either have been truly absent or could have been 
under-recorded. 
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Subjects with unknown COPD-status (predominantly those who did not attend an 
assessment) differed from those in the derivation sample across a number of 
demographic characteristics (Table 5.4) - they were generally younger (mean age 
55.8 years versus 59.6, respectively), a higher proportion were female (52.5% versus 
48.4%), of unknown ethnic group, and current smokers (33.5% versus 15.8%), and 
had a slightly higher mean body mass index (28.1 versus 27.1) and lower 
socioeconomic status.  
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Table 5.2 Characteristics extracted from electronic health records (development sample) 
  COPD 
(n=198 [8.3%]) 
Non-COPD 
(n=2200 [91.7%]) 
Missing data 
  n (%) n (%) n (%) 
Age (years) Mean (SD) 60.8 (9.6) 59.5 (10.7) 7 (0.3) 
 40-49 30 (15.2) 528 (24.0)   
 50-59 54 (27.3) 621 (28.2)   
 60-69 74 (37.4) 595 (27.0)   
 70-79 40 (20.2) 456 (20.7)   
Sex Male 107 (54.0) 1,128 (51.3) 4 (0.2) 
Smoking status Never 37 (18.7) 744 (33.8) 11 (0.5) 
 Former 95 (48.0) 1,135 (51.6)   
 Current 65 (32.8) 311 (14.1)   
IMD score Median (IQR) 37.4 (19.8-41.3) 23.3 (19.8-41.3) 0 (0.0) 
Comorbidities Asthma 10 (5.1) 29 (1.3) Unknown** 
 IHD 11 (5.6) 146 (6.6)   
 Heart failure 3 (1.5) 20 (0.9)   
 Diabetes 17 (8.6) 192 (8.7)   
 Stroke 2 (1.0) 18 (0.8)   
 Tuberculosis 3 (1.5) 11 (0.5)   
 Osteoporosis 4 (2.0) 37 (1.7)   
 Depression/anxiety* 36 (18.2) 335 (15.2)   
 LRTIs* 41 (20.7) 233 (10.6)   
Symptoms* Cough 61 (30.8) 385 (17.5) Unknown** 
 Dyspnoea 23 (11.6) 78 (3.5)   
 Wheeze 30 (15.2) 362 (16.5)   
 Sputum 11 (5.6) 43 (2.0)   
 Unintended weight loss 2 (1.0) 9 (0.4)   
Prescriptions* Salbutamol 74 (37.4) 251 (11.4) Unknown** 
 Prednisolone 40 (20.2) 138 (6.3)   
 Antibiotics ǂ 116 (58.6) 783 (35.6)   
 IMD=Index of Multiple Deprivation (a measure of socioeconomic status based on participants’ 
residential postcodes- higher scores indicate higher levels of socioeconomic deprivation), 
IQR=interquartile range, LRTI=lower respiratory tract infection, OR=odds ratio, SD=standard deviation 
*Recorded within previous three years of commencing case finding at the registered practice 
**It was unknown whether absence of a record of comorbidities, symptoms and prescriptions in 
electronic health records was due to true absence of those factors or due to under-recording. 
ǂ Antibiotics=amoxicillin, clarithromycin, co-amoxiclav, erythromycin, doxycycline, and cefalexin 
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Table 5.3 Self-reported characteristics (development sample) 
  COPD 
(n=198 [8.3%]) 
Non-COPD 
(n=2,200 [91.7]) 
Missing 
data 
  n (%) n (%) n (%) 
Ethnic group White 173 (87.4) 1,864 (84.7) 112 (4.7) 
 Mixed 2 (1.0) 16 (0.7)   
 Asian 9 (4.5) 100 (4.5)   
 Black 4 (2.0) 98 (4.5)   
 Other 3 (1.5) 17 (0.8)   
Smoking pack years Median (IQR) 24.8 (8-38) 12.9 (5.25-26.25) 1327 (55.3) 
Occupational exposures (VGDF) 80 (40.4) 688 (31.3) 69 (2.9) 
Body mass index (BMI) Mean (SD) 27.4 (5.1) 27.0 (4.6) 677 (28.2) 
 <18.5 3 (1.5) 6 (0.3)   
 18.5-24 39 (19.7) 582 (26.5)   
 25-29 49 (24.7) 656 (29.8)   
 >=30 34 (17.2) 352 (16.0)   
Self-reported symptoms      Unknown* 
Chronic cough 84 (42.4) 272 (12.4)   
Weather-induced cough 59 (29.8) 217 (9.9)   
Chronic phlegm 58 (29.3) 195 (8.9)   
MRC dyspnoea score 1 63 (31.8) 1,627 (74.0)   
 2 59 (29.8) 318 (14.5)   
 3 30 (15.2) 105 (4.8)   
 4 27 (13.6) 98 (4.5)   
 5 19 (9.6) 52 (2.4)   
Activities limited by dyspnoea 88 (44.4) 297 (13.5)   
Unable to lie flat at night 78 (39.4) 480 (21.8)   
Chronic rhinorrhoea 74 (37.4) 511 (23.2)   
IQR=interquartile range, OR=odds ratio, SD=standard deviation, VGDF=previous exposure to 
vapours, gas, dust or fumes 
* It was unknown whether absence of self-reported symptoms on returned screening questionnaires 
was due to them being truly absent or due to under-reporting. 
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Table 5.4 Characteristics of subjects with known and unknown COPD status 
  COPD status  
known 
COPD status  
unknown 
  (n=2398)  (n=752) 
  n (%) n (%) 
Age (years) Mean (SD) 59.6 (10.6) 55.8 (10.1) 
Sex Male 1235 (51.6) 356 (47.2) 
 Missing 4 (0.2) 2 (0.3) 
Ethnic group White 2037 (85.0) 521 (69.0) 
 Mixed 18 (0.8) 7 (0.9) 
 Asian 109 (4.6) 48 (6.4) 
 Black 102 (4.3) 51 (6.8) 
 Other  20 (0.8) 8 (1.1) 
 Missing 112 (4.7) 120 (15.9) 
Smoking status Never 781 (32.6) 105 (13.9) 
 Former 1230 (51.3) 279 (37.0) 
 Current 376 (15.7) 268 (33.5) 
 Missing 11 (0.5) 103 (13.6) 
Smoking pack years  Median (IQR) 13.5 (6-27) 17.1 (7-29) 
 Missing 1327 (55.3) 533 (70.9) 
Occupational exposures (VGDF) 768 (32.0) 268 (35.5) 
 Missing 69 (2.9) 49 (6.5) 
Body Mass Index (BMI) Mean (SD) 27.1 (4.7) 28.1 (5.9) 
 <18.5 9 (0.5) 5 (0.66) 
 18.5-25 621 (36.1) 144 (19.1) 
 25-30 705 (41.0) 178 (23.6) 
 ≥30 386 (22.4) 137 (18.2) 
 Missing 677 (28.2) 291 (38.5) 
IMD score Median (IQR) 23.3 (20-41) 37.4 (20-45) 
IMD= Index of Multiple Deprivation (a measure of socioeconomic status based on postcodes), 
IQR=interquartile range, SD=standard deviation 
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5.4.3 Model results 
Complete data for candidate predictors was available for 2380 patients (99.2%) in the 
development sample (Table 5.5). The final model of GP-recorded factors included 
smoking status, age, dyspnoea, and salbutamol and antibiotic prescriptions. Age was 
included as two fractional polynomial terms since it was not linear in the logit scale. A 
likelihood ratio test comparing the final model to the full model with all candidate 
predictors was not statistically significant (p=0.185). No significant interactions were 
found. The shrinkage factor was 1, which indicates that there was no evidence of 
over-fitting in the final model (Table 5.6). 
5.4.4 Internal validation 
When applied to the development sample the apparent c-statistic was 0.76 (95% CI 
0.73 to 0.80), and was 0.76 (95% 0.72 to 0.79) after correcting for over-fitting using 
bootstrapping. Although smoking status and age were the most important predictors 
in the model, restricting the model to just these variables reduced the c-statistic to 
0.65 (95% CI 0.60 to 0.69).  
5.4.5 External validation: population characteristics 
Among 1097 subjects in the external validation population, 77 (7.0%) had COPD 
(Table 5.7). The mean age was 60.1 years and 51.6% were male, which was similar 
to the development sample. Again, a significantly greater proportion of subjects with 
COPD were current smokers (31.2% versus 17.1%, respectively). However, 
participants in the external validation sample had a slightly higher socioeconomic 
status than those in the development sample (median IMD score 20.2 versus 23.3, 
respectively). 1083 subjects (98.7%) had complete data on all candidate predictors. 
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5.4.6 External validation: model performance  
The developed model demonstrated similar discrimination characteristics when 
applied to the external validation sample (c-statistic 0.74 [95% CI 0.68 to 0.80]; 
Figure 5.2) and performed better than our previously developed clinical score (c-
statistic 0.70 [95% CI 0.64 to 0.76] in the external validation sample). In the external 
validation sample the final model showed excellent calibration of observed to 
predicted COPD risk up to 10%, but slightly over-estimated the predicted risk from 
10% to 30%, beyond which comparisons were unreliable due to small sample sizes 
(Table 5.8).  
5.4.7 Implementation in clinical practice 
As the cut-point to define high risk is increased the number of assessments needed 
for each new diagnosis of COPD falls, although this is also accompanied by a 
reduction in sensitivity (Table 5.9). The optimum cut-point should balance both 
sensitivity and specificity, taking into consideration costs and resource availability. At 
a cut-point of 7.5% (i.e. classing subjects with a predicted risk ≥7.5% as high risk), 
the model is estimated in the external validation sample to have a sensitivity of 
68.8% (95% CI 57.3 to 78.9%), specificity of 68.8% (95% CI 65.8 to 71.6%) and 
would require seven patients (95% CI 6 to 10) to undergo a diagnostic assessment to 
identify one with COPD.  
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Figure 5.2 Receiver operator characteristic curve for the TargetCOPD model in the external 
validation sample (c-statistic 0.74 [95% CI 0.68 to 0.80]) 
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Table 5.5 Candidate predictors evaluated in the multivariable logistic regression model 
  Unadjusted Adjusted 
  OR (95% CI) p OR (95% CI) p 
Age (years) 40-49 Reference category Reference category 
 50-59 1.53 (0.97, 2.43) 0.070 1.66 (1.02, 2.70) 0.043* 
 60-69 2.19 (1.41, 3.40) <0.001* 2.63 (1.64, 4.23) <0.001* 
 70-79 1.54 (0.95, 2.52) 0.082 1.72 (1.01, 2.93) 0.044* 
Sex Male 1.11 (0.83, 1.49) 0.471 1.04 (0.76, 1.43) 0.800 
Smoking status Never smoked Reference category Reference category 
 Ex-smoker 1.68 (1.14, 2.49) 0.009* 1.71 (1.13, 2.59) 0.012* 
 Current smoker 4.20 (2.75, 6.43) <0.001* 5.58 (3.50, 8.89) <0.001* 
Asthma  3.98 (1.91, 8.30) <0.001* 1.44 (0.62, 3.37) 0.400 
LRTIs** 2.20 (1.52, 3.19) <0.001* 1.00 (0.84, 1.19) 0.977 
Symptoms** Cough 2.10 (1.52, 2.89) <0.001* 1.00 (0.68, 1.47) 0.986 
 Dyspnoea 3.58 (2.19, 5.84) <0.001* 2.19 (1.27, 3.76) 0.005* 
 Wheeze 0.91 (0.61, 1.36) 0.635 1.14 (0.73, 1.76) 0.564 
 Sputum 2.95 (1.50, 5.82) 0.002* 1.55 (0.71, 3.37) 0.270 
Prescriptions** Salbutamol 4.63 (3.38, 6.36) <0.001* 3.05 (2.01, 4.62) <0.001* 
 Prednisolone 3.78 (2.57, 5.57) <0.001* 1.76 (1.09, 2.84) 0.020* 
 Antibiotics ǂ 2.56 (1.90, 3.44) <0.001* 1.52 (1.06, 2.18) 0.023* 
Based on data extracted from electronic health records for 2380 subjects in the development sample. 
Candidate predictors are presented as binary variables unless specified otherwise. 
LRTI=lower respiratory tract infection, OR=odds ratio 
*Statistically significant at the p<0.05 level 
**Recorded within previous 3 years 
ǂ Antibiotics=amoxicillin, clarithromycin, co-amoxiclav, erythromycin, doxycycline, and cefalexin 
 
Table 5.6 Final model 
Predictor β* (95% CI) p 
Age3 1.43 x 10-4 (6.11 x 10-5, 2.26 x 10-4) 0.001 
Age3 x ln[age] -3.18 x 10-5 (-5.02 x 10-5, -1.34 x 10-5) 0.001 
Ex-smoker 0.51 (0.10, 0.91) 0.015 
Current smoker 1.60 (1.14, 2.05) <0.001 
Dyspnoea** 0.72 (0.18, 1.26) 0.010 
Number of salbutamol prescriptions** 0.045 (0.015, 0.075) 0.003 
≥1 salbutamol prescription** 0.99 (0.56, 1.42) <0.001 
≥1 antibiotic prescription** 0.47 (0.13, 0.80) 0.007 
Constant -6.16 (-7.63, -4.70) <0.001 
*Regression coefficient 
**Recorded within the previous three years 
Predicted probability of undiagnosed COPD= ex/(1+ex)  
Where x= (1.43 x 10-4 x age3) – (3.18 x 10-5 x ln[age]) + (0.51 x ex-smoker [Y/N]) + (1.60 x current 
smoker [Y/N]) + (0.72 x dyspnoea [Y/N]) + (0.045 x no. of salbutamol prescriptions) + (0.99 x 
salbutamol prescriptions [Y/N]) + (0.47 x antibiotic prescriptions [Y/N]) -6.16  
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Table 5.7 Demographic characteristics (external validation sample) 
  COPD 
(n=77 [7.0%]) 
Non-COPD 
(n=1020 [93.0%]) 
Missing data 
  n (%) n (%) n (%) 
Age* Mean (SD) 62.2 (10.1) 59.9 (10.8) 6 (0.5 
Sex* Male 39 (50.6) 484 (47.5) 2 (0.2) 
Ethnic group** White 72 (93.5) 855 (83.8) 79 (7.2) 
 Mixed 1 (1.3) 9 (0.9)   
 Asian 1 (1.3) 45 (4.4)   
 Black  2 (2.6) 26 (2.5)   
 Other 1 (1.3) 6 (0.6)   
Smoking status* Never 21 (27.3) 456 (44.7)   
 Former 32 (41.6) 382 (37.5)   
 Current 24 (31.2) 174 (17.1)   
Pack years** Median (IQR) 28.5 (9-40) 15 (5.5-25) 685 (62.4) 
BMI** Mean (SD) 27.5 (5.05) 27.2 (4.8) 367 (33.5) 
 <18.5 0 (0.0) 12 (1.2)   
 18.5-24 16 (20.8) 203 (19.9)   
 25-29 19 (24.7) 304 (29.8)   
 >=30 13 (16.9) 163 (16.0)   
IMD score* Median (IQR) 20.2 (10.9-37.4) 20.2 (10.9-37.4) 0 (0.0) 
IMD=Index of Multiple Deprivation (a measure of socioeconomic status- higher scores represent 
higher levels of socioeconomic deprivation), IQR=interquartile range 
*Recorded on electronic health records 
**Self-reported  
 
Table 5.8 Model calibration 
 Development sample 
(n=2380) 
External validation sample 
(n=1083) 
Predicted 
Risk (%) 
COPD Non-COPD Observed 
Risk (%) 
COPD Non-COPD Observed 
Risk (%) 
0-9 84 1,781 4.5 35 780 4.3 
10-19 53 271 16.4 20 158 11.2 
20-29 33 89 27.0 11 51 17.7 
30-39 11 17 39.3 6 9 40.0 
40-49 8 15 34.8 3 4 42.9 
50-59 4 6 40.0 0 2 0.0 
60-69 1 3 25.0 0 0 0.0 
70-79 2 0 100.0 1 2 33.3 
80-89 1 0 100.0 0 0 0.0 
90-100 0 1 0.0 1 0 100.0 
Total 197 2183 8.3 77 1006 7.1 
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Table 5.9 Diagnostic accuracy of the final model in the external validation sample (n=1083) 
Cut-point 
(%) 
Sensitivity (%) 
(95% CI) 
Specificity (%) 
(95% CI) 
Correctly 
Classified (%) 
LR+  (95% CI) LR-  (95% CI) PPV 
(%)  
(95% CI)  NPV 
(%)  
 (95% CI) NND  (95% CI) 
≥2.5 97.4 (90.9, 99.7) 12.5 (10.5, 14.7) 18.6 1.11 (1.07, 1.16) 0.21 (0.05, 0.82) 7.9 (6.2, 9.8) 98.4 (94.5, 99.8) 13 (11, 17) 
≥5.0 80.5 (69.9, 88.7) 48.4 (45.3, 51.5) ) 50.7 1.56 (1.38, 1.77) 0.40 (0.25, 0.64) 10.7 (8.3, 13.5) 97.0 (95.1, 98.3) 10 (8, 13) 
≥7.5 68.8 (57.3, 78.9) 68.8 (65.8, 71.6) 68.8 2.21 (1.85, 2.63) 0.45 (0.32, 0.63) 14.4 (11.0, 18.5) 96.6 (95.1, 97.8) 7 (6, 10) 
≥10.0 54.5 (42.8, 65.9) 77.5 (74.8, 80.1) 75.9 2.43 (1.92, 3.07) 0.59 (0.46, 0.75) 15.7 (11.5, 20.6) 95.7 (94.1, 97.0) 7 (5, 9) 
≥12.5 46.8 (35.3, 58.5) 82.3 (79.8, 84.6) 79.8 2.64 (2.01, 3.47) 0.65 (0.52, 0.80) 16.8 (12.1, 22.5) 95.3 (93.7, 96.6) 6 (5, 9) 
≥15.0 41.6 (30.4, 53.4) 87.0 (84.7, 89.0) 83.8 3.19 (2.34, 4.35) 0.67 (0.56, 0.81) 19.6 (13.8, 26.6) 95.1 (93.5, 96.4) 6 (4, 8) 
≥17.5 33.8 (23.4, 45.4) 91.9 (90.0, 93.5) 87.7 4.14 (2.85, 6.03) 0.72 (0.61, 0.85) 24.1 (16.4, 33.3) 94.8 (93.2, 96.1) 5 (3, 7) 
≥20.0 28.6 (18.8, 40.0) 93.2 (91.5, 94.7) 88.6 4.23 (2.77, 6.44) 0.77 (0.66, 0.88) 24.4 (16.0, 34.6) 94.5 (92.9, 95.8) 5 (3, 6) 
≥22.5 20.8 (12.4, 31.5) 95.2 (93.7, 96.5) 89.9 4.36 (2.60, 7.30) 0.83 (0.74, 0.93) 25.0 (15.0, 37.4) 94.0 (92.4, 95.4) 4 (3, 7) 
≥25.0 14.3 (7.4, 24.1) 97.1 (95.9, 98.1) 91.2 4.96 (2.58, 9.53) 0.88 (0.81, 0.97) 27.5 (14.6, 43.9) 93.7 (92.0, 95.1) 4 (3, 7) 
≥30.0 14.3 (7.4, 24.1) 98.3 (97.3, 99.0) 92.3 8.45 (4.11, 17.4) 0.87 (0.80, 0.96) 39.3 (21.5, 59.4) 93.7 (92.1, 95.1) 3 (2, 5) 
≥35.0 10.4 (4.6, 19.4) 98.8 (97.9, 99.4) 92.5 8.71 (3.67, 20.7) 0.91 (0.84, 0.98) 40.0 (19.1, 63.9) 93.5 (91.9, 94.9) 3 (2, 6) 
≥40.0 6.5 (2.1, 14.5) 99.2 (98.4, 99.7) 92.6 8.17 (2.74, 24.4) 0.94 (0.89, 1.00) 38.5 (13.9, 68.4) 93.3 (91.6, 94.7) 3 (2, 8) 
≥45.0 2.6 (0.3, 9.1) 99.3 (98.6, 99.7) 92.4 3.73 (0.79, 17.7) 0.98 (0.95, 1.02) 22.2 (2.8, 60.0) 93.0 (91.3, 94.5) 5 (2, 36) 
≥50.0 2.6 (0.3, 9.1) 99.6 (99.0, 99.9) 92.7 6.53 (1.22, 35.1) 0.98 (0.94, 1.01) 33.3 (4.3, 77.7) 93.0 (91.3, 94.5) 3 (2, 23) 
LR=likelihood ratio, PPV=positive predictive value, NPV=negative predictive value, NND=number of diagnostic assessments needed per case detected
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5.5 Discussion 
5.5.1 Principal findings 
From a large case finding trial in primary care (11) the TargetCOPD model has been 
developed and externally validated to predict patients’ risk of having undiagnosed 
COPD using data from electronic health records. The model incorporates five factors 
commonly recorded in general practice- smoking status, age, dyspnoea, and 
prescriptions of salbutamol and antibiotics commonly prescribed for LRTIs. When 
externally validated, the model discriminated reasonably well between patients with 
and without COPD and performed better than the previously developed clinical score 
(Chapter 4), which relied on incident COPD from routine records rather than actively 
case found patients. In the newly developed model, a cut-point of ≥7.5% would 
expect to identify about 70% of patients with undiagnosed COPD, needing seven 
diagnostic assessments to identify one patient with undiagnosed COPD (although 
use of higher cut-points could reduce this number at the expense of reducing 
sensitivity).  
5.5.2 Comparison with existing literature 
Several models have previously been developed for assessing risk of undiagnosed 
COPD (Table 5.10). Most recently, a clinical score was developed and externally 
validated in Chapter 4 of this thesis using routine case control data from a large 
primary care dataset. This differed from the newly developed model in that it included 
LRTIs and history of asthma but not age (since this was used as a matching factor in 
the study design), history of dyspnoea or prescriptions of antibiotics as predictors. 
The exclusion of age was a particularly important limitation in the previous model 
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since it is well established that risk of COPD rises with this factor.(22) A history of 
asthma and LRTIs were both found to be strong predictors of incident COPD in the 
previous study but were not statistically significant in the full multivariable model used 
in the current analysis (although they were highly significant in the unadjusted 
analysis). A likely explanation is that prescriptions of salbutamol and antibiotics are 
closely associated with asthma and LRTIs, respectively, and are possibly better 
documented in electronic health records. Thus they may be reflecting similar clinical 
features. 
Kotz and colleagues also recently developed and internally validated a prediction 
model for COPD using longitudinal data from general practices in Scotland.(8) Their 
model included age, smoking status, socioeconomic deprivation, and history of 
asthma but only considered a limited range of risk factors and was not externally 
validated. Furthermore, use of a UK-specific index of socioeconomic deprivation 
limits its applicability to other health systems. Unfortunately the final model was not 
reported so it was not possible to externally validate it in the current dataset. Their 
model, like the clinical score in Chapter 4, was developed on incident cases of COPD 
diagnosed through routine care, the disease status of which may have been 
misclassified because of underdiagnosis (9) and misdiagnosis.(10) The TargetCOPD 
model has the advantage of having been developed on case found patients based on 
a standardised definition of COPD that included quality assured spirometry 
confirmation. Also the characteristics of patients included in the current analysis are 
more likely to be representative of those that would be identified through a case 
finding process. 
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Both previous models however were based on a large sample size using nationally 
representative data and demonstrated good discrimination characteristics for 
identifying incident GP-diagnosed COPD. The newly developed TargetCOPD model 
partially overlaps with these previous models, notably including age, smoking status 
and possible proxies for asthma (salbutamol prescriptions) and LRTIs (antibiotics 
prescriptions) as important predictors. The previously developed model (Chapter 4) 
also showed reasonably good discrimination characteristics in the current analysis (c-
statistic 0.70 [95% CI 0.64 to 0.76]), although this was lower than that for the newly 
developed model and significantly lower than that shown in the previous external 
validation (c-statistic 0.85 [95% CI 0.83 to 0.86]), which was based entirely on data 
from electronic health records. This highlights that the performance of prediction 
models should be interpreted cautiously when validated solely on routine data 
without adequate verification of disease status.  
Price and colleagues developed a screening questionnaire for COPD using data from 
a case finding study involving two general practices.(5, 23) Their questionnaire 
included eight self-reported risk factors (age, smoking exposure in pack years, BMI, 
symptoms of wheeze, weather-affected cough, phlegm without a cold, morning 
phlegm and history of allergies) and has been widely validated, demonstrating a 
combined sensitivity of 64.5% (95% CI 59.9 to 68.8) and specificity of 65.2% [95% CI 
52.9 to 75.8%; Chapter 2]). This requires 22 patients to complete the questionnaire 
and 8 to undergo a diagnostic assessment to identify one patient with undiagnosed 
COPD. The TargetCOPD model showed higher discrimination characteristics, 
incorporates fewer variables (five versus eight, respectively), and has the important 
advantage of not relying on patients to respond to a questionnaire.  
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Finally, other models have also been developed for COPD using routine healthcare 
data (24-26) but are unlikely to be applicable in a primary care setting due to the 
predictors included, many of which are not routinely recorded (Table 5.10).  
5.5.3 Strengths 
A range of risk factors were investigated and the model developed and validated on a 
population with no prior diagnosis of COPD that was screened in a wide range of 
general practices. A robust case definition was employed which is likely to be 
representative of clinically significant, undiagnosed COPD. The analysis adjusted for 
over-fitting using bootstrapping and shrinkage of coefficients, and the developed 
model was externally validated, which increases the likelihood of its validity in other 
primary care populations. The final model incorporates a small number of commonly 
recorded factors which should ensure its applicability in routine primary care. 
5.5.4 Weaknesses 
A smaller sample size was used than several other studies reporting the 
development of COPD risk models from routine healthcare data,(8, 24) including the 
model developed in Chapter 4. Although the study was adequately powered for the 
number of risk factors considered for the model selection, a larger sample size would 
have enabled estimation of the parameters with greater precision. Ideally a larger 
sample size would have been used for external validation of the model since 
simulation-based estimates suggest at least 100 outcome events are required.(27) 
The model showed excellent calibration up to 10% but slight over-prediction from 10 
to 30%, in the external validation sample, in which the sample size was too small to 
provide reliable comparisons. .  
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It was unclear whether the lower than expected predictive ability of risk factors 
previously shown to identify patients with COPD, such as a history of LRTIs, was due 
to variability in clinical coding, limitations in the range of clinical codes extracted, or 
differences in the outcome being predicted (i.e. truly undiagnosed COPD versus GP-
diagnosed COPD). Also there are potential limitations in the use of antibiotics as a 
predictor since the included antibiotics may well have been prescribed for suspected 
infections other than LRTIs. However the included antibiotics were chosen to reflect 
those most likely to be prescribed for a LRTI in primary care and the aim was to 
evaluate whether these prescriptions were associated with the presence of 
undiagnosed COPD independent of records of previous LRTIs. 
Finally, the response to the questionnaire was low (25.7%), which is likely to have 
introduced response bias. Subjects who did not respond to the questionnaire may 
have felt untroubled by respiratory symptoms (either because such symptoms were 
absent or unrecognised) and therefore deemed the questionnaire not relevant to 
them. Conversely they may simply belong to a more hard-to-reach population who 
are unlikely to respond to questionnaires either because of cultural or socioeconomic 
factors. Furthermore a significant proportion (32.5%) of subjects who responded to 
the questionnaire and reported symptoms did not attend a spirometry assessment. 
They differed from those included in the analysis across a number of demographic 
characteristics and the validity of the model in such patients could not be determined. 
Thus the model is best considered applicable to populations of individuals that are 
likely to respond to questionnaire surveys and are willing to attend subsequent 
clinical assessment. 
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5.5.5 Implications for clinicians, policymakers and research 
The TargetCOPD model has been developed to help primary care services stratify 
patients according to their risk of undiagnosed COPD for targeted systematic case 
finding (Figure 5.3). It could be used to help prioritise referral for diagnostic 
assessment, including spirometry, or for further screening (e.g. using handheld flow 
meters). Since it relies entirely on routinely recorded data from electronic health 
records, it could be fully integrated with clinical information systems. Finally, the 
TargetCOPD model should be externally validated in other primary care populations 
and its effectiveness in practice evaluated in RCTs, where the impact of using the 
model on patient outcomes can be evaluated as well as the associated costs.(28) 
5.5.6 Conclusion 
The TargetCOPD model has been developed and externally validated for assessing 
the risk of undiagnosed COPD among patients in primary care. This is the first risk 
prediction model for COPD that has been derived from patients identified through 
systematic case finding and uses routine data from electronic health records. It 
should be readily applicable in primary care and can be used to help identify patients 
at high risk of COPD to improve access to appropriate clinical care. The model 
should be externally validated in further populations and its impact on clinical care 
and outcomes evaluated in RCTs. 
  
187 
 
 
  
Individual with chronic 
respiratory symptoms 
Primary care consultation Clinical information system 
aids risk stratification 
Decision on further 
investigation (e.g. 
spirometry) 
Software application 
(online or smartphone) 
Invite for screening or 
diagnostic assessment 
Pre-selection of patients at 
high risk of COPD- 
integrated with clinical 
information systems 
GP consultation 
Figure 5.3 Potential strategies for applying the TargetCOPD risk model 
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Table 5.10 Comparison of existing risk prediction models for COPD 
Model/clinical 
score 
Development Validation Predictors c-statistic 
(95% CI) 
Strengths Limitations 
TargetCOPD* Retrospective cohort analysis 
of a case finding cluster RCT 
& routine data from 13 general 
practices 
Internal and external 
validation using data 
from subjects who 
completed a screening 
questionnaire and 
performed spirometry 
Age 
Smoking 
Dyspnoea 
Salbutamol 
Antibiotics 
External 
0.74 
(0.68-0.80) 
Developed and validated on subjects 
with previously undiagnosed COPD 
confirmed by quality controlled 
spirometry. 
Can be integrated with clinical 
information systems.  
Good discrimination performance. 
Dependent on quality of clinical coding  
Haroon 2014* 
(Chapter 4) 
Case control study using 
routine data from 360 general 
practices. 
Internal and external 
validation using routine 
data 
Smoking 
Salbutamol 
Asthma 
Lower 
respiratory 
tract infections 
External 
0.85  
(0.83-0.86) in 
original study 
0.70 
(0.64-0.76) in 
current study 
Developed on large sample size. 
Can be integrated with clinical 
information systems.  
High discrimination performance. 
Considered wide range of risk factors. 
Predicts physician-diagnosed COPD.ǂ 
Excluded age and sex as predictors. 
Dependent on quality of clinical coding  
Kotz 2014(8)* Retrospective cohort study 
using routine data from 239 
general practices. 
Internal validation using 
routine data 
Age 
Smoking 
Socioeconomic 
status 
Asthma 
Internal 
0.85  
(0.84-0.85)  
in males 
0.83  
(0.83-0.84)  
in females 
Developed on large sample size. 
Can be integrated with clinical 
information systems.  
High discrimination performance. 
Estimates 10 year risk of incident 
COPD. 
Predicts physician-diagnosed COPD. ǂ 
Limited range of risk factors explored. 
Includes a UK-specific index of 
socioeconomic deprivation (limiting 
applicability to other health systems). 
Dependent on quality of clinical coding 
Smidth 
2012(26) 
Cross-sectional analysis of 
routine data from seven 
general practices, secondary 
care registers and an RCT. 
Internal and external 
validation using routine 
data and data from an 
RCT 
Chronic lung 
disease 
Respiratory 
medication 
Previous 
spirometry 
Not reported High positive predictive value. Predicts physician-diagnosed COPD. ǂ 
Requires prior diagnosis of chronic lung 
disease. 
Requires data linkage between primary 
and secondary care. 
Difficult to administer. 
Mapel 
2010(25) 
Case control study using 
routine data from four 
hospitals and 18 general 
practices. 
Internal and external 
validation using routine 
data 
Antibiotics 
Respiratory & 
cardiovascular 
medications 
Not reported Only used data on medication 
prescriptions, which are likely to be 
well recorded. 
Developed on large sample size. 
Predicts physician-diagnosed COPD. ǂ 
 
Mapel 
2006(24) 
Case control study using 
routine data from secondary 
care 
Internal and external 
validation using routine 
data 
19 healthcare 
utilization 
characteristics 
including cor 
pulmonale and 
asthma 
Not reported Developed on large sample size. 
Can be integrated with clinical 
information systems. 
 
Predicts physician-diagnosed COPD. ǂ 
Model includes large number of 
predictors. 
Includes predictors unlikely to be routinely 
recorded in primary care. 
Excluded smoking status as a predictor. 
* Likely to be readily applicable in primary care. ǂ Potential misclassification of disease (COPD) status during model development and validation.  
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5.6 Supplementary Tables 
Table S5.1 Clinical codes used to exclude patients with COPD 
Read Code 
(version 2) 
Description 
H31 Chronic bronchitis 
H32 Emphysema 
H36 Mild chronic obstructive pulmonary disease 
H37 Moderate chronic obstructive pulmonary disease 
H38 Severe chronic obstructive pulmonary disease 
H39 Very severe chronic obstructive pulmonary disease 
H3A End stage chronic obstructive airways disease 
H3y Other specified chronic obstructive airways disease 
H3z Chronic obstructive airways disease NOS 
 
Table S5.2 Clinical codes used for data extraction 
Variables Read code (version 2) Read code (version 3) 
Cough  171.. XE0qn 
Dyspnoea 173.., excl. 1731, 1737, 173A, 
173E, 173c, 173d, 173e 
XE0qq, R060A, excl. 1731 
Wheeze  1737. XE0qs, X76If, excl. XaCH9 
Sputum/phlegm  4E…, 1716., 4JF5.00 X76I2, X7ABC, XE26N, X76Hy, 
Xa0Yb, X76I5, excl. X76I9  
Unintended weight 
loss  
1625.., 1D1A.00 XE0qb, XaKwR, YA081, XaXTs 
LRTI  H06z0, H06z1, H2… X1004, X100E, XE0Xt 
Asthma  H33.. H33..  
LRTI=lower respiratory tract infection 
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CHAPTER 6: CASE FINDING FOR 
COPD IN PRIMARY CARE: A 
QUALITATIVE STUDY OF THE 
VIEWS OF HEALTH 
PROFESSIONALS  
6.1 Abstract 
Introduction 
COPD is common but largely underdiagnosed. A number of case finding initiatives 
have been evaluated in primary care but few studies have explored the views of 
service providers on implementing this in practice. 
Methods 
20 semi-structured interviews were conducted from March to September 2014 among 
GPs, nurses and managers from practices participating in a large COPD case finding 
trial based in primary care in the West Midlands, UK. Participants’ views were sought 
to explore perceived benefits, harms, barriers and facilitators to implementing case 
finding for COPD in practice. Interviews were transcribed and analysed using the 
framework method.  
Results 
Participants felt that case finding improves patient care, including smoking cessation 
and access to healthcare but also acknowledged potential harms to providers 
(increase in workload) and to patients (overdiagnosis). Insufficient resources, poor 
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knowledge of COPD, and limited access to diagnostic services were viewed as 
barriers to diagnosis while provision of community respiratory services, including 
COPD specialist nurses, and support from secondary care were thought to be 
facilitators. Participants also expressed a need for more education on COPD for both 
patients and clinicians. 
Conclusion 
Care providers believe early detection of COPD improves patient care but also has 
accompanying harms. Barriers to diagnosing COPD, such as insufficient expertise in 
primary care and limited access to diagnostic services in the community should be 
explored and addressed. The knowledge and attitudes of the public about COPD and 
its symptoms should also be investigated to inform future education and awareness-
raising strategies.  
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6.2 Introduction 
Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and 
mortality (1) and represents a significant cost to health services and society.(2) 
However, much of the disease burden remains undiagnosed (3) and there has been 
a policy drive to identify COPD early through systematic case finding.(4) This has 
been accompanied by the evaluation of a number of case finding strategies (5, 6) as 
described in the previous chapters of this thesis. However there has been a paucity 
of research exploring the views of primary care practitioners on these initiatives or 
factors influencing the ability of health services to screen for and diagnose COPD.  
A study in Tasmania conducted semi-structured interviews and focus groups to 
explore the views of patients with COPD and their general practitioners (GPs) on 
factors influencing the diagnosis of COPD.(7) This found that GPs intentionally 
avoided early diagnosis as a result of harbouring nihilistic attitudes towards COPD 
and misperceiving patient expectations. Patients reported receiving the diagnosis 
from other sources and were frustrated by delayed diagnosis.  
Another study by the same authors randomly assigned eight practices to either 
deliver optimised usual care or opportunistic assessment with spirometry for over 35 
year old ever smokers routinely attending primary care.(8) At the end of the study, 
focus groups were conducted with participating GPs to explore their views on each 
approach. They felt that organised follow-up, especially with spirometry was essential 
but would increase an already high workload and increase costs for patients. They 
also expressed a need for assistance with interpreting spirometry but felt its use 
prompted them to record their patients’ smoking status and initiate discussions about 
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smoking cessation. Some also questioned the value of diagnosing COPD in the 
absence of a cure. 
54 general practices were recently enrolled in a large pragmatic cluster randomised 
controlled trial (RCT) in the West Midlands, UK comparing the effectiveness and 
cost-effectiveness of targeted case finding for COPD against routine care.(9). 
Interviews were undertaken with participating healthcare providers to gain insights 
into their views on case finding for COPD, and to discern factors that might influence 
their ability to make a diagnosis.  
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6.3 Methods 
6.3.1 Study design 
I conducted semi-structured interviews with primary care service providers. 
Interviews were conducted from March to September 2014 and were audio-recorded 
and transcribed verbatim. Memos were made shortly after each interview to 
summarise key points and reflections. 
6.3.2 Participants 
One GP, nurse and manager was invited from each of the 54 general practices 
participating in the TargetCOPD trial.(9) Practices were selected to represent a wide 
range of population and practice characteristics. Eligible participants were posted an 
invitation letter as well as up to two reminders.  
6.3.3 Sample size  
The aim was to recruit 5-10 participants of each profession across at least five 
general practices with a minimum sample size of 20. Eventual sample size was 
determined by the reaching of theoretical saturation (i.e. no new concepts arising 
from the data).(10, 11) 
6.3.4 Interviews 
One-to-one semi-structured interviews were conducted either at practices (n=9) or 
over the telephone (n=11) using a topic prompt (see Box) and had a mean duration 
of 23 minutes (range 13 to 38 minutes). Repeat interviews were not conducted and 
transcripts were not returned to participants for comment. 
  
197 
 
Box 1. Topic prompt 
 Please tell me about any experience you have had looking after patients with COPD. 
 What are your thoughts on screening or case finding for COPD?  
 How do you think it would be best to identify undiagnosed patients with COPD in the 
community? 
 Does your practice take part in any COPD case-finding activities? Please tell me 
about this.  
 What might be the barriers to case finding and identifying patients with COPD? 
 What would help primary care services identify patients with COPD? 
 We are developing an electronic tool for GPs which will help them identify which of 
their patients are at high risk of undiagnosed COPD. Do you think such a tool would 
be useful? Do you think it would be used in practice and if so in what way? 
 Is there anything else you would like to comment about screening or case finding for 
COPD? 
6.3.5 Analysis  
Interviews were analysed using the framework method.(12) In brief, transcripts were 
read to identify codes or themes referring to specific topics. Two transcripts 
considered to be particularly rich and informative were independently coded by 
myself and my supervisors and compared to create an initial coding framework. I 
coded all subsequent transcripts and built on this framework. A framework matrix was 
then constructed, tabulating quotes by their associated codes and participant type. 
Emergent themes were then discussed and finalised. The analysis was performed 
using NVivo version 10. 
6.3.6 Ethical approval 
Ethical approval was provided by the Solihull National Research Ethics Service 
committee (reference: 11/WM/0403). All identifiable data were held on an encrypted 
database. 
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6.4 Results 
6.4.1 Practice and participant characteristics 
162 care providers were invited to participate, from which 20 participants (ten GPs, 
seven practice nurses, and three practice managers) from 16 practices were 
interviewed (Tables 6.1 and 6.2). Practices had a range of patient list sizes with most 
having 5-10,000 patients and the majority serving relatively socioeconomically 
deprived populations. Approximately one third of practices had been in the case 
finding arm of the trial and all had been involved in recruiting patients for a large 
COPD cohort study (the Birmingham COPD Study). Most GPs (70%) interviewed 
were male and all practice nurses and managers were female. Participants had been 
in practice on average for thirteen or more years. 
  Table 6.1 Practice characteristics 
  N (%) 
Total number of practices  16 (100) 
Patient list size 0-5000 5 (31.3) 
 5000-10,000 8 (50.0) 
 >10,000 3 (18.8) 
IMD quintile 1 (most deprived) 8 (50.0) 
 2 1 (6.3) 
 3 3 (18.8) 
 4 4 (25.0) 
 5 (least deprived) 0 (0) 
Intervention arm Targeted case finding 6 (37.5) 
 Routine care 10 (62.5) 
IMD=Index of Multiple Deprivation (measure of socioeconomic deprivation based on postcodes) 
Table 6.2 Participant characteristics 
 GP Nurse Practice 
manager 
Total 
Number (%) 10 (50) 7 (35) 3 (15) 20 (100) 
Mean age in years (range) 44.7 (31-73) 46.7 (33-54) 57.7 (55-61) 47.4 (31-73) 
Male (%) 7 (70) 0 (0) 0 (0) 7 (35) 
Mean years in practice 
(range) 
13.7 (2-35) 15.7 (10-25) 16.7 (12-25) 14.9 (2-35) 
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6.4.2 Views on case finding 
Participants were generally of the opinion that early detection of COPD was 
beneficial for both patients and health services. Several felt that early detection 
improved smoking cessation, helped instigate positive changes to other lifestyle 
behaviours (e.g. exercise), and improved quality of life and disease prognosis by 
enabling earlier access to care. Some also felt that it would be cost-saving for health 
services in the long term. 
I guess the main advantage of screening is presumably to pick up the disease 
early so that… I mean COPD is to some extent preventable and particularly if 
you treat it early and I guess the biggest advantage is… you can encourage 
them to stop smoking… if we treat it early, treat it effectively then hopefully 
there’ll be fewer hospital admissions and therefore reducing the costs. (GP 8) 
Several potential harms were also highlighted including the impact on health 
services, such as increased workload, resources and costs, as well as patients, 
including the risk of overdiagnosis, the implications of diagnostic labelling on 
insurance costs and creating anxiety. 
…it’s just that impact on workload really, whether primary care would just be 
overwhelmed if we started screening… you could end up labelling people, 
which can have a huge impact, and they are fine. (Nurse 6) 
6.4.3 Diagnostic strategies 
Participants mainly reported that patients were investigated for COPD on an 
opportunistic basis when consulting the health services, particularly when presenting 
with suggestive symptoms. Others discussed using a more active approach such as 
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screening at smoking cessation clinics. A wide range of factors were considered to 
be important triggers for considering COPD such as smoking status and a history of 
asthma. Participants also highlighted the potential of clinical information systems to 
help identify and flag high risk patients. 
Also looking at computer data, we can set up searches on our computers, but 
it depends on how active people are at putting the information on the 
computer, then we can pull that information… (Nurse 4) 
Spirometry was described as essential for making a diagnosis of COPD while 
screening tests such as handheld flow meters and respiratory questionnaires were 
discussed as potentially useful for assessing risk prior to diagnostic assessment. 
Some handheld flow meters were reported to feedback lung age which was 
highlighted by several participants as being useful for promoting smoking cessation. 
Handheld flow meters were also described as quick and easy to use within a 
consultation.  
If someone has got appropriate symptoms, a smoking history, and a low FEV1 
over V6, then we’ll bring them in for formal spirometry… overall I think it’s not 
an unreasonable way to triage the people into proper spirometry. I think the 
key thing is not to make the diagnosis on the handheld stuff. (GP 7) 
Most participants felt that use of electronic risk prediction tools would be useful for 
identifying patients at high risk of undiagnosed COPD and even to help communicate 
risk to patients. Ease of use, provision of technical support, integration with existing 
clinical information systems, and the generation of automated prompts on electronic 
health records were seen as important factors for their implementation.  
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I think it’s because we (nurses) always like something to refer to and we like to 
use tools, and I think sometimes that helps just to show the patient as well. 
Because we use a tool to assess cardiovascular risk… I found it useful, 
because it illustrates to them for example if they’re a smoker you can calculate 
their risk as a smoker, and then show them if you weren’t a smoker it would be 
this… So that’s a visual thing for them to see. (Nurse 5) 
A number of participants also highlighted the importance of being able to refer to 
secondary care, particularly for more challenging clinical presentations. One single-
handed GP also commented on the need to refer patients to secondary care for 
medico-legal protection.  
6.4.4 Barriers to case finding for COPD 
Limitation of time, finances and resources were seen as important barriers to 
implementing case finding and diagnosing COPD. Participants felt that primary care 
services were already stretched to capacity managing patients with established 
COPD and a lack of additional funding and resources would prohibit the 
implementation of case finding. 
…just managing the patients who are already on the COPD register is a hell of 
an onerous task anyway so going out and case finding… there’s a cost 
implication, there’s a man-time implication so unless it’s well-resourced it’s not 
going to happen. (GP 6) 
There was also felt to be a significant lack of knowledge and expertise on COPD in 
primary care. This included poor understanding of spirometry, difficulties 
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distinguishing between COPD, asthma and COPD-asthma overlap disease, and 
under recognition of the signs of COPD. 
I suspect as a profession, we’re not very good at picking up early signs of 
COPD either… Partly because we, again, attribute a lot of their symptoms to 
their social habits- smoking, lack of activity, environment. (GP 3) 
Limited access to diagnostic services was also cited as a barrier, particularly in 
smaller practices, which often lack provision of in-house spirometry. Challenges to 
providing spirometry included costs of equipment and training, quality assurance, and 
availability of appropriately trained staff.  
…you can’t refer for spirometry, the only thing we could possibly do is buddy 
up with other practices, but not every practice has a practice nurse available to 
do spirometry or has a spirometry machine. (Practice Manager 1) 
However some participants did comment on the gradual improvement of diagnostic 
testing for COPD in the community. 
It’s getting better I think. I think there was a phase where people were just 
doing spirometry willy-nilly without necessarily having the right equipment, the 
training to use it properly. I think there has been a lot of improvement, 
particularly over the last couple of years with the accreditation… (GP 3)  
Several patient-related factors were also described as barriers to diagnosing COPD. 
This included poor attendance at primary care, and late presentation with advanced 
disease. Patients were perceived to sometimes try to cope with symptoms for as long 
as possible without consulting the health services until suffering an acute 
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exacerbation. Some felt that patients often under-recognised the significance of their 
symptoms or were not always forthcoming about them or their smoking habits. 
…a lot of patients have symptoms but they just think that’s what they should 
have because they’re smokers so they don’t often seek advice. (Nurse 7) 
There was also a view that awareness of COPD among the general public was low, 
that patients were more likely to be aware of the more severe stages of the disease, 
and that smokers with undiagnosed COPD often have low expectations of their 
health. They also felt that communicating information about COPD was challenging. 
If you said to the average man on the street, ‘What’s COPD?’ they wouldn’t 
even know what it was… when you do try to explain it to them, you get people 
going into panic mode then because it doesn’t sound very nice… there’s just 
not enough educational publicity surrounding it. (Practice Manager 1) 
Cultural barriers were also discussed, which present both challenges to 
communicating risk as well as making a diagnosis because of under-recognition of 
exposures more common in the developing world such as indoor air pollution from 
cooking fuels. 
I think there is a linguistic barrier; increasing numbers of patients are from 
ethnic minorities and getting them up and looking at them, and actually 
understanding where their exposure has been…. You get all the little Asian 
ladies who cooked on open fires indoors and have COPD from that, but then 
they’re not smokers… So I think there’s a lot of cultural things going on here. 
(GP 7) 
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6.4.5 Facilitators for diagnosing COPD 
Training of health professionals was seen as one of the key facilitators for case 
finding and diagnosing COPD. Particular importance was attributed to spirometry 
training and acquiring a diploma in COPD, which several participating nurses had 
already achieved.  
…two of our nurses are going to do a spirometry course to become more up-
to-date and obviously qualified in doing spirometry, then we could offer more 
access to spirometry and possibly set up a breathing clinic… (Nurse 4) 
Access to community respiratory services, including specialist COPD nurses, and 
support from secondary care and community outreach were also seen as important, 
particularly since expertise on respiratory medicine in primary care was generally 
perceived to be low. Participants also discussed the importance of sharing diagnostic 
services between practices, which was especially important for smaller practices with 
limited service capacity. 
…if say a patient was suspected with COPD and I’ve sent them off for 
spirometry, we normally send them off to a local service where they have this 
spirometry, and I guess luckily for us we do have a respiratory consultant 
reporting the spirometry findings as well which gives us recommendations. 
(GP 8) 
The importance of educating patients and the public about COPD, including ethnic 
minority populations, was also discussed. This included communicating the 
symptoms of COPD, disseminating information at a community level, and use of 
social marketing and mass publicity. 
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I think more patient education, more information out there, more publicity… I 
think it’s got to be in the media really… If you’ve got these sort of symptoms 
then see your GP, get it checked… (Practice Manager 1) 
6.4.6 Perceptions of patients’ responses to receiving a diagnosis of 
COPD 
Patients’ responses to being diagnosed with COPD were perceived to be quite 
variable. Most participants felt that patients accepted their diagnosis and worked with 
their clinicians to improve their lifestyle behaviours, particularly in relation to smoking. 
Patients were perceived to sometimes even be relieved by the diagnosis since this 
allows them to attribute a cause to their chronic symptoms. 
I’ve not really had any genuine reluctance to accept a diagnosis… I think they 
take on board what they have been told… take on board the fact that by 
making lifestyle changes, they can significantly slow the progress of the 
process they have started. (GP 4) 
However it was acknowledged that patients were often shocked and upset by the 
diagnosis, particularly if they had family members who had severe disease, and also 
that there were implications for insurance costs and potentially employment. Some 
felt that patients were occasionally very reluctant to accept the diagnosis, particularly 
when they had no wish to give up smoking.  
I think because it is a big shock, it is a big diagnosis, as I said it’s got lots of 
implications with insurance. I think it frightens patients as well because they 
look at the worst case scenario and associations with oxygen… (GP 2) 
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6.5 Discussion 
6.5.1 Main findings 
Case finding for COPD is to some extent already occurring in primary care and some 
healthcare providers believe that this will benefit patient care at the expense of 
applying high workload and cost pressures on the health service, as well as risking 
overdiagnosis and creating anxiety among patients (Figure 6.1). Primary care 
providers are opportunistically diagnosing patients when presented with a suggestive 
clinical history while others are keen to undertake active case finding using a range 
of approaches.  
However, some important barriers to case finding were identified- limited service 
capacity, insufficient expertise on COPD and interpretation of spirometry, and 
restricted (but improving) access to diagnostic services were highlighted. Perceived 
poor awareness of COPD and its symptoms among the public and the difficulty of 
communicating a diagnosis of COPD were also seen as barriers.  
Investing in the training of healthcare professionals on COPD and spirometry, 
improving access to community respiratory services including specialist 
COPD/respiratory nurses, and education campaigns to improve awareness of COPD 
in the general population, were all suggested to improve the identification of patients 
with undiagnosed COPD.  
Finally, healthcare professionals recognise that receiving a diagnosis of COPD can 
be an upsetting and life-changing event and patients’ health beliefs and their 
response to the diagnosis can play an important role in subsequent management. 
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Effective communication of the diagnosis is thus an important component of patient 
care. 
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Figure 6.1 Summary of themes discussed by participants 
 
Diagnosis of COPD 
Strategies 
Opportunistically 
diagnose patients when 
presenting with relevant 
signs and symptoms 
Actively seek out 
patients with 
undiagnosed COPD 
Patient selection 
guided by clinical 
history 
Use of screening & 
diagnostic tests 
Referral to secondary 
care or community 
respiratory services 
Patients’ 
response 
Positive: 
 Accept diagnosis 
 Make positive lifestyle choices 
 Stop smoking 
 Relief from understanding 
cause of symptoms 
 
Negative: 
 Shocked and upset 
 Denial 
 No change in health behaviours 
 
 
Views on 
case finding 
Benefits: 
 Improve smoking cessation and 
other lifestyle behaviours 
 Improve disease prognosis 
 Provision of appropriate healthcare 
 
Harms: 
 Resource implications 
 Over-diagnosis 
 Cause anxiety 
 Insurance costs for patients 
 
Facilitators 
 Education and training of 
health professionals about 
COPD and spirometry. 
 Education of the public 
about COPD and its 
symptoms. 
 
Improve access to diagnostic services: 
 Community respiratory services 
 Specialist COPD nurses 
 Support from secondary care 
 Sharing diagnostic services in 
primary care 
 
Barriers 
Primary care: 
 Limited time, money and manpower 
 Insufficient expertise  
 Limited access to diagnostic services 
 
 
Patients: 
 Poor attendance 
 Late presentation 
 Poor recognition of 
symptoms 
 Poor awareness of COPD 
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6.5.2 Relationship to other studies 
Like Walters and colleagues (7, 8) the current study found that additional workload 
and resource requirements associated with case finding, as well as poor knowledge 
and confidence with spirometry interpretation, are likely to be barriers to diagnosing 
COPD in primary care. However unlike their study, participants in the current study 
did not express views of therapeutic nihilism. Instead they largely felt that early 
intervention was likely to improve patient outcomes. Patients with COPD participating 
in a qualitative study in Sweden that explored their perspectives on receiving a 
diagnosis suggested that they would prefer the diagnosis to be given at an early 
stage.(13) This also aligns with findings by Walters and colleagues (7) and the views 
expressed by health professionals in the current study.  
A recent analysis of a large primary care database showed that opportunities to 
diagnose COPD in primary care are frequently missed.(14) This was also 
acknowledged by participants in the current study and a number of reasons for this 
were postulated including health service and patient-related factors, such as under-
recognition of symptoms. Also participants felt that there is a low awareness of 
COPD among primary care users and the general public and this has previously 
been shown in a number of surveys.(15-17) 
6.5.3 Strengths and limitations 
A variety of stakeholders were sampled to acquire a range of both clinical and 
nonclinical perspectives. Participants were from a number of practices with a wide 
range of characteristics, including those that had participated in both the case finding 
and routine care arms of the TargetCOPD trial.(9) However, only a small proportion 
210 
 
(12.3%) of health professionals who were invited agreed to participate, despite 
receiving a written invitation and two reminder letters. This is likely to have introduced 
a response bias from a more select group of primary care providers who may 
potentially be more engaged with COPD care. The views expressed by the 
participants may therefore not fully reflect those among all healthcare providers who 
participated in the TargetCOPD trial. Also patients were not interviewed as part of 
this study so the views expressed were from a care provider perspective and may not 
necessarily reflect what patients personally experience. Transcripts were not 
returned to participants for validation of the themes and the interpretation of the 
transcripts could have been influenced by the prior beliefs of the author who is 
involved in the evaluation of COPD case finding. The findings of this study should 
therefore be interpreted in that light. 
6.5.4 Implications for policy, practice, and research 
Improving the diagnosis of COPD in primary care may require investment in 
community respiratory services and training of health professionals on COPD and 
performance and interpretation of spirometry. Further research should explore public 
perceptions of COPD, including awareness of symptoms, and understanding of the 
full spectrum of disease. Greater awareness may improve the likelihood that patients 
with undiagnosed disease access the appropriate services. 
The benefits and harms of case finding highlighted in this study should be evaluated 
empirically in the long term follow-up of case finding trials. The findings of this study 
should also be compared to the views of patients and explore the issues and 
implications surrounding the receipt of a diagnosis, addressing both the benefits and 
harms. The acceptability and feasibility of case finding strategies should be 
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qualitatively evaluated among care providers and patients alongside clinical trials 
evaluating their effectiveness.  
6.5.5 Conclusion 
The diagnosis of COPD in primary care may be improved by increasing access to 
community respiratory services and investing in the training of health professionals 
on COPD and spirometry. The benefits and harms of case finding should be 
empirically assessed in longitudinal studies to evaluate the overall effectiveness of 
detecting COPD early. Finally, the knowledge and attitudes of the public about COPD 
and its symptoms should be investigated to inform future education and awareness-
raising initiatives and help those with undiagnosed disease access the appropriate 
care.  
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CHAPTER 7: DISCUSSION 
7.1 Summary of principal findings 
Chronic obstructive pulmonary disease (COPD) is an important cause of morbidity 
and mortality (1, 2) but is widely underdiagnosed.(3) A significant proportion of 
people with undiagnosed COPD are likely to benefit from interventions such as 
smoking cessation support, pulmonary rehabilitation, and influenza vaccination.(4) 
Although there is a policy drive to identify people with undiagnosed COPD, (5) the 
most effective approach is currently unknown.(6) The interlinked studies reported in 
this thesis have examined the evidence, developed tools, and explored views on 
strategies to improve case finding for COPD in primary care. Chapters 2 and 3 report 
two systematic reviews evaluating the accuracy and effectiveness of screening tests 
and diagnostic strategies. Chapters 4 and 5 report the development and external 
validation of two readily applicable prediction models for assessing the risk of 
undiagnosed COPD using routine healthcare data. Finally, Chapter 6 reports a 
qualitative study exploring the views of healthcare professionals on case finding for 
COPD.  
7.1.1 Chapter 2 
Case finding is likely to be resource intensive, potentially requiring the clinical 
assessment of a large number of patients. The efficiency of case finding could be 
improved by using screening tests that can accurately discriminate between patients 
with and without disease to identify those most likely to benefit from further diagnostic 
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assessment. The accuracy of screening tests for COPD had not previously been 
formally summarised and their relative accuracy was therefore unknown.  
The systematic review in Chapter 2 evaluated the diagnostic accuracy of screening 
tests for COPD, incorporating evidence from ten studies. Only studies assessing 
screening questionnaires (the most widely evaluated of which was the COPD 
Diagnostic Questionnaire [CDQ] (7, 8)) and handheld flow meters met the inclusion 
criteria. There were very few comparative studies which meant that the review largely 
relied on indirect comparisons, which could potentially be biased because of 
differences in population and study characteristics. However the two studies that 
directly compared screening tests (9, 10) gave similar results to the indirect 
comparisons. There were also methodological limitations with inadequate blinding 
between index and reference tests, and a physiological definition of COPD was 
mostly used, relying on the presence of airflow limitation, which may not be truly 
representative of clinical disease. However the one study that only included subjects 
with respiratory symptoms (11) produced estimates of sensitivity and specificity for 
the CDQ that were broadly similar to studies that did not explicitly recruit subjects 
with respiratory symptoms. Meta-analyses of similar studies suggested that handheld 
flow meters are significantly more accurate than the CDQ for identifying patients with 
undiagnosed airflow limitation and potentially clinical COPD. The review highlighted 
the need for further diagnostic accuracy studies that directly compare alternative 
screening tests (including those not evaluated in the review such as peak flow 
meters) and use a clinical definition of COPD that requires the presence of relevant 
symptoms (see 1.3) as well as airflow limitation. 
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7.1.2 Chapter 3 
Knowledge of the accuracy of screening tests does not in itself provide information 
on the overall effectiveness of case finding strategies since this also depends on the 
uptake of screening and diagnostic tests by the target population. A number of 
studies have evaluated the effectiveness of case finding approaches for COPD but 
had not been previously summarised. The second systematic review in this thesis 
(Chapter 3) summarised the effectiveness of alternative approaches to case finding 
for COPD, incorporating data from 39 primary studies. Again these were largely non-
comparative (mostly single arm before-after studies) and were highly heterogeneous 
in terms of study design, target population, recruitment methods, screening tests, and 
diagnostic criteria. It therefore relied on indirect comparisons to identify factors 
associated with the yield from different case finding approaches, such as the patient 
population, method of recruitment, and use of screening tests. The included studies 
were of variable methodological quality, mainly used physiological definitions of 
COPD and often did not report the size and characteristics of the eligible population, 
which are important for making inferences about the overall effectiveness of case 
finding initiatives in primary care populations.  
The findings show that any case finding approach is likely to identify a substantial 
burden of previously undiagnosed disease. The findings from comparative studies 
suggest that nurse-led case finding using written invitations for spirometry may be 
more effective than usual care, that screening questionnaires should ideally be 
scored and further follow-up arranged by practices rather than directed by patients, 
and that opportunistic case finding among patients clinically suspected to have 
COPD is likely to be more effective than more widespread public invitation for 
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spirometry testing. The findings from indirect comparisons suggest that uptake of 
spirometry testing is likely to be higher when this is offered opportunistically at routine 
primary care visits than when offered through a mailed invitation, that the yield may 
be higher when targeting ever smokers with a history of respiratory symptoms, and 
that use of screening tests such as questionnaires or handheld flow meters prior to 
spirometry may reduce the number of diagnostic assessments needed per case 
detected. The review highlighted the need for well conducted RCTs comparing the 
relative effectiveness of alternative case finding strategies, and addressing the 
methodological limitations found in previous studies, such as reporting of eligible 
populations and indeterminate results. The review did not consider the costs of each 
approach, which ideally should be modelled alongside RCTs. 
7.1.3 Chapters 4 and 5 
Case finding is likely to involve the invitation of a large number of patients for 
assessment, and is therefore likely to be costly and resource intensive. One way to 
potentially improve the efficiency of the process is to risk stratify patients in order to 
identify those most likely to benefit from further clinical assessment. This could 
reduce the number of clinical assessments needed to identify each additional case. 
This is already part of routine practice in certain clinical domains such as 
cardiovascular disease (12) and could potentially be incorporated for COPD using 
routine healthcare data.(13) Use of routinely recorded healthcare data to risk stratify 
patients has the advantage of being less dependent on patient response (unlike 
screening questionnaires) and is likely to require less resources than the application 
of screening tests (such as handheld flow meters). 
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The next two chapters in this thesis (Chapters 4 and 5) report the development and 
validation of two models that use routine healthcare data to estimate the risk of 
undiagnosed COPD among patients in primary care. The first model was developed 
using case control data from a large primary care database drawn from general 
practices in England. The main derived model included only four routinely recorded 
risk factors- smoking status, and history of lower respiratory tract infections (LRTIs), 
salbutamol prescriptions, and asthma. This showed high discrimination 
characteristics when externally validated and at a score cut-point of ≥2.5 was 
estimated to require only five diagnostic assessments to identify one patient with 
COPD (although this did not consider nonresponse), which is potentially far fewer 
than would be required than when inviting all ever smokers for diagnostic spirometry 
(~19 diagnostic assessments required per case detected). However the study was 
limited by the case definition used which was a diagnosis of COPD documented 
through routine care. Cases and controls may have been misclassified because of 
the underdiagnosis and misdiagnosis of COPD known to exist in primary care (3, 14) 
and cases identified through routine care may not necessarily be representative of 
those that would be identified through case finding.  
Nevertheless this analysis was highly informative for the development of a second 
model (the TargetCOPD model) which was derived from a large cluster RCT for 
COPD in primary care (the TargetCOPD trial).(15) This has the advantage over 
previous models of having been developed on data from patients who had been 
diagnosed through systematic case finding using quality controlled spirometry and 
the most up-to-date and comprehensive lung function reference equations.(16) The 
final model incorporated five predictors that are routinely recorded in electronic health 
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records- age, smoking status, history of dyspnoea, and prescriptions of salbutamol 
and antibiotics indicated for lower respiratory tract infections. This model was able to 
discriminate reasonably well between patients with and without COPD when 
externally validated (c-statistic 0.74 [95% CI 0.68 to 0.80]). The calibration (matching 
of predicted and observed risk) was good up to 10%, but slightly overestimated 
observed risks up to 30%, although this may have been affected by the small sample 
size in the external validation population. The previously developed model was also 
externally validated in this dataset and showed slightly worse discrimination 
characteristics than the TargetCOPD model (c-statistic 0.70 [95% CI 0.64 to 0.76]). 
Unlike the TargetCOPD model, the previous model cannot be used to estimate 
absolute risk of COPD since it was developed on case control data. Also the previous 
model did not include age since this had been used as a matching factor in the study 
design. Both models are probably incorporating markers of overlapping clinical 
factors since prescriptions of salbutamol are more likely in patients with asthma, and 
prescriptions of relevant antibiotics more likely in those with a history of LRTIs.   
Using the TargetCOPD model at the suggested cut-point of ≥7.5% to prompt referral 
for further clinical assessment, seven patients would require a diagnostic assessment 
(including spirometry) to identify one with undiagnosed COPD (although this could be 
reduced by raising the cut-point at the expense of lowering sensitivity). This is the 
first prediction model derived from patients with COPD who were diagnosed 
exclusively through systematic case finding and uses routine data from electronic 
health records. It is likely to be readily applicable and integrated with clinical 
information systems to risk stratify patients for undiagnosed COPD and help prioritise 
further diagnostic assessment. However the model still needs to be validated in other 
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populations and its impact on clinical practice and patient outcomes evaluated in 
RCTs before its routine use can be recommended. 
7.1.4 Chapter 6 
Finally, to contextualise the findings of the previous chapters to everyday general 
practice and understand the potential barriers and facilitators to identifying patients 
with undiagnosed COPD, 20 primary care providers, including GPs, nurses and 
managers, were interviewed. Findings from these interviews suggest that healthcare 
professionals view case finding as beneficial for improving patient outcomes but may 
also risk overstretching healthcare resources, as well as potentially causing 
overdiagnosis, and creating anxiety among patients. Healthcare providers appear to 
be keen to use novel methods for assessing risk of COPD, such as using handheld 
flow meters and risk prediction software. However there was felt to be a lack of 
expertise on COPD and the use and interpretation of spirometry as well as the 
healthcare capacity to undertake case finding. The findings suggest that improving 
access to community respiratory services, including specialist COPD/respiratory 
nurses, increasing education on COPD and spirometry for primary care health 
professionals, and increasing awareness of COPD and its symptoms among the 
general public may help improve the timely diagnosis of COPD and the 
implementation of case finding for COPD in primary care. These factors should be 
empirically evaluated in ongoing and future case finding studies and as part of 
respiratory service evaluations.  
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7.2 Relationship to other reports 
The National Institute for Health and Care Excellence (NICE) recommend that a 
diagnosis of COPD should be considered in ever smokers aged over 35 years who 
have chronic respiratory symptoms in the absence of clinical features of asthma,(17) 
and that opportunistic case finding should be based on the presence of risk factors 
(age and smoking) and symptoms. Using a simple decision tree model, they 
surmised that this approach was likely to be cost-effective. The model focused 
exclusively on the benefits of smoking cessation therapy, incorporated evidence from 
a limited number of studies, and relied on a number of basic assumptions including 
differences in treatment compliance between patients diagnosed early versus late 
(although sensitivity analyses were performed to account for some of these 
variables).  
The systematic reviews presented in Chapters 2 and 3 of this thesis should help 
inform policy on case finding for COPD and should be considered in future guideline 
reviews. Their findings support the effectiveness of opportunistically targeting ever 
smokers with respiratory symptoms to optimise the diagnostic yield but additionally 
highlight potential improvements in the efficiency of this process by screening with 
either respiratory questionnaires or handheld flow meters prior to performing 
diagnostic spirometry. Future guidelines should also consider the potential benefits of 
using risk prediction models or clinical scores to improve the efficiency of case finding 
and their utility for triaging patients for further diagnostic assessment. 
The Outcomes Strategy for COPD and Asthma in England advocated early 
recognition of COPD through opportunistic and active case finding although it did not 
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provide specific guidance on optimal approaches.(5) The systematic review in 
Chapter 3 provides some evidence that opportunistically inviting patients at high risk 
of COPD for assessment may improve the uptake. However this was based on 
indirect comparisons and needs to be empirically tested in adequately powered and 
well conducted RCTs. The findings from the qualitative study in Chapter 6 of this 
thesis also suggest that policy on case finding must consider the current capacity 
within primary care to diagnose and manage patients with COPD, including the need 
for good access to community respiratory services and education and training on 
community respiratory medicine. 
In 2008 the US Preventive Service Task Force conducted a systematic review on 
screening for COPD using spirometry and recommended against it because they 
estimated that hundreds of patients would need to be screened in order to prevent a 
single exacerbation and that screening would largely uncover patients with early 
disease for whom there are limited therapeutic options.(18) However this review 
looked at screening asymptomatic individuals for airflow obstruction, which is not 
equivalent to identifying clinical COPD, the latter requiring a compatible clinical 
presentation including the presence of relevant symptoms.(17) The systematic 
reviews in Chapters 2 and 3 provide evidence on alternative strategies for identifying 
clinical COPD that are likely to be more efficient than performing spirometry on a 
population-wide basis. They also highlight that although the majority of patients 
identified through case finding have mild disease, a significant proportion (~20%) 
actually have moderate-to-severe disease who would likely benefit from evidence 
based interventions recommended in national and international guidelines.(17, 19)  
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An analysis of the Health Survey for England suggested that targeted case finding 
among symptomatic smokers aged over 40 years would be more efficient than 
general population screening and over three quarters of those diagnosed with COPD 
could benefit from further treatment such as smoking cessation support, pulmonary 
rehabilitation, immunisations and inhaled therapies.(4)  There is also some limited 
evidence from subgroup analyses of RCTs that patients with mild-to-moderate 
disease may benefit from inhaled pharmacotherapy, (20, 21) including reductions in 
exacerbations and improved health status compared to placebo, although this is 
currently an area of ongoing research. Patients with mild-to-moderate COPD have 
impaired health status,(22) reduced physical activity,(23) and a higher mortality risk 
than people without COPD.(24) Early intervention among these patients may improve 
COPD-related morbidity and mortality (25) and this should be evaluated 
prospectively in RCTs that primarily recruit patients with mild-to-moderate disease 
(GOLD stage I-II).  
The UK National Screening Committee recently reviewed and recommended against 
screening for COPD due to a lack of RCTs, insufficient evidence on outcomes from 
early intervention, uncertainty on the comparative effectiveness of alternative 
screening tests, and incomplete implementation of current prevention activities.(6) 
The report however also concluded that case finding among symptomatic individuals 
with more developed COPD is cost-effective and should continue. The findings from 
the systematic reviews in this thesis agree that there are indeed a lack of RCTs and 
those that have been conducted are highly heterogeneous. However they also offer 
suggestions for the design of future trials evaluating the effectiveness of alternative 
case finding strategies and partly bridge the evidence gap by synthesising the 
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findings of previous case finding studies, summarising evidence on target 
populations, recruitment methods, and screening tests. This is currently the most 
comprehensive evaluation of alternative strategies for COPD case finding in primary 
care and should offer important information to be considered in future policy reviews.  
7.3 Implications for policy, practice and research 
The findings from this thesis suggest that handheld flow meters (e.g. COPD-6®) are 
a more accurate screening test than the CDQ for detecting patients with airflow 
limitation and potentially clinical COPD. Opportunistic invitation of ever smokers with 
a history of respiratory symptoms (or lower respiratory tract infections) to a screening 
assessment using either a respiratory questionnaire (e.g. CDQ) or handheld flow 
meter, and referring those with a positive test for diagnostic assessment, may be 
more efficient for identifying patients with undiagnosed COPD than directly inviting all 
ever smokers for diagnostic spirometry. However this should be evaluated in 
rigorously conducted RCTs that address the methodological limitations highlighted in 
the systematic reviews (Chapters 2 and 3), particularly ensuring that COPD is 
defined clinically (as opposed to just physiologically). 
Another way to potentially improve the efficiency of case finding is to stratify patients 
according to their risk of undiagnosed COPD using routinely recorded data from 
electronic health records. This could enable primary care services to select patients 
at the highest risk of undiagnosed disease who would most likely benefit from further 
clinical assessment. The newly developed and externally validated TargetCOPD 
model can be used to estimate the risk of undiagnosed COPD among patients in 
primary care using routine data from electronic health records. Use of this model may 
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further improve the efficiency of case finding although this should first be validated in 
other populations and empirically tested in RCTs to evaluate its impact on clinical 
outcomes and costs before recommendations on its use in routine practice can be 
made.  
Modelled estimates suggest that use of the TargetCOPD model to identify and select 
high risk patients could significantly reduce the number of screening and diagnostic 
assessments needed for each new case detected (Table 7.1). For example, use of 
the model to select high risk patients and invitation of those with a predicted risk of 
≥7.5% for a screening assessment with handheld flow meters may reduce the 
number of screening assessments from 23 to 9 and diagnostic assessments from 5 
to 3 per case detected. This could be empirically tested in a cluster RCT (clustering 
by general practices) comparing routine care against targeted case finding using the 
TargetCOPD model to identify high risk patients before offering a screening or 
diagnostic assessment. The effectiveness of this approach could be measured by the 
number of new diagnoses of COPD, cost per additional case detected, impact on 
clinical care (e.g. access to smoking cessation services and pulmonary 
rehabilitation), and clinical outcomes such as smoking quit rates, hospitalisations, 
and health related quality of life. If shown to be clinically useful, the TargetCOPD 
model could be readily applied by integrating it with clinical information systems. The 
cut-point used by the model to prompt referral for further clinical assessment could 
be determined by the available service capacity within primary care and by cost-
effectiveness analyses. 
The capacity within primary care to undertake case finding for COPD needs to be 
evaluated, including access to community respiratory services, diagnostic spirometry, 
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and education and training on community respiratory medicine. This may be 
particularly important for contextualising the findings of the ongoing National COPD 
Audit programme.(26) More must also be done to gauge the general public’s 
awareness of COPD, including its symptoms, and gain a patient perspective on case 
finding. This could help inform future strategies for improving awareness of the 
condition, which may help patients with undiagnosed disease access the appropriate 
care in a timelier manner. 
The findings of this thesis can only be used to comment on the effectiveness of 
approaches to case finding in terms of their accuracy and yield, as well as the views 
of health professionals. However they cannot be used to comment on the clinical 
benefits of case finding such as impact on health-related quality of life and disease 
prognosis. These must first be evaluated through long-term prospective studies 
before firm recommendations on the early detection of COPD can be made.  
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Table 7.1 Modelled estimates of screening for COPD among patients aged over 40 years with no prior diagnosis  
Patient selection Screening test Diagnostic test Sensitivity Specificity NNS* NND* 
Ever smokers None Spirometry 100 100 N/A 19 
Ever smokers COPD Diagnostic Questionnaire (cut-point ≥19.5)**  Spirometry 64.5 65.2 29 11 
Ever smokers Handheld flow meter**  Spirometry 79.9 84.4 23 5 
TargetCOPD model (cut-point ≥7.5%) None Spirometry 68.8 68.8 N/A 7 
TargetCOPD model (cut-point ≥7.5%) Handheld flow meter**  Spirometry 45.5 96.8 9 3 
NNS=number-needed-to-screen to identify one patient with undiagnosed COPD 
NND=number of diagnostic assessments needed for each new case of COPD detected 
*Based on a prevalence of undiagnosed COPD of 5.5% 
**Based on the meta-analyses in Chapter 2 
NB. Estimates do not consider patient response/uptake 
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7.4 Strengths and limitations 
Evidence on the diagnostic accuracy of screening tests for COPD and the 
effectiveness of case finding approaches were evaluated in two systematic reviews. 
Each review followed a robust peer reviewed protocol (27) which should minimise 
bias in the inclusion, appraisal and synthesis of the evidence. However the test 
accuracy review (Chapter 2) only included evidence on screening questionnaires and 
handheld flow meters since studies evaluating other screening tests such as peak 
flow meters and chest radiography did not meet the pre-specified inclusion criteria. 
The findings of both reviews should be interpreted in light of the quality of the 
included evidence. As was previously highlighted, included studies were largely non-
comparative and were highly heterogeneous with several important limitations in 
design such as poor reporting of eligible populations and indeterminate results, and 
lack of blinding between index and reference tests. Importantly, studies often used a 
physiological definition of COPD, most commonly using the fixed ratio of FEV1/FVC 
to define airflow obstruction, whereas clinical guidelines recommend using a 
definition that also includes presence of compatible symptoms, and/or relevant risk 
factors.(17)  
The clinical score reported in Chapter 4 was developed from a large primary care 
database and explored a wide range of risk factors that was informed by an 
extensive literature search. The main limitation of this score was that it was based on 
predicting COPD that had been diagnosed through routine practice. The accuracy of 
this case definition was likely to be affected by both under-diagnosis and 
misdiagnosis.(3, 14) Another important limitation was that age and sex were not 
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examined as predictors since these had been used as matching factors in the case 
control data. Nevertheless the findings from this chapter were instrumental in 
informing the development of the TargetCOPD model. The latter attempted to 
overcome these limitations by using data from a large cluster randomised case 
finding trial (15) that performed quality controlled spirometry assessments among 
symptomatic patients with no prior diagnosis of COPD and used a strict definition of 
airflow obstruction that accounted for age, sex and ethnicity biases in lung 
function.(16) This also allowed evaluation of age and sex as potential predictors. Key 
strengths of the model are that it showed good discrimination characteristics when 
externally validated, and relies entirely on routinely recorded data from electronic 
health records to estimate absolute risk of undiagnosed COPD, enabling its potential 
integration with primary care clinical information systems. 
Another strength of this programme of work has been the mixed methods approach 
to evaluating the question of how to improve case finding for COPD in primary care. 
In addition to the quantitative research conducted through the systematic reviews 
and the risk prediction modelling studies, a qualitative study was also conducted to 
gain a health services perspective on the potential benefits and harms of case finding 
as well as the barriers and facilitators encountered in everyday general practice.  
7.5 Further planned research 
I began my academic journey on the epidemiology of COPD by conducting a pilot 
RCT comparing two approaches to case finding in primary care (Figure 7.1).(28) This 
led to the development of the series of interlinked studies incorporated in this thesis. 
Undertaking this programme of work has similarly sparked ideas for ongoing 
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research which I hope to achieve in collaboration with the Birmingham Lung 
Improvement Studies (BLISS) programme. Below is an outline of some of the future 
projects I am considering. 
Although findings from the systematic review in Chapter 3 suggest that screening 
symptomatic ever smokers with either questionnaires or handheld flow meters may 
improve the efficiency of case finding, it did not consider the use of risk prediction 
models to select high risk patients, or consider costs. Although the NICE guidelines 
did include a cost-effectiveness analysis of opportunistic case finding, this included a 
fairly simple model using limited assumptions.(17) Therefore a robust economic 
model incorporating evidence from the systematic reviews in chapters 2 and 3 as 
well as future trials, and that includes detailed sensitivity analyses, is needed to 
further help inform policy makers on the optimal approach to case finding for COPD. 
Data on a subset of 13 practices enrolled in the TargetCOPD trial (29) were used for 
the development and validation of the TargetCOPD model. The BLISS programme 
intends to extract data on all 26 practices enrolled in the case finding arm of the trial, 
which offers an opportunity to validate and revise the model using a larger sample 
size, and potentially investigate a wider range of risk factors. 
Healthcare providers participating in the TargetCOPD trial were informed of patients 
meeting the study definition of COPD. The BLISS programme plans to collect data 
relevant to the management of these patients, which will enable their quality of care 
to be audited against clinical guideline recommendations and NICE standards.(30) 
This is a critical aspect of case finding since one of its main purposes is to enable 
early access to care in order to improve quality of life and disease prognosis. 
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Associations between practice and patient factors and the quality of care received 
can also be explored. In addition, patients identified with COPD through the 
TargetCOPD trial have been entered into a large cohort study (the Birmingham 
COPD Cohort), which will enable comparison of their clinical outcomes with those 
identified through routine care. 
The COPD Assessment Test (CAT) has been widely evaluated for the assessment of 
health-related quality of life in patients with COPD (31) and was completed by 
participants attending spirometry assessments in the TargetCOPD trial.(29) This 
offers an opportunity to assess the accuracy of the CAT questionnaire as a potential 
screening tool for COPD, although this can only be tested among patients who 
explicitly reported experiencing chronic respiratory symptoms.(32)  
Finally, the feasibility and effectiveness of the TargetCOPD model should be 
evaluated in a cluster RCT to assess its impact on clinical practice and patient 
outcomes. One potential trial suggested above could involve evaluating the 
effectiveness of a multistage screening process in which high risk patients are initially 
identified using the TargetCOPD model, and then invited for screening assessments 
using handheld flow meters and/or screening questionnaires, before referral for a full 
diagnostic assessment.  
7.6 Conclusions 
Handheld flow meters have higher test accuracy than the COPD Diagnostic 
Questionnaire for identifying patients with undiagnosed airflow limitation and 
potentially clinical COPD. Opportunistic invitation of symptomatic ever smokers to 
undertake screening assessments, using either screening questionnaires or 
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handheld flow meters, followed by diagnostic assessment in those with a positive 
screening test, may be more efficient for identifying undiagnosed COPD than directly 
inviting all ever smokers for diagnostic spirometry. However the quality of the 
available evidence is limited and there is a need for well conducted RCTs directly 
comparing the effectiveness of different case finding strategies. 
The TargetCOPD model has been developed to help stratify patients in primary care 
according to their risk of undiagnosed COPD using routine data from electronic 
health records. External validation of this model has shown that it can discriminate 
between patients with and without COPD reasonably well and may help primary care 
services identify patients at high risk who could be targeted for systematic case 
finding. However it still needs to be validated in other populations before its routine 
use can be recommended. 
The capacity of primary care services to undertake case finding needs to be 
evaluated, including access to community respiratory services and the education and 
training needs of healthcare professionals on COPD and diagnostic assessment. 
Further research is also needed to compare alternative case finding strategies 
through high quality RCTs, model their cost-effectiveness including potential clinical 
benefits and harms, and evaluate the management and outcomes of patients who 
are diagnosed with COPD through case finding.  
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Figure 7.1 My academic journey in COPD epidemiology 
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Appendix 1: PRISMA checklist for Chapter 2 
Section/topic  # Checklist item  Reported on 
page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  27 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; 
data sources; study eligibility criteria, participants, and interventions; study 
appraisal and synthesis methods; results; limitations; conclusions and implications 
of key findings; systematic review registration number.  
27 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  29 
Objectives  4 Provide an explicit statement of questions being addressed with reference to 
participants, interventions, comparisons, outcomes, and study design (PICOS).  
29 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web 
address), and, if available, provide registration information including registration 
number.  
30 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report 
characteristics (e.g., years considered, language, publication status) used as 
criteria for eligibility, giving rationale.  
30 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact 
with study authors to identify additional studies) in the search and date last 
searched.  
30 
Search  8 Present full electronic search strategy for at least one database, including any 
limits used, such that it could be repeated.  
30, 31 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in 
systematic review, and, if applicable, included in the meta-analysis).  
31 
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Section/topic  # Checklist item  Reported on 
page #  
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, 
independently, in duplicate) and any processes for obtaining and confirming data 
from investigators.  
31 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding 
sources) and any assumptions and simplifications made.  
31 
Risk of bias in individual studies  12 Describe methods used for assessing risk of bias of individual studies (including 
specification of whether this was done at the study or outcome level), and how 
this information is to be used in any data synthesis.  
32 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  30 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, 
including measures of consistency (e.g., I2) for each meta-analysis.  
32 
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence 
(e.g., publication bias, selective reporting within studies).  
N/A 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, 
meta-regression), if done, indicating which were pre-specified.  
32 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the 
review, with reasons for exclusions at each stage, ideally with a flow diagram.  
34, 35 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study 
size, PICOS, follow-up period) and provide the citations.  
34, 36, 37, 52, 56, 
60 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level 
assessment (see item 12).  
38, 39, 40, 62 
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) 
simple summary data for each intervention group (b) effect estimates and 
confidence intervals, ideally with a forest plot.  
41, 42, 44, 56, 60 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and 
measures of consistency.  
41, 43, 44, 46  
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  N/A 
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Section/topic  # Checklist item  Reported on 
page #  
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, 
meta-regression [see Item 16]).  
45 
  
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main 
outcome; consider their relevance to key groups (e.g., healthcare providers, 
users, and policy makers).  
47 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-
level (e.g., incomplete retrieval of identified research, reporting bias).  
49 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and 
implications for future research.  
51 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., 
supply of data); role of funders for the systematic review.  
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Appendix 2: PRISMA checklist for Chapter 3 
Section/topic  # Checklist item  Reported on 
page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  65 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; 
data sources; study eligibility criteria, participants, and interventions; study 
appraisal and synthesis methods; results; limitations; conclusions and 
implications of key findings; systematic review registration number.  
65 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  67 
Objectives  4 Provide an explicit statement of questions being addressed with reference to 
participants, interventions, comparisons, outcomes, and study design (PICOS).  
67 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web 
address), and, if available, provide registration information including registration 
number.  
69 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report 
characteristics (e.g., years considered, language, publication status) used as 
criteria for eligibility, giving rationale.  
69 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact 
with study authors to identify additional studies) in the search and date last 
searched.  
69 
Search  8 Present full electronic search strategy for at least one database, including any 
limits used, such that it could be repeated.  
30, 31 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in 
systematic review, and, if applicable, included in the meta-analysis).  
69 
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Section/topic  # Checklist item  Reported on 
page #  
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, 
independently, in duplicate) and any processes for obtaining and confirming data 
from investigators.  
69 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding 
sources) and any assumptions and simplifications made.  
69 
Risk of bias in individual studies  12 Describe methods used for assessing risk of bias of individual studies (including 
specification of whether this was done at the study or outcome level), and how 
this information is to be used in any data synthesis.  
70 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  69, 70 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, 
including measures of consistency (e.g., I2) for each meta-analysis.  
70 
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence 
(e.g., publication bias, selective reporting within studies).  
N/A 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, 
meta-regression), if done, indicating which were pre-specified.  
70 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the 
review, with reasons for exclusions at each stage, ideally with a flow diagram.  
71 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study 
size, PICOS, follow-up period) and provide the citations.  
72, 81, 93 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level 
assessment (see item 12).  
77 
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) 
simple summary data for each intervention group (b) effect estimates and 
confidence intervals, ideally with a forest plot.  
79, 83, 84, 105, 115, 
121 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and 
measures of consistency.  
85 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  N/A 
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Section/topic  # Checklist item  Reported on 
page #  
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, 
meta-regression [see Item 16]).  
85 
  
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main 
outcome; consider their relevance to key groups (e.g., healthcare providers, 
users, and policy makers).  
87 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-
level (e.g., incomplete retrieval of identified research, reporting bias).  
89 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, 
and implications for future research.  
92 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., 
supply of data); role of funders for the systematic review.  
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Appendix 3: TRIPOD Checklist for Chapter 3: Prediction Model Development and Validation 
Section/Topic Item  Checklist Item Page 
Title and abstract 
Title 1 D;V Identify the study as developing and/or validating a multivariable prediction model, the target population, 
and the outcome to be predicted. 
126 
Abstract 2 D;V Provide a summary of objectives, study design, setting, participants, sample size, predictors, outcome, 
statistical analysis, results, and conclusions. 
126 
Introduction 
Background 
and objectives 
3a D;V Explain the medical context (including whether diagnostic or prognostic) and rationale for developing or 
validating the multivariable prediction model, including references to existing models. 
128 
3b D;V Specify the objectives, including whether the study describes the development or validation of the model 
or both. 
128 
Methods 
Source of 
data 
4a D;V Describe the study design or source of data (e.g., randomized trial, cohort, or registry data), separately for 
the development and validation data sets, if applicable. 
130 
4b D;V Specify the key study dates, including start of accrual; end of accrual; and, if applicable, end of follow-up.  130 
Participants 5a D;V Specify key elements of the study setting (e.g., primary care, secondary care, general population) 
including number and location of centres. 
130 
5b D;V Describe eligibility criteria for participants.  130 
5c D;V Give details of treatments received, if relevant.  N/A 
Outcome 6a D;V Clearly define the outcome that is predicted by the prediction model, including how and when assessed.  130 
6b D;V Report any actions to blind assessment of the outcome to be predicted.  N/A 
Predictors 7a D;V Clearly define all predictors used in developing the multivariable prediction model, including how and 
when they were measured. 
130, 131, 132 
7b D;V Report any actions to blind assessment of predictors for the outcome and other predictors.  N/A 
Sample size 8 D;V Explain how the study size was arrived at. 131 
Missing data 9 D;V Describe how missing data were handled (e.g., complete-case analysis, single imputation, multiple 
imputation) with details of any imputation method.  
133 
Statistical 
analysis 
methods 
10a D Describe how predictors were handled in the analyses.  133 
10b D Specify type of model, all model-building procedures (including any predictor selection), and method for 
internal validation. 
133 
10c V For validation, describe how the predictions were calculated.  133 
10d D;V Specify all measures used to assess model performance and, if relevant, to compare multiple models.  133 
10e V Describe any model updating (e.g., recalibration) arising from the validation, if done. N/A 
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Section/Topic Item  Checklist Item Page 
Risk groups 11 D;V Provide details on how risk groups were created, if done.  N/A 
Development 
vs. validation 
12 V For validation, identify any differences from the development data in setting, eligibility criteria, outcome, 
and predictors.  
133 
Results 
Participants 13a D;V Describe the flow of participants through the study, including the number of participants with and without 
the outcome and, if applicable, a summary of the follow-up time. A diagram may be helpful.  
135 
13b D;V Describe the characteristics of the participants (basic demographics, clinical features, available 
predictors), including the number of participants with missing data for predictors and outcome.  
135, 137, 138 
13c V For validation, show a comparison with the development data of the distribution of important variables 
(demographics, predictors and outcome).  
135, 141 
Model 
development  
14a D Specify the number of participants and outcome events in each analysis.  135 
14b D If done, report the unadjusted association between each candidate predictor and outcome. 137, 138 
Model 
specification 
15a D Present the full prediction model to allow predictions for individuals (i.e., all regression coefficients, and 
model intercept or baseline survival at a given time point). 
135, 139 
15b D Explain how to use the prediction model. 139 
Model 
performance 
16 D;V Report performance measures (with CIs) for the prediction model. 136 
Model-
updating 
17 V If done, report the results from any model updating (i.e., model specification, model performance). N/A 
Discussion 
Limitations 18 D;V Discuss any limitations of the study (such as nonrepresentative sample, few events per predictor, missing 
data).  
149 
Interpretation 19a V For validation, discuss the results with reference to performance in the development data, and any other 
validation data.  
N/A 
19b D;V Give an overall interpretation of the results, considering objectives, limitations, results from similar 
studies, and other relevant evidence.  
146, 151 
Implications 20 D;V Discuss the potential clinical use of the model and implications for future research.  150 
Other information 
Supplementary 
information 
21 D;V Provide information about the availability of supplementary resources, such as study protocol, Web 
calculator, and data sets.  
N/A 
Funding 22 D;V Give the source of funding and the role of the funders for the present study.  Acknowledgements 
*Items relevant only to the development of a prediction model are denoted by D, items relating solely to a validation of a prediction model are denoted by V, and items 
relating to both are denoted D;V.   
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Appendix 5: TRIPOD Checklist for Chapter 5: Prediction Model Development and Validation 
Section/Topic Item  Checklist Item Page 
Title and abstract 
Title 1 D;V Identify the study as developing and/or validating a multivariable prediction model, the target population, 
and the outcome to be predicted. 
157 
Abstract 2 D;V Provide a summary of objectives, study design, setting, participants, sample size, predictors, outcome, 
statistical analysis, results, and conclusions. 
157 
Introduction 
Background 
and objectives 
3a D;V Explain the medical context (including whether diagnostic or prognostic) and rationale for developing or 
validating the multivariable prediction model, including references to existing models. 
159 
3b D;V Specify the objectives, including whether the study describes the development or validation of the model 
or both. 
159, 160 
Methods 
Source of 
data 
4a D;V Describe the study design or source of data (e.g., randomized trial, cohort, or registry data), separately for 
the development and validation data sets, if applicable. 
161 
4b D;V Specify the key study dates, including start of accrual; end of accrual; and, if applicable, end of follow-up.  161 
Participants 5a D;V Specify key elements of the study setting (e.g., primary care, secondary care, general population) 
including number and location of centres. 
161 
5b D;V Describe eligibility criteria for participants.  161 
5c D;V Give details of treatments received, if relevant.  N/A 
Outcome 6a D;V Clearly define the outcome that is predicted by the prediction model, including how and when assessed.  162 
6b D;V Report any actions to blind assessment of the outcome to be predicted.  N/A 
Predictors 7a D;V Clearly define all predictors used in developing the multivariable prediction model, including how and 
when they were measured. 
163, 164 
7b D;V Report any actions to blind assessment of predictors for the outcome and other predictors.  N/A 
Sample size 8 D;V Explain how the study size was arrived at. 163 
Missing data 9 D;V Describe how missing data were handled (e.g., complete-case analysis, single imputation, multiple 
imputation) with details of any imputation method.  
164 
Statistical 
analysis 
methods 
10a D Describe how predictors were handled in the analyses.  164 
10b D Specify type of model, all model-building procedures (including any predictor selection), and method for 
internal validation. 
164 
10c V For validation, describe how the predictions were calculated.  165 
10d D;V Specify all measures used to assess model performance and, if relevant, to compare multiple models.  165 
10e V Describe any model updating (e.g., recalibration) arising from the validation, if done. N/A 
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Section/Topic Item  Checklist Item Page 
Risk groups 11 D;V Provide details on how risk groups were created, if done.  165 
Development 
vs. validation 
12 V For validation, identify any differences from the development data in setting, eligibility criteria, outcome, 
and predictors.  
165 
 
Participants 13a D;V Describe the flow of participants through the study, including the number of participants with and without 
the outcome and, if applicable, a summary of the follow-up time. A diagram may be helpful.  
167, 168 
13b D;V Describe the characteristics of the participants (basic demographics, clinical features, available 
predictors), including the number of participants with missing data for predictors and outcome.  
168, 170, 171, 172 
13c V For validation, show a comparison with the development data of the distribution of important variables 
(demographics, predictors and outcome).  
173, 177 
Model 
development  
14a D Specify the number of participants and outcome events in each analysis.  168, 173 
14b D If done, report the unadjusted association between each candidate predictor and outcome. 176 
Model 
specification 
15a D Present the full prediction model to allow predictions for individuals (i.e., all regression coefficients, and 
model intercept or baseline survival at a given time point). 
176 
15b D Explain how to use the prediction model. 176 
Model 
performance 
16 D;V Report performance measures (with CIs) for the prediction model. 174 
Model-
updating 
17 V If done, report the results from any model updating (i.e., model specification, model performance). N/A 
Discussion 
Limitations 18 D;V Discuss any limitations of the study (such as nonrepresentative sample, few events per predictor, missing 
data).  
182 
Interpretation 19a V For validation, discuss the results with reference to performance in the development data, and any other 
validation data.  
179 
19b D;V Give an overall interpretation of the results, considering objectives, limitations, results from similar 
studies, and other relevant evidence.  
179, 183 
Implications 20 D;V Discuss the potential clinical use of the model and implications for future research.  173 
Other information 
Supplementary 
information 
21 D;V Provide information about the availability of supplementary resources, such as study protocol, Web 
calculator, and data sets.  
N/A 
Funding 22 D;V Give the source of funding and the role of the funders for the present study.  Acknowledgements 
*Items relevant only to the development of a prediction model are denoted by D, items relating solely to a validation of a prediction model are denoted by V, and items 
relating to both are denoted D;V.   
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Appendix 6: TargetCOPD screening questionnaire 
TargetCOPD POSTAL QUESTIONNAIRE TO PATIENTS 
 
PATIENT ID_______________ 
Thank you for taking the time to fill in this questionnaire.  Your 
input is very valuable so please complete as many questions as 
you are able and return in the reply-paid envelope. Alternatively 
you may complete this form online at    
                                     https://www.pc-crtu.bham.ac.uk/Target 
Please try to answer every question with the closest answer 
possible by ticking the appropriate box.  
SECTION 1: YOUR LUNG HEALTH 
1. (a) Do you usually have a cough (either during the day, or night, or 
first thing in the morning)? 
Yes    
No     (If No, go to Q2)  
(b) Do you usually cough like this on most days for 3 consecutive 
months or   more during the year?   
Yes    → If yes, for how many years have you had this cough? 
..............years 
No 
 (c) Does the weather affect your cough?  Yes       No 
2. (a) Do you ever cough up phlegm from your chest when you don’t 
have a cold  
Yes        
No      (If No, go to Q3) 
 (b) Do you usually bring up phlegm from your chest (either during the 
day, or night, or first thing in the morning)?  Yes        No 
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(c) Do you bring up phlegm on most days for 3 consecutive months or 
more during the year?   
Yes      →  If yes, for how many years have you had trouble with 
phlegm?   ......................... years 
No 
3.  Have you had wheezing or whistling in the chest in the past 12 
months?   
Yes    → If yes, how frequently do you wheeze?  
Occasionally More often 
No 
4.  Are you troubled by shortness of breath when hurrying on level 
ground or walking up a slight hill?  
Yes       No      
5. Do you get short of breath walking with other people of your own age 
on level ground or have to stop for breath after about 15 minutes 
when walking at your own pace?   
Yes       No   
6. Do you have to stop for breath after walking about 100m or after a 
few minutes on level ground?  
Yes       No 
7. Are you too breathless to leave the house, or breathless while 
dressing or undressing?   
Yes       No 
8. Can you lie flat at night?        
  
Yes        
No       →  If no, how many pillows do you need in 
total?.................................. 
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9. Do you have or have you had any allergies?    
Yes        
No       (If No, go to Q11) 
10. If yes, what type of allergies? (tick any that apply) 
Hay fever Eczema Skin allergies Allergic rhinitis (nose/eye 
symptoms) 
Food allergies  Other      (please 
specify)……………..........…………………. 
11. Do you usually have a blocked or running nose? Yes       No 
12. Over the last year has your breathing kept you from doing as much 
as you used to?  Yes       No 
 
SECTION 2: YOUR GENERAL HEALTH AND 
CIRCUMSTANCES 
13. How would you describe your health in general?   
Very good    Good       Fair          Bad         Very bad 
 
14. Has a doctor ever said you have (please tick any that apply): 
Asthma    High blood pressure 
COPD    Diabetes 
Chronic bronchitis  Stroke   
Emphysema   Lung cancer 
Heart disease   Tuberculosis   
Heart failure    Depression  
Other medical condition (please specify) 
……………………………………………… 
 
15. Have you ever had a paid job?  
Yes Please state the occupation you have been employed in 
most of your life 
………………………...................................................................................
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....................................................................................................................
..................................... 
Please describe what you do/did in this job  
………………………………………………………………………..............
......……………………………………………………………………………
………………………………………………………………………………
………………………………………………………………………………
………………………………………………………… 
No  
  
16. Have you ever worked in a job which exposed you to vapours, gas, 
dust or fumes?  
Yes        
No  (If No, go to Q18) 
17. If yes, for how many years have you been exposed? 
......................................... 
18. (a) Have you ever smoked as much as one cigarette a day (or one 
cigar a week or an ounce of tobacco a month) for as long as one 
year?    Yes        
No     (If No, go to Q19) 
(b) (b) How much do/did you smoke a day?   
.............cigarettes/day  ................cigars/week..........oz or ...........g 
tobacco/week 
(c) How old were you when you started smoking?.................... 
(d) Do you still smoke?   
Yes     (If Yes, go to Q19)   
No 
(e) How old were you when you finally stopped 
smoking?......................  
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19. In most weeks, how many hours per week are you exposed to 
other people’s      tobacco smoke? ............................. 
 
20. What is your current height without shoes? …… metres  or 
……feet...…inches 
21.  What is your current weight without shoes? …….kg  
or……stone…..pounds 
22. Please indicate your date of birth:   ……………………. 
23. Sex: Male     Female 
24. How would you class your ethnic group? (Please tick one) 
White      
English/Welsh/Scottish/Northern 
Irish/British 
Irish      
Gypsy/Irish Traveller 
Any other white background 
 
Mixed / multiple ethnic groups  
White & Black Caribbean   
White & Black African   
White & Asian 
Other mixed 
 
Asian / Asian British 
Indian 
Pakistani 
 
Bangladeshi 
Chinese 
Any other Asian background 
 
Black / African / Caribbean / Black 
British 
African 
Caribbean 
Any other Black / African / 
Caribbean background 
 
Other ethnic group 
Arab 
Other 
Prefer not to say 
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SECTION 3: CONTACT INFORMATION 
25. Title……………….    First 
name…………..............................................………… 
Surname 
………………..…………………………......................................……..... 
26. Address……………………………………………………………………
…………………………………………………………………………………
…………………………………………………………………………………
…………………………………………………………………………………
….................................................................... 
27. Postcode……………………………………...........................…………
…………… 
28. Telephone number
 Home:………………………………............………………
 Mobile:……...........................……………………………………………
…………… 
29. Email 
address……………………………………….....……………………………
… 
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30. You may be invited for further assessment; to help us schedule 
these appropriately please indicate your preferred appointment times 
(tick any when you are available)   
 
Monday  morning  afternoon  evening   
Tuesday  morning  afternoon  evening 
Wednesday morning  afternoon  evening 
Thursday  morning  afternoon  evening 
Friday  morning  afternoon  evening 
Saturday  morning  afternoon  evening 
 
THANK YOU FOR TAKING THE TIME TO FILL OUT THIS QUESTIONNAIRE! 
PLEASE RETURN AS INDICATED USING EITHER THE REPLY-PAID ENVELOPE OR  
ONLINE AT  
https://www.pc-crtu.bham.ac.uk/Target 
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Appendix 7: Consolidated criteria for reporting qualitative studies 
(COREQ): 32-item checklist 
No Item Guide questions/description Page 
Domain 1: 
Research team 
and reflexivity 
   
Personal 
Characteristics 
   
1. Interviewer/facilitator Which author/s conducted the interview or 
focus group? 
193 
2. Credentials What were the researcher's credentials? E.g. 
PhD, MD 
N/A 
3. Occupation What was their occupation at the time of the 
study? 
N/A 
4. Gender Was the researcher male or female? N/A 
5. Experience and training What experience or training did the 
researcher have? 
N/A 
Relationship with 
participants 
   
6. Relationship 
established 
Was a relationship established prior to study 
commencement? 
193 
7. Participant knowledge 
of the interviewer 
What did the participants know about the 
researcher? e.g. personal goals, reasons for 
doing the research 
N/A 
8. Interviewer 
characteristics 
What characteristics were reported about the 
interviewer/facilitator? e.g. Bias, 
assumptions, reasons and interests in the 
research topic 
206 
Domain 2: study 
design 
   
Theoretical 
framework 
   
9. Methodological 
orientation and Theory 
What methodological orientation was stated 
to underpin the study? e.g. grounded theory, 
discourse analysis, ethnography, 
phenomenology, content analysis 
194 
Participant 
selection 
   
10. Sampling How were participants selected? e.g. 
purposive, convenience, consecutive, 
snowball 
193 
11. Method of approach How were participants approached? e.g. 
face-to-face, telephone, mail, email 
193 
12. Sample size How many participants were in the study? 195 
13. Non-participation How many people refused to participate or 
dropped out? Reasons? 
195 
Setting    
14. Setting of data 
collection 
Where was the data collected? e.g. home, 
clinic, workplace 
195 
15. Presence of non-
participants 
Was anyone else present besides the 
participants and researchers? 
193 
16. Description of sample What are the important characteristics of the 
sample? e.g. demographic data, date 
195 
Data collection    
17. Interview guide Were questions, prompts, guides provided by 194 
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the authors? Was it pilot tested? 
18. Repeat interviews Were repeat interviews carried out? If yes, 
how many? 
193 
19. Audio/visual recording Did the research use audio or visual 
recording to collect the data? 
193 
20. Field notes Were field notes made during and/or after the 
interview or focus group? 
193 
21. Duration What was the duration of the interviews or 
focus group? 
193 
22. Data saturation Was data saturation discussed? 193 
23. Transcripts returned Were transcripts returned to participants for 
comment and/or correction? 
193 
Domain 3: 
analysis and 
findings 
   
Data analysis    
24. Number of data coders How many data coders coded the data? 194 
25. Description of the 
coding tree 
Did authors provide a description of the 
coding tree? 
N/A 
26. Derivation of themes Were themes identified in advance or derived 
from the data? 
194 
27. Software What software, if applicable, was used to 
manage the data? 
194 
28. Participant checking Did participants provide feedback on the 
findings? 
N/A 
Reporting    
29. Quotations presented Were participant quotations presented to 
illustrate the themes / findings? Was each 
quotation identified? e.g. participant number 
195-
202 
30. Data and findings 
consistent 
Was there consistency between the data 
presented and the findings? 
195-
202 
31. Clarity of major themes Were major themes clearly presented in the 
findings? 
205 
32. Clarity of minor themes Is there a description of diverse cases or 
discussion of minor themes? 
185-
202 
 
